

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
**Abilify**

---

**Products Affected**

- ABILIFY ORAL TABLET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD), Autistic Disorder, Tourette's Disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A Documented diagnosis of Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD), Autistic Disorder, or Tourette's Disorder
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Abilify

---

## Products Affected

- ABILIFY ORAL SOLUTION

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD), Autistic Disorder, Tourette's Disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A Documented diagnosis of Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD), Autistic Disorder, or Tourette's Disorder
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	30 ML Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Abilify Discmelt

---

## Products Affected

- ABILIFY DISCMELT

PA Criteria	Criteria Details
<b>Covered Uses</b>	Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD), Autistic Disorder, Tourette's Disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A Documented diagnosis of Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD), Autistic Disorder, or Tourette's Disorder
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Abstral

## Products Affected

- ABSTRAL

PA Criteria	Criteria Details
<b>Covered Uses</b>	For pain due to malignant diagnosis only
<b>Exclusion Criteria</b>	Use in non-malignant pain
<b>Required Medical Information</b>	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))



<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: October 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Acamprosate Calcium

---

## Products Affected

- *acamprosate calcium*

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Accu-Chek Active

---

## Products Affected

- ACCU-CHEK ACTIVE

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Accu-Chek Aviva

---

## Products Affected

- ACCU-CHEK AVIVA IN VITRO STRIP

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Accu-Chek Aviva Plus

---

## Products Affected

- ACCU-CHEK AVIVA PLUS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Accu-Chek Aviva Plus

---

## Products Affected

- ACCU-CHEK AVIVA PLUS IN VITRO

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Accu-Chek Compact Plus

---

## Products Affected

- ACCU-CHEK COMPACT PLUS

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Accu-Chek Compact Plus Care

### Products Affected

- ACCU-CHEK COMPACT PLUS CARE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Accu-Chek Multiclix Lancet Dev

## Products Affected

- ACCU-CHEK MULTICLIX LANCET  
DEV

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Accu-Chek Nano SmartView

## Products Affected

- ACCU-CHEK NANO SMARTVIEW

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Accu-Chek SmartView

---

## Products Affected

- ACCU-CHEK SMARTVIEW

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Accu-Chek Voicemate

## Products Affected

- ACCU-CHEK VOICEMATE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Accutrend Glucose

---

## Products Affected

- ACCUTREND GLUCOSE

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aciphex

## Products Affected

- ACIPHEX

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of one of the following: Gastroesophageal reflux disease, Complications related to GERD (e.g. esophageal strictures, Barrett's Esophagus), Peptic ulcer disease, Treatment and prevention of gastroduodenal ulcers associated with NSAIDs, Zollinger-Ellison Syndrome, or Helicobacter pylori eradication (Additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 capsule Per 1 DAY
<b>Notes/References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: November 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# AcipHex Sprinkle

## Products Affected

- ACIPHEX SPRINKLE

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Gastroesophageal reflux disease, Complications related to GERD (e.g. esophageal strictures, Barrett's Esophagus), Peptic ulcer disease, Treatment and prevention of gastroduodenal ulcers associated with NSAIDs, Zollinger-Ellison Syndrome, or Helicobacter pylori eradication (Additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required). In addition for approval the following criteria must also be met: Documentation of an inability to swallow tablets/capsules.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 capsule Per 1 Day
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: November 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Acitretin

---

## Products Affected

- *acitretin*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Actemra

## Products Affected

- ACTEMRA SUBCUTANEOUS\*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 SYRINGES Per 28 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Actemra

---

## Products Affected

- ACTEMRA INTRAVENOUS\*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Actiq

## Products Affected

- ACTIQ

PA Criteria	Criteria Details
<b>Covered Uses</b>	For pain due to malignant diagnosis only
<b>Exclusion Criteria</b>	Use in non-malignant pain
<b>Required Medical Information</b>	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))

<b>QL Criteria</b>	4 loz Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: October 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Activella

---

## Products Affected

- ACTIVELLA

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Actonel

---

## Products Affected

- ACTONEL ORAL TABLET 150 MG

<b>QL Criteria</b>	0.04 tabs Per 1 DAYS
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Actonel

---

## Products Affected

- ACTONEL ORAL TABLET 30 MG, 5 MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Actonel

---

## Products Affected

- ACTONEL ORAL TABLET 35 MG

<b>QL Criteria</b>	4 tablets Per 1 month
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Actoplus Met

---

## Products Affected

- ACTOPLUS MET

<b>QL Criteria</b>	2 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Actoplus met XR

---

## Products Affected

- ACTOPLUS MET XR

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Actos

---

## Products Affected

- ACTOS

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Acura Blood Glucose Test

---

## Products Affected

- ACURA BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Adalat CC

---

## Products Affected

- ADALAT CC ORAL TABLET  
EXTENDED RELEASE 24 HR\* 30 MG,  
90 MG

<b>QL Criteria</b>	1 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Adalat CC

---

## Products Affected

- ADALAT CC ORAL TABLET  
EXTENDED RELEASE 24 HR\* 60 MG

<b>QL Criteria</b>	2 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Adcirca

## Products Affected

- ADCIRCA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Adderall

---

## Products Affected

- ADDERALL

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Adderall XR

---

## Products Affected

- ADDERALL XR

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Adefovir Dipivoxil

---

## Products Affected

- *adefovir dipivoxil*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Adempas

## Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 TABS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Adrenaclick

---

## Products Affected

- ADRENACLICK INJECTION

<b>QL Criteria</b>	1 DEVI Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advair Diskus

---

## Products Affected

- ADVAIR DISKUS INHALATION  
AEROSOL POWDER, BREATH  
ACTIVATED 100-50 MCG/DOSE, 250-50  
MCG/DOSE

<b>QL Criteria</b>	1 diskus Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advair Diskus

---

## Products Affected

- ADVAIR DISKUS INHALATION  
AEROSOL POWDER, BREATH  
ACTIVATED 500-50 MCG/DOSE

<b>QL Criteria</b>	2 diskus Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advair HFA

---

## Products Affected

- ADVAIR HFA

<b>QL Criteria</b>	1 inhaler Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advance Intuition Meter

---

## Products Affected

- ADVANCE INTUITION METER

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Advance Intuition Test

---

## Products Affected

- ADVANCE INTUITION TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advate

---

## Products Affected

- ADVATE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advicor

---

## Products Affected

- ADVICOR ORAL TABLET EXTENDED  
RELEASE 24 HR\* 1000-20 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advicor

---

## Products Affected

- ADVICOR ORAL TABLET EXTENDED  
RELEASE 24 HR\* 1000-40 MG, 500-20  
MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advicor

---

## Products Affected

- ADVICOR ORAL TABLET EXTENDED  
RELEASE 24 HR\* 750-20 MG

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advocate Blood Glucose Monitor

---

## Products Affected

- ADVOCATE BLOOD GLUCOSE MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advocate Duo

---

## Products Affected

- ADVOCATE DUO DEVICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advocate Redi-Code

---

## Products Affected

- ADVOCATE REDI-CODE DEVICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Advocate Redi-Code

---

## Products Affected

- ADVOCATE REDI-CODE IN VITRO

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advocate Redi-Code+

---

## Products Affected

- ADVOCATE REDI-CODE+

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advocate Redi-Code+ Test

---

## Products Affected

- ADVOCATE REDI-CODE+ TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Advocate Test

---

## Products Affected

- ADVOCATE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Adzenys XR-ODT

## Products Affected

- ADZENYS XR-ODT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Attention deficit hyperactivity disorder (ADHD)
<b>Exclusion Criteria</b>	Documentation of a diagnosis of either adult ADHD or of childhood ADHD onset with history of previous treatment and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment)
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aerospan

---

## Products Affected

- AEROSPAN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Asthma
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Asthma
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	Step Therapy. Medical Exception for Flovent Diskus and Flovent HFA: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Afeditab CR

---

## Products Affected

- *afeditab cr oral tablet extended release 24 hr\* 30 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Afeditab CR

---

## Products Affected

- *afeditab cr oral tablet extended release 24 hr\* 60 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Afinitor

---

## Products Affected

- AFINITOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Afinitor Disperz

## Products Affected

- AFINITOR DISPERZ

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tabs Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Afrezza

## Products Affected

- AFREZZA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes, Type 2 Diabetes
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of ALL of the following: (1) In patients with type 1 diabetes, concomitant use of long-acting insulin (e.g., Levamir or Lantus), (2) In all Patients, no history of chronic lung disease such as asthma or Chronic Obstructive Pulmonary Disease (COPD), and (3) Detailed medical history documenting physical examination and spirometry (FEV1) to identify potential lung disease in all patients.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Afrezza

## Products Affected

- AFREZZA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes, Type 2 Diabetes
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of ALL of the following: (1) In patients with type 1 diabetes, concomitant use of long-acting insulin (e.g., Levamir or Lantus), (2) In all Patients, no history of chronic lung disease such as asthma or Chronic Obstructive Pulmonary Disease (COPD), and (3) Detailed medical history documenting physical examination and spirometry (FEV1) to identify potential lung disease in all patients.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Afstyla

---

## Products Affected

- AFSTYLA

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# AgaMatrix AMP Test

---

## Products Affected

- AGAMATRIX AMP TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# AgaMatrix Jazz Test

---

## Products Affected

- AGAMATRIX JAZZ TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# AgaMatrix KeyNote Test

---

## Products Affected

- AGAMATRIX KEYNOTE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# AgaMatrix Presto

## Products Affected

- AGAMATRIX PRESTO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# AgaMatrix Presto Pro Meter

## Products Affected

- AGAMATRIX PRESTO PRO METER

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# AgaMatrix Presto Test

---

## Products Affected

- AGAMATRIX PRESTO TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Akynzeo

---

## Products Affected

- AKYNZEO

<b>QL Criteria</b>	2 capsules Per 1 month
<b>Notes/ References</b>	Annual Review: 03/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aldara

---

## Products Affected

- ALDARA

<b>QL Criteria</b>	48 packet Per 112 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aldurazyme

---

## Products Affected

- ALDURAZYME

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alecensa

## Products Affected

- ALECENSA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	8 capsules Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alendronate Sodium

---

## Products Affected

- *alendronate sodium oral tablet 70 mg, 35 mg*

<b>QL Criteria</b>	4 tablets Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Alendronate Sodium

---

## Products Affected

- *alendronate sodium oral tablet 40 mg, 10 mg, 5 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alfuzosin HCl ER

---

## Products Affected

- *alfuzosin hcl er*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Almotriptan Malate

---

## Products Affected

- *almotriptan malate*

<b>QL Criteria</b>	6 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alogliptin Benzoate

---

## Products Affected

- *alogliptin benzoate*

<b>QL Criteria</b>	1 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alogliptin-Metformin HCl

---

## Products Affected

- *alogliptin-metformin hcl*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alogliptin-Pioglitazone

---

## Products Affected

- *alogliptin-pioglitazone*

<b>QL Criteria</b>	1 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alora

---

## Products Affected

- ALORA

<b>QL Criteria</b>	8 patches Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alosetron HCl

## Products Affected

- *alose tron hcl*

PA Criteria	Criteria Details
<b>Covered Uses</b>	severe diarrhea-predominant irritable bowel syndrome (IBS)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Patient is female, and has a documented diagnosis of severe diarrhea-predominant irritable bowel syndrome (IBS) including one or more of the following: frequent and severe abdominal pain/discomfort, frequent urgency or fecal incontinence or disability or restriction of daily activities due to IBS, AND patient has chronic IBS symptoms generally lasting 6 months or longer, AND anatomic or biochemical abnormalities of the gastrointestinal tract have been excluded
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Step Therapy
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Alphanate/VWF Complex/Human

## Products Affected

- ALPHANATE/VWF COMPLEX/HUMAN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# AlphaNine SD

---

## Products Affected

- ALPHANINE SD

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ALPRAZolam ER

---

## Products Affected

- *alprazolam er*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ALPRAZolam XR

---

## Products Affected

- *alprazolam xr*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alprolix

---

## Products Affected

- ALPROLIX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Altavera

---

## Products Affected

- *altavera*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Altprev

---

## Products Affected

- ALTOPREV

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Alvesco

---

## Products Affected

- ALVESCO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Asthma
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Asthma
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	Step Therapy. Medical Exception for Flovent Diskus and Flovent HFA: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Alyacen 1/35

---

## Products Affected

- *alyacen 1/35*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Alyacen 7/7/7

---

### Products Affected

- *alyacen 7/7/7*

<b>QL Criteria</b>	1.5 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ambien

---

## Products Affected

- AMBIEN ORAL TABLET 10 MG

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ambien

---

## Products Affected

- AMBIEN ORAL TABLET 5 MG

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ambien CR

---

## Products Affected

- AMBIEN CR

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amerge

---

## Products Affected

- AMERGE

<b>QL Criteria</b>	9 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amethia

---

## Products Affected

- *amethia*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amethia Lo

---

## Products Affected

- *amethia lo*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Amethyst

---

## Products Affected

- *amethyst*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amitiza

---

## Products Affected

- AMITIZA

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amlodipine Besylate-Valsartan

---

## Products Affected

- *amlodipine besylate-valsartan*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amlodipine-Atorvastatin

---

## Products Affected

- *amlodipine-atorvastatin*

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amnesteem

## Products Affected

- *amnesteem*

PA Criteria	Criteria Details
<b>Covered Uses</b>	severe recalcitrant nodular or cystic acne
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Member already has evidence of scarring and member is enrolled in the FDA iPLEDGE program (females of childbearing potential ONLY)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	5 months
<b>Other Criteria</b>	For coverage of additional quantities (greater than 2 capsules per day) member must meet the following criteria: Patient requires more than 2 capsules per day to reach the appropriate dose for weight, and this is the members FIRST course of therapy or member now requires a second course of therapy and it has been at least 8 weeks after the first course was initiated (2 month holiday), and member has recieved a cumulative dose of less than 120 mg/kg during a course of therapy lasting 20 weeks or less.
<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amphetamine-Dextroamphet ER

---

## Products Affected

- *amphetamine-dextroamphet er*

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Amphetamine-Dextroamphetamine

---

## Products Affected

- *amphetamine-dextroamphetamine*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ampyra

---

## Products Affected

- AMPYRA

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Amturnide

---

## Products Affected

- AMTURNIDE

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# AndroGel

## Products Affected

- ANDROGEL TRANSDERMAL GEL 50 MG/5GM (1%)

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 10 gm packets Per 1 day
<b>Notes/References</b>	Annual Review: 02/2016

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

# AndroGel

## Products Affected

- ANDROGEL TRANSDERMAL GEL 25 MG/2.5GM (1%)

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 25 gram packet Per 1 day
<b>Notes/References</b>	Annual Review: 02/2016

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

# AndroGel

## Products Affected

- ANDROGEL TRANSDERMAL GEL  
20.25 MG/1.25GM (1.62%)

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 1.25 gm packet Per 1 day
<b>Notes/References</b>	Annual Review: 02/2016

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

# AndroGel

## Products Affected

- ANDROGEL TRANSDERMAL GEL 40.5 MG/2.5GM (1.62%)

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	5 grams-2 packets Per 1 day
<b>Notes/References</b>	Annual Review: 02/2016



<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

# AndroGel Pump

## Products Affected

- ANDROGEL PUMP TRANSDERMAL  
GEL 12.5 MG/ACT (1%)

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	10 grams Per 1 day
<b>Notes/References</b>	Annual Review: 02/2016

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

# AndroGel Pump

## Products Affected

- ANDROGEL PUMP TRANSDERMAL  
GEL 20.25 MG/ACT (1.62%)

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 pumps Per 1 day
<b>Notes/References</b>	Annual Review: 02/2016

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

# Angeliq

---

## Products Affected

- ANGELIQ

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Anoro Ellipta

---

## Products Affected

- ANORO ELLIPTA

<b>QL Criteria</b>	60 BLISTERS Per 30 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Antara

---

## Products Affected

- ANTARA ORAL CAPSULE 30 MG, 90 MG

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Anzemet

---

## Products Affected

- ANZEMET ORAL

<b>QL Criteria</b>	5 tablets Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# APAP-Caff-Dihydrocodeine

---

## Products Affected

- *apap-caff-dihydrocodeine oral capsule*

<b>QL Criteria</b>	10 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Apri

---

## Products Affected

- *apri*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Apriso

---

## Products Affected

- APRISO

<b>QL Criteria</b>	4 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aptensio XR

## Products Affected

- APTENSIO XR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Attention deficit hyperactivity disorder (ADHD)
<b>Exclusion Criteria</b>	Documentation of a diagnosis of either adult ADHD or of childhood ADHD onset with history of previous treatment and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment)
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aptiom

---

## Products Affected

- APTIOM ORAL TABLET 600 MG, 200 MG

<b>QL Criteria</b>	2 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aptiom

---

## Products Affected

- APTIOM ORAL TABLET 800 MG, 400 MG

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aranelle

---

## Products Affected

- *aranelle*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



## Aranesp (Albumin Free)

### Products Affected

- ARANESP (ALBUMIN FREE)  
INJECTION SOLUTION 25 MCG/ML,  
300 MCG/ML, 40 MCG/ML, 100  
MCG/ML, 200 MCG/ML, 150  
MCG/0.75ML, 10 MCG/0.4ML, 60  
MCG/ML
- ARANESP (ALBUMIN FREE)  
INJECTION

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Erythropoiesis_Stimulating_Agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Erythropoiesis_Stimulating_Agents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Arava

---

## Products Affected

- ARAVA

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Arcalyst

---

## Products Affected

- ARCALYST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/immunomodulators_CAP.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/immunomodulators_CAP.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Arcapta Neohaler

---

## Products Affected

- ARCAPTA NEOHALER

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Chronic Obstructive Pulmonary Disorder (COPD)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Chronic obstructive pulmonary disease (COPD)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/References</b>	Annual Review: 07/2016
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aricept

---

## Products Affected

- ARICEPT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Alzheimer's Disease
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
<b>Age Restrictions</b>	less than 40 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aricept ODT

---

## Products Affected

- ARICEPT ODT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Alzheimer's Disease
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
<b>Age Restrictions</b>	less than 40 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ARIPiprazole

---

## Products Affected

- *aripiprazole oral tablet dispersible*
- *aripiprazole oral tablet*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ARIPiprazole

---

## Products Affected

- *aripiprazole oral solution*

<b>QL Criteria</b>	30 ml Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Arixtra

---

## Products Affected

- ARIXTRA

<b>QL Criteria</b>	2 syringes Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Armodafinil

## Products Affected

- *armodafinil oral tablet 200 mg, 150 mg, 250 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 Day

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Armodafinil

## Products Affected

- *armodafinil oral tablet 50 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 day

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Arnuity Ellipta

## Products Affected

- ARNUITY ELLIPTA

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Asthma
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy. Medical Exception for Flovent Diskus and Flovent HFA: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
Notes/References	Annual Review: 06/2016
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Asacol HD

---

## Products Affected

- ASACOL HD

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ascensia Autodisc Test

---

## Products Affected

- ASCENSIA AUTODISC TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



## Assure 3 Test

---

### Products Affected

- ASSURE 3 TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Assure 4 Meter

---

### Products Affected

- ASSURE 4 METER

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Assure 4 Test

---

### Products Affected

- ASSURE 4 TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Assure Platinum

---

## Products Affected

- ASSURE PLATINUM

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Assure Platinum Meter

---

## Products Affected

- ASSURE PLATINUM METER

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Assure Pro Blood Glucose Meter

---

## Products Affected

- ASSURE PRO BLOOD GLUCOSE  
METER

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Assure Pro Test

---

## Products Affected

- ASSURE PRO TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Astagraf XL

---

## Products Affected

- ASTAGRAF XL ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 0.5  
MG

<b>QL Criteria</b>	1 CP24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Astagraf XL

---

## Products Affected

- ASTAGRAF XL ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 1 MG

<b>QL Criteria</b>	4 CP24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Atacand

---

## Products Affected

- ATACAND ORAL TABLET 32 MG

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Atacand

---

## Products Affected

- ATACAND ORAL TABLET 4 MG, 16 MG, 8 MG

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Atacand HCT

---

## Products Affected

- ATACAND HCT ORAL TABLET 32-25 MG, 32-12.5 MG

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Atacand HCT

---

## Products Affected

- ATACAND HCT ORAL TABLET 16-12.5  
MG

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Atelvia

---

## Products Affected

- ATELVIA

<b>QL Criteria</b>	4 tablets Per 1 month
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Atorvastatin Calcium

---

## Products Affected

- *atorvastatin calcium oral*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Atripla

---

## Products Affected

- ATRIPLA

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Aubagio

---

## Products Affected

- AUBAGIO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Auvi-Q

---

## Products Affected

- AUVI-Q INJECTION

<b>QL Criteria</b>	2 pens Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Avalide

---

## Products Affected

- AVALIDE ORAL TABLET 150-12.5 MG

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Avalide

---

## Products Affected

- AVALIDE ORAL TABLET 300-12.5 MG

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Avandamet

## Products Affected

- AVANDAMET ORAL TABLET 2-1000  
MG

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	An adult patient with a documented diagnosis of type 2 diabetes mellitus and all of the following: unable to achieve adequate glycemic control (HbA1C lab value greater than 6.5%) despite the use of other medications, and, in consultation with their healthcare provider, has decided not to take Actos (pioglitazone) for medical reasons.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Avandia

## Products Affected

- AVANDIA

PA Criteria	Criteria Details
Covered Uses	Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	An adult patient with a documented diagnosis of type 2 diabetes mellitus and all of the following: unable to achieve adequate glycemic control (HbA1C lab value greater than 6.5%) despite the use of other medications, and, in consultation with their healthcare provider, has decided not to take Actos (pioglitazone) for medical reasons.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Avapro

---

## Products Affected

- AVAPRO

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Aviane

---

## Products Affected

- *aviane*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# AVINza

---

## Products Affected

- AVINZA

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Avita

## Products Affected

- *avita external gel*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Avita

## Products Affected

- *avita external cream*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	50 grams Per 1 fill
<b>Notes/References</b>	

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

# Avodart

---

## Products Affected

- AVODART

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Avonex

---

## Products Affected

- AVONEX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 doses Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Avonex Pen

---

## Products Affected

- AVONEX PEN INTRAMUSCULAR\*

<b>QL Criteria</b>	4 pens Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Avonex Prefilled

---

## Products Affected

- AVONEX PREFILLED  
INTRAMUSCULAR\*

<b>QL Criteria</b>	4 pens Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Axert

---

## Products Affected

- AXERT

<b>QL Criteria</b>	6 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Azilect

---

## Products Affected

- AZILECT

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Azor

---

## Products Affected

- AZOR

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Azulfidine

---

## Products Affected

- AZULFIDINE

<b>QL Criteria</b>	8 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Azulfidine EN-tabs

---

## Products Affected

- AZULFIDINE EN-TABS

<b>QL Criteria</b>	8 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Azurette

---

## Products Affected

- *azurette*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Balsalazide Disodium

---

## Products Affected

- *balsalazide disodium*

<b>QL Criteria</b>	9 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Balziva

---

## Products Affected

- *balziva*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Banzel

---

## Products Affected

- BANZEL ORAL TABLET

<b>QL Criteria</b>	8 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Baraclude

---

## Products Affected

- BARACLUDE ORAL TABLET

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bayer Breeze 2 Test

---

## Products Affected

- BAYER BREEZE 2 TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bayer Contour Link Monitor

## Products Affected

- BAYER CONTOUR LINK MONITOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bayer Contour Monitor

---

## Products Affected

- BAYER CONTOUR MONITOR DEVICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bayer Contour Monitor

## Products Affected

- BAYER CONTOUR MONITOR KIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYSs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bayer Contour Next EZ

## Products Affected

- BAYER CONTOUR NEXT EZ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bayer Contour next Link

## Products Affected

- BAYER CONTOUR NEXT LINK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Bayer Contour Next Monitor

## Products Affected

- BAYER CONTOUR NEXT MONITOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bayer Contour Next Test

---

## Products Affected

- BAYER CONTOUR NEXT TEST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	30 strips Per 30 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bayer Contour Next USB Monitor

## Products Affected

- BAYER CONTOUR NEXT USB MONITOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bayer Contour Test

## Products Affected

- BAYER CONTOUR TEST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	30 strips Per 30 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bayer Contour USB

## Products Affected

- BAYER CONTOUR USB

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bebulin

---

## Products Affected

- BEBULIN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bebulin VH

---

## Products Affected

- BEBULIN VH

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Belbuca

## Products Affected

- BELBUCA

PA Criteria	Criteria Details
<b>Covered Uses</b>	Pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
<b>Exclusion Criteria</b>	Acute or severe bronchial asthma, known or suspected gastrointestinal obstruction, including paralytic ileus
<b>Required Medical Information</b>	(1)Patient is 18 years of age or older and has a documented diagnosis of chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment, (2)Alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain (i.e. non-opioid analgesics or immediate-release opioids), (3)Is not being used in combination with other long-acting opioid therapy, and (4)Is NOT being used for the treatment of opioid dependence
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 films Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Belsomra

---

## Products Affected

- BELSOMRA

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# BeneFIX

## Products Affected

- BENEFIX INTRAVENOUS\* SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Benicar

---

## Products Affected

- BENICAR

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Benicar HCT

---

## Products Affected

- BENICAR HCT

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Benlysta

---

## Products Affected

- BENLYSTA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/benlysta.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/benlysta.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Berinert

---

## Products Affected

- BERINERT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/hereditary_angioedema.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/hereditary_angioedema.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Betaseron

## Products Affected

- BETASERON SUBCUTANEOUS\* KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 box (15 vials) Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bethkis

---

## Products Affected

- BETHKIS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ID/Aminoglycosides.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ID/Aminoglycosides.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	56 ampules Per 30 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: February 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Bevespi Aerosphere

---

## Products Affected

- BEVESPI AEROSPHERE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Chronic Obstructive Pulmonary Disorder (COPD)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Chronic obstructive pulmonary disease (COPD)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 inhaler Per 30 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Beyaz

---

## Products Affected

- BEYAZ

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# BG Star Test

---

## Products Affected

- BG STAR TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bicalutamide

---

## Products Affected

- *bicalutamide*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bimatoprost

---

## Products Affected

- *bimatoprost ophthalmic*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	open-angle glaucoma, ocular hypertension
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of glaucoma or ocular hypertension
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 28, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bivigam

---

## Products Affected

- BIVIGAM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Boniva

---

## Products Affected

- BONIVA ORAL TABLET 150 MG

<b>QL Criteria</b>	0.04 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bosulif

---

## Products Affected

- BOSULIF ORAL TABLET 100 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Bosulif

## Products Affected

- BOSULIF ORAL TABLET 500 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Botox

---

## Products Affected

- BOTOX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/botulinum_toxin.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/botulinum_toxin.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Botox Cosmetic

---

## Products Affected

- BOTOX COSMETIC  
INTRAMUSCULAR\* SOLUTION  
RECONSTITUTED 50 UNIT

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/botulinum_toxin.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/botulinum_toxin.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bravelle

---

## Products Affected

- BRAVELLE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Breeze 2 Blood Glucose System

## Products Affected

- BREEZE 2 BLOOD GLUCOSE SYSTEM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Breo Ellipta

---

## Products Affected

- BREO ELLIPTA INHALATION  
AEROSOL POWDER, BREATH  
ACTIVATED 100-25 MCG/INH

<b>QL Criteria</b>	2 blister Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Breo Ellipta

---

## Products Affected

- BREO ELLIPTA INHALATION  
AEROSOL POWDER, BREATH  
ACTIVATED 200-25 MCG/INH

<b>QL Criteria</b>	1 inhaler Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Brevicon (28)

---

### Products Affected

- BREVICON (28)

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Briellyn

---

## Products Affected

- *briellyn*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Brilinta

---

## Products Affected

- BRILINTA

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Brintellix

---

## Products Affected

- BRINTELLIX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Major depressive disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of major depressive disorder
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: October 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Brisdelle

---

## Products Affected

- BRISDELLE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Vasomotor symptoms associated with menopause
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of moderate to severe vasomotor symptoms associated with menopause
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Briviact

## Products Affected

- BRIVIACT ORAL SOLUTION

PA Criteria	Criteria Details
Covered Uses	Partial-onset seizure
Exclusion Criteria	
Required Medical Information	A documented diagnosis of partial-onset seizures AND documented concurrent therapy with one of the following: carbamazepine, divalproex dr/er/sprinkle, gabapentin, lamotrigine, levetiracetam/ER, oxcarbazepine, phenytoin, topiramate, valproic acid, or zonisamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	20 ML Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Briviact

## Products Affected

- BRIVIACT ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Partial-onset seizure
Exclusion Criteria	
Required Medical Information	A documented diagnosis of partial-onset seizures AND documented concurrent therapy with one of the following: carbamazepine, divalproex dr/er/sprinkle, gabapentin, lamotrigine, levetiracetam/ER, oxcarbazepine, phenytoin, topiramate, valproic acid, or zonisamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Brovana

---

## Products Affected

- BROVANA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Chronic Obstructive Pulmonary Disorder (COPD)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Chronic obstructive pulmonary disease (COPD)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 milliliters Per 1 day
<b>Notes/References</b>	Annual Review: 07/2016
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Budesonide

## Products Affected

- *budesonide inhalation*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Asthma
<b>Exclusion Criteria</b>	Budesonide inhalation solution is NOT covered for members greater than 8 years of age, for children 5-8 years of age who are able to use metered-dose inhalers, for use in primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required, and for use in acute bronchospasms.
<b>Required Medical Information</b>	Covered for the maintenance treatment of asthma and as prophylactic therapy in children 1-4 years of age, or in children 5-8 years of age if unable to use metered dose inhalers.
<b>Age Restrictions</b>	Less than 8 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year, up to the age of 8 years of age
<b>Other Criteria</b>	Medical Exception: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: November 24, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Budesonide

## Products Affected

- *budesonide inhalation*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Asthma
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For ages 5-8 documented inability to use metered dose inhalers
<b>Age Restrictions</b>	Less than 8 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Up to the age of 8
<b>Other Criteria</b>	No prior authorization required for children 1-4 years of age. Medical Exception for Pulmicort Respules: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bunavail

## Products Affected

- BUNAVAIL

PA Criteria	Criteria Details
<b>Covered Uses</b>	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
<b>Exclusion Criteria</b>	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
<b>Required Medical Information</b>	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months = current enrollment

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at <a href="http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jsp">http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jsp</a> . Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Buphenyl

## Products Affected

- BUPHENYL ORAL POWDER 3 GM/TSP • BUPHENYL ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 31, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Buprenorphine HCl

## Products Affected

- *buprenorphine hcl sublingual tablet*  
*sublingual 2 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
<b>Exclusion Criteria</b>	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
<b>Required Medical Information</b>	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months = current enrollement

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
Updated 12/2016

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at <a href="http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx">http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx</a>. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
<b>QL Criteria</b>	0.8 tabs Per 1 DAYS
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Buprenorphine HCl

## Products Affected

- *buprenorphine hcl sublingual tablet*  
*sublingual 8 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
<b>Exclusion Criteria</b>	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
<b>Required Medical Information</b>	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months = current enrollement

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
Updated 12/2016

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at <a href="http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx">http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx</a> . Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
<b>QL Criteria</b>	3 tablets Per 1 Day
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Buprenorphine HCl-Naloxone HCl

## Products Affected

- *buprenorphine hcl-naloxone hcl*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
<b>Exclusion Criteria</b>	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
<b>Required Medical Information</b>	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months = current enrollement

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at <a href="http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx">http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx</a> . Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Buproban

---

## Products Affected

- *buproban*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# BuPROPion HCl

---

## Products Affected

- *bupropion hcl oral*

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## BuPROPion HCl ER (Smoking Det)

---

### Products Affected

- *bupropion hcl er (smoking det)*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## BuPROPion HCl ER (SR)

---

### Products Affected

- *bupropion hcl er (sr)*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## BuPROPion HCl ER (XL)

---

### Products Affected

- *bupropion hcl er (xl)*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Butorphanol Tartrate

---

## Products Affected

- *butorphanol tartrate nasal*

<b>QL Criteria</b>	2 bottles Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Butrans

---

## Products Affected

- BUTRANS

<b>QL Criteria</b>	4 patches (1 box) Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bydureon

---

## Products Affected

- BYDUREON SUBCUTANEOUS\*  
SUSPENSION RECONSTITUTED

<b>QL Criteria</b>	4 vials Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bydureon

---

## Products Affected

- BYDUREON SUBCUTANEOUS\* 2 MG

<b>QL Criteria</b>	4 pens Per 1 month
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Byetta 10 MCG Pen

---

## Products Affected

- BYETTA 10 MCG PEN  
SUBCUTANEOUS\*

<b>QL Criteria</b>	1 pen Per 1 month
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Byetta 5 MCG Pen

---

## Products Affected

- BYETTA 5 MCG PEN  
SUBCUTANEOUS\*

<b>QL Criteria</b>	1 pen Per 1 month
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bystolic

---

## Products Affected

- BYSTOLIC ORAL TABLET 10 MG, 2.5 MG, 5 MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Bystolic

---

## Products Affected

- BYSTOLIC ORAL TABLET 20 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Byvalson

---

## Products Affected

- BYVALSON

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Hypertension
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of Hypertension
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Cabometyx

## Products Affected

- CABOMETYX

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Calcitonin (Salmon)

---

### Products Affected

- *calcitonin (salmon)*

<b>QL Criteria</b>	1 bottle Per 1 month
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Camila

---

## Products Affected

- *camila*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Camrese

---

## Products Affected

- *camrese*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Camrese Lo

---

## Products Affected

- *camrese lo*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Canasa

---

## Products Affected

- CANASA

<b>QL Criteria</b>	1 suppository Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Candesartan Cilexetil

---

## Products Affected

- *candesartan cilexetil oral tablet 8 mg, 4 mg, 16 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Candesartan Cilexetil-HCTZ

---

## Products Affected

- *candesartan cilexetil-hctz*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Caprelsa

---

## Products Affected

- CAPRELSA ORAL TABLET 100 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Caprelsa

## Products Affected

- CAPRELSA ORAL TABLET 300 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Carbaglu

---

## Products Affected

- CARBAGLU

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 31, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cardizem LA

---

## Products Affected

- CARDIZEM LA ORAL TABLET  
EXTENDED RELEASE 24 HR\* 240 MG

<b>QL Criteria</b>	2 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cardizem LA

---

## Products Affected

- CARDIZEM LA ORAL TABLET  
EXTENDED RELEASE 24 HR\* 120 MG,  
360 MG

<b>QL Criteria</b>	1 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cardura XL

---

## Products Affected

- CARDURA XL

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CareSens N Glucose System

---

## Products Affected

- CARESENS N GLUCOSE SYSTEM

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CareSens N Glucose Test

---

## Products Affected

- CARESENS N GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Carimune NF

---

## Products Affected

- CARIMUNE NF INTRAVENOUS\*  
SOLUTION RECONSTITUTED 6 GM, 12  
GM

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cartia XT

---

## Products Affected

- *cartia xt oral capsule extended release 24 hour 180 mg, 120 mg, 300 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cartia XT

---

## Products Affected

- *cartia xt oral capsule extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Casodex

---

## Products Affected

- CASODEX

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cayston

---

## Products Affected

- CAYSTON

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Caziant

---

## Products Affected

- *caziant*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CeleBREX

---

## Products Affected

- CELEBREX

<b>QL Criteria</b>	2 CAPS Per 1 DAY
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Celecoxib

---

## Products Affected

- *celecoxib oral*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# CeleXA

---

## Products Affected

- CELEXA ORAL TABLET

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cenestin

---

## Products Affected

- CENESTIN ORAL TABLET 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cenestin

---

## Products Affected

- CENESTIN ORAL TABLET 1.25 MG

<b>QL Criteria</b>	2 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cerdelga

---

## Products Affected

- CERDELGA

<b>QL Criteria</b>	1 capsule Per 2 dayss
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cerezyme

---

## Products Affected

- CERZYME INTRAVENOUS\*  
SOLUTION RECONSTITUTED 400  
UNIT

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cesamet

---

## Products Affected

- CESAMET

<b>QL Criteria</b>	2 capsules Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cesia

---

## Products Affected

- *cesia*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cetrotide

## Products Affected

- CETROTIDE SUBCUTANEOUS\* KIT  
0.25 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Cevimeline HCl

---

## Products Affected

- *cevimeline hcl*

<b>QL Criteria</b>	3 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Chantix

---

## Products Affected

- CHANTIX

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Chantix Continuing Month Pak

---

### Products Affected

- CHANTIX CONTINUING MONTH PAK

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Chantix Starting Month Pak

---

### Products Affected

- CHANTIX STARTING MONTH PAK

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Chateal

---

## Products Affected

- *chateal*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Chenodal

## Products Affected

- CHENODAL

PA Criteria	Criteria Details
<b>Covered Uses</b>	For treatment of cholesterol-type gallstones in patients over 18 years of age and have tried and failed 2 years of generic Actigall (ursodiol) therapy and are not able to undergo surgery due to systemic disease or age, and for treatment of diagnosed Cerebrotendinous Xanthomatosis (CTX) in patients over 18 years of age
<b>Exclusion Criteria</b>	Intrahepatic duct calculus, Chronic constipation in patients with cholesterol gallstones, Prophylaxis of recurrent gallstones, Hyperlipidemia, Rheumatoid Arthritis
<b>Required Medical Information</b>	Prior to initial coverage for gallstone disease, a cholecystogram or other appropriate imaging studies is required to determine presence of radiolucent gallstones, stones that are transparent to x-rays. Due to high risk of hepatotoxicity and adverse effects, for the first 3 months, authorization is required each month pending hepatic function tests (for both gallstones and CTX). After initial 3 months, authorization required every 3 months for length of treatment, pending hepatic function tests. At 6 months prior to authorization, the following results are required, serum cholesterol levels, hepatic function test, and cholecystogram (monitor dissolution of stones). Safety of use beyond a total of 24 months has not been established
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 month (initial authorization), 3 month (reauthorization)
<b>Other Criteria</b>	Max authorization up to 2 years
<b>Notes/References</b>	

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

# Cholbam

---

## Products Affected

- CHOLBAM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Cholbam.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Cholbam.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Chorionic Gonadotropin

## Products Affected

- *chorionic gonadotropin intramuscular\**

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cialis

## Products Affected

- CIALIS ORAL TABLET 5 MG

PA Criteria	Criteria Details
<b>Covered Uses</b>	diagnosis of benign prostatic hyperplasia
<b>Exclusion Criteria</b>	Erectile dysfunction (ED) diagnosis is not covered except for members with ED benefit rider or Fully Insured (FI) members in the state of NY.
<b>Required Medical Information</b>	A documented diagnosis of diagnosis of benign prostatic hyperplasia
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year (30 tablets every 30 days)
<b>Other Criteria</b>	Member has failed two alpha blockers (e.g. Cardura (doxazosin), Hytrin (terazosin), Flomax (tamsulosin), Uroxatral (alfuzosin), Rapaflo (silodosin) and failed one 5-alpha reductase inhibitor (e.g. Avodart (dutasteride), Proscar (finasteride), Jalyn (dutasteride/tamsulosin).
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	Annual Review: 07/2016
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cimzia

## Products Affected

- CIMZIA SUBCUTANEOUS\* KIT 2 X  
200 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 kit Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cimzia Prefilled

## Products Affected

- CIMZIA PREFILLED

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 kit Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cimzia Starter Kit

## Products Affected

- CIMZIA STARTER KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 kit Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cinqair

---

## Products Affected

- CINQAIR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/RESP/Cinqair.html">http://www.aetna.com/products/rxnonmedicare/data/2016/RESP/Cinqair.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cinryze

---

## Products Affected

- CINRYZE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/hereditary_angioedema.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/hereditary_angioedema.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Citalopram Hydrobromide

---

## Products Affected

- *citalopram hydrobromide oral tablet 10 mg, 20 mg*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Citalopram Hydrobromide

---

## Products Affected

- *citalopram hydrobromide oral tablet 40 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Claravis

## Products Affected

- *claravis*

PA Criteria	Criteria Details
<b>Covered Uses</b>	severe recalcitrant nodular or cystic acne
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Member already has evidence of scarring and member is enrolled in the FDA iPLEDGE program (females of childbearing potential ONLY)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	5 months
<b>Other Criteria</b>	For coverage of additional quantities (greater than 2 capsules per day) member must meet the following criteria: Patient requires more than 2 capsules per day to reach the appropriate dose for weight, and this is the members FIRST course of therapy or member now requires a second course of therapy and it has been at least 8 weeks after the first course was initiated (2 month holiday), and member has recieved a cumulative dose of less than 120 mg/kg during a course of therapy lasting 20 weeks or less.
<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clarinet

---

## Products Affected

- CLARINEX ORAL TABLET

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clarinet-D 12 Hour

---

## Products Affected

- CLARINEX-D 12 HOUR

<b>QL Criteria</b>	2 TB12 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Clever Chek Auto-Code

---

### Products Affected

- CLEVER CHEK AUTO-CODE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clever Chek Auto-Code System

---

## Products Affected

- CLEVER CHEK AUTO-CODE SYSTEM

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Clever Chek Auto-Code Test

---

### Products Affected

- CLEVER CHEK AUTO-CODE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clever Chek Auto-Code Voice

---

## Products Affected

- CLEVER CHEK AUTO-CODE VOICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Clever Chek Auto-Code Voice

---

## Products Affected

- CLEVER CHEK AUTO-CODE VOICE IN VITRO

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clever Chek Test

---

## Products Affected

- CLEVER CHEK TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clever Choice Auto-Code System

---

## Products Affected

- CLEVER CHOICE AUTO-CODE SYSTEM

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Clever Choice Auto-Code Test

---

### Products Affected

- CLEVER CHOICE AUTO-CODE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clever Choice Micro System

## Products Affected

- CLEVER CHOICE MICRO SYSTEM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clever Choice Micro Test

---

## Products Affected

- CLEVER CHOICE MICRO TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clever Choice Mini System

---

## Products Affected

- CLEVER CHOICE MINI SYSTEM

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Climara

---

## Products Affected

- CLIMARA

<b>QL Criteria</b>	0.15 patch Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Climara Pro

---

## Products Affected

- CLIMARA PRO

<b>QL Criteria</b>	1 box (4 patches) Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloNIDine HCl ER

---

## Products Affected

- *clonidine hcl er*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Attention deficit hyperactivity disorder (ADHD)Note: diagnosis criteria only applies to members greater than 18 years old. Step therapy requirement applies to all member regardless of age.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	18 or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: October 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clopidogrel Bisulfate

---

## Products Affected

- *clopidogrel bisulfate*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloZAPine

---

## Products Affected

- *clozapine oral tablet dispersible 200 mg*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloZAPine

---

## Products Affected

- *clozapine oral tablet 100 mg*
- *clozapine oral tablet dispersible 100 mg*

<b>QL Criteria</b>	9 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloZAPine

---

## Products Affected

- *clozapine oral tablet 25 mg, 50 mg*
- *clozapine oral tablet dispersible 25 mg*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloZAPine

---

## Products Affected

- *clozapine oral tablet dispersible 12.5 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CloZAPine

---

## Products Affected

- *clozapine oral tablet 200 mg*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# CloZAPine

---

## Products Affected

- *clozapine oral tablet dispersible 150 mg*

<b>QL Criteria</b>	6 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clozaril

---

## Products Affected

- CLOZARIL ORAL TABLET 100 MG

<b>QL Criteria</b>	9 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Clozaril

---

## Products Affected

- CLOZARIL ORAL TABLET 25 MG

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Colazal

---

## Products Affected

- COLAZAL

<b>QL Criteria</b>	9 caps Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Colchicine

---

## Products Affected

- *colchicine oral tablet*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Colcrlys

---

## Products Affected

- COLCRYS

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Colyte with Flavor Packs

---

## Products Affected

- COLYTE WITH FLAVOR PACKS ORAL SOLUTION RECONSTITUTED 227.1 GM

<b>QL Criteria</b>	4 liters Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CombiPatch

---

## Products Affected

- COMBIPATCH

<b>QL Criteria</b>	8 patches Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



## Cometriq (100 mg Daily Dose)

### Products Affected

- COMETRIQ (100 MG DAILY DOSE)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 kits Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Cometriq (140 mg Daily Dose)

### Products Affected

- COMETRIQ (140 MG DAILY DOSE)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Cometriq (60 mg Daily Dose)

### Products Affected

- COMETRIQ (60 MG DAILY DOSE)

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 kits Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Complera

---

## Products Affected

- COMPLERA

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Concerta

---

## Products Affected

- CONCERTA ORAL TABLET  
EXTENDEDRELEASE\* 27 MG, 54 MG,  
18 MG

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Concerta

---

## Products Affected

- CONCERTA ORAL TABLET  
EXTENDEDRELEASE\* 36 MG

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Control AST

---

## Products Affected

- CONTROL AST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Control Test

---

## Products Affected

- CONTROL TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Copaxone

---

## Products Affected

- COPAXONE SUBCUTANEOUS\*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cordran

---

## Products Affected

- CORDRAN EXTERNAL TAPE

<b>QL Criteria</b>	1 roll Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Coreg CR

---

## Products Affected

- COREG CR

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Corifact

---

## Products Affected

- CORIFACT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Corlanor

## Products Affected

- CORLANOR

PA Criteria	Criteria Details
<b>Covered Uses</b>	FDA labeled use for heart failure
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of stable, symptomatic chronic heart failure with left ventricular ejection fraction less than or equal to 35%, who are in sinus rhythm with resting heart rate greater than or equal to 70 beats per minute, and who are on maximally tolerated doses of beta-blockers (bisoprolol/bisoprolol-HCTZ, carvedilol, carvedilol CR, metoprolol succinate/metoprolol succinate-HCTZ, nebivolol) or have a documented contraindication to beta-blocker use.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: July 25, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cosentyx

---

## Products Affected

- COSENTYX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cosentyx Sensoready Pen

---

## Products Affected

- COSENTYX SENSOREADY PEN  
SUBCUTANEOUS\* 150 MG/ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cotellic

---

## Products Affected

- COTELLIC

<b>QL Criteria</b>	63 tablets Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Cozaar

---

## Products Affected

- COZAAR ORAL TABLET 50 MG, 25 MG

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Crestor

---

## Products Affected

- CRESTOR

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Cryselle-28

---

### Products Affected

- *cryselle-28*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CVS Nicotine

---

## Products Affected

- *cvs nicotine transdermal patch 24 hr 7 mg/24hr, 14 mg/24hr*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CVS Nicotine Polacrilex

---

## Products Affected

- *cvs nicotine polacrilex mouth/throat lozenge 4 mg*

<b>QL Criteria</b>	20 EA Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# CVS NTS Step 1

---

## Products Affected

- *cvs nts step 1*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cyclafem 1/35

---

## Products Affected

- *cyclafem 1/35*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cyclafem 7/7/7

---

## Products Affected

- *cyclafem 7/7/7*

<b>QL Criteria</b>	1.5 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Cyclessa

---

## Products Affected

- CYCLESSA

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cycloset

---

## Products Affected

- CYCLOSET

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cymbalta

---

## Products Affected

- CYMBALTA ORAL CAPSULE  
DELAYED RELEASE PARTICLES 30  
MG

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cymbalta

---

## Products Affected

- CYMBALTA ORAL CAPSULE  
DELAYED RELEASE PARTICLES 20  
MG

<b>QL Criteria</b>	2 CAPS Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cymbalta

---

## Products Affected

- CYMBALTA ORAL CAPSULE  
DELAYED RELEASE PARTICLES 60  
MG

<b>QL Criteria</b>	1 CAPS Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cystagon

---

## Products Affected

- CYSTAGON

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Cystaran

---

## Products Affected

- CYSTARAN

<b>QL Criteria</b>	2 ML Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Daklinza

---

## Products Affected

- DAKLINZA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Daklinza

---

## Products Affected

- DAKLINZA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 EA Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Daliresp

---

## Products Affected

- DALIRESP

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Severe COPD (GOLD stage 3 or 4)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of severe (Stage III) or very severe (StageIV) chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Step Therapy
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Darifenacin Hydrobromide ER

---

## Products Affected

- *darifenacin hydrobromide er*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dasetta 1/35

---

## Products Affected

- *dasetta 1/35*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Dasetta 7/7/7

---

### Products Affected

- *dasetta 7/7/7*

<b>QL Criteria</b>	1.5 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Daysee

---

## Products Affected

- *daysee*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Daytrana

---

## Products Affected

- DAYTRANA

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Deblitane

---

## Products Affected

- DEBLITANE

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Delzicol

---

## Products Affected

- DELZICOL

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Depo-Provera

---

## Products Affected

- DEPO-PROVERA INTRAMUSCULAR\*  
SUSPENSION 150 MG/ML

<b>QL Criteria</b>	1 syringe Per 90 dayss
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Depo-SubQ Provera 104

---

## Products Affected

- DEPO-SUBQ PROVERA 104  
SUBCUTANEOUS\* SUSPENSION

<b>QL Criteria</b>	1 syringe Per 90 dayss
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Descovy

---

## Products Affected

- DESCOVY

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Desloratadine

---

## Products Affected

- *desloratadine*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Desogen

---

## Products Affected

- DESOGEN

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Desoxyn

---

## Products Affected

- DESOXYN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Attention deficit hyperactivity disorder (ADHD), Narcolepsy
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of ADHD or Narcolepsy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tablets Per 1 DAYS
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Desvenlafaxine Fumarate ER

---

## Products Affected

- *desvenlafaxine fumarate er*

<b>QL Criteria</b>	1 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Detrol LA

---

## Products Affected

- DETROL LA

<b>QL Criteria</b>	1 capsule Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dexedrine

## Products Affected

- DEXEDRINE ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Attention deficit disorder, Attention deficit hyperactivity disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	3 CAPS Per 1 DAYS
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dexedrine

---

## Products Affected

- *dexedrine oral tablet*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Attention deficit hyperactivity disorder (ADHD), Narcolepsy
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of ADHD or Narcolepsy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tabs Per 1 DAYS
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dexilant

## Products Affected

- DEXILANT

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of one of the following: Gastroesophageal reflux disease, Complications related to GERD (e.g. esophageal strictures, Barrett's Esophagus), Peptic ulcer disease, Treatment and prevention of gastroduodenal ulcers associated with NSAIDs, Zollinger-Ellison Syndrome, or Helicobacter pylori eradication (Additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: November 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dexmethylphenidate HCl

---

## Products Affected

- *dexmethylphenidate hcl*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dexmethylphenidate HCl ER

---

## Products Affected

- *dexmethylphenidate hcl er oral capsule*  
*extended release 24 hour 30 mg, 10 mg, 5*  
*mg, 15 mg, 40 mg*

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dexmethylphenidate HCl ER

---

## Products Affected

- *dexmethylphenidate hcl er oral capsule  
extended release 24 hour 20 mg*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dextroamphetamine Sulfate

---

## Products Affected

- *dextroamphetamine sulfate oral tablet*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Dextroamphetamine Sulfate

---

## Products Affected

- *dextroamphetamine sulfate oral solution*

<b>QL Criteria</b>	40 milliliters Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dextroamphetamine Sulfate ER

## Products Affected

- *dextroamphetamine sulfate er*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Attention deficit disorder, Attention deficit hyperactivity disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 capsules Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diazepam

---

## Products Affected

- *diazepam gel*

<b>QL Criteria</b>	1 box Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diclegis

---

## Products Affected

- DICLEGIS

<b>QL Criteria</b>	4 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diclofenac Sodium

---

## Products Affected

- *diclofenac sodium transdermal gel 1 %*

<b>QL Criteria</b>	200 GM Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diclofenac Sodium

---

## Products Affected

- *diclofenac sodium transdermal solution*

<b>QL Criteria</b>	10 ML Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dificid

---

## Products Affected

- DIFICID

<b>QL Criteria</b>	20 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dihydroergotamine Mesylate

---

## Products Affected

- *dihydroergotamine mesylate nasal*

<b>QL Criteria</b>	8 bottles Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Diltiazem CD

---

## Products Affected

- *diltiazem cd oral capsule extended release*  
24 hour 180 mg, 120 mg

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem CD

---

## Products Affected

- *diltiazem cd oral capsule extended release*  
24 hour 240 mg

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem HCl ER

---

## Products Affected

- *diltiazem hcl er oral capsule extended release 24 hour 120 mg, 180 mg*
- *diltiazem hcl er oral capsule extended release 12 hour 120 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem HCl ER

---

## Products Affected

- *diltiazem hcl er oral capsule extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem HCl ER Beads

---

## Products Affected

- *diltiazem hcl er beads oral capsule*  
*extended release 24 hour 120 mg, 180 mg,*  
*300 mg, 360 mg, 420 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem HCl ER Beads

---

## Products Affected

- *diltiazem hcl er beads oral capsule  
extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem HCl ER Coated Beads

---

## Products Affected

- *diltiazem hcl er coated beads oral capsule  
extended release 24 hour 360 mg, 180 mg,  
300 mg, 120 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diltiazem HCl ER Coated Beads

---

## Products Affected

- *diltiazem hcl er coated beads oral capsule  
extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Dilt-XR

---

## Products Affected

- *dilt-xr oral capsule extended release 24 hour 120 mg, 180 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dilt-XR

---

## Products Affected

- *dilt-xr oral capsule extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diovan

---

## Products Affected

- DIOVAN

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Diovan HCT

---

## Products Affected

- DIOVAN HCT

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dipentum

---

## Products Affected

- DIPENTUM

<b>QL Criteria</b>	4 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ditropan XL

---

## Products Affected

- DITROPAN XL

<b>QL Criteria</b>	2 tablets Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dolophine

---

## Products Affected

- DOLOPHINE

<b>QL Criteria</b>	6 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Donepezil HCl

## Products Affected

- *donepezil hcl oral tablet 5 mg, 23 mg*
- *donepezil hcl oral tablet dispersible*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Alzheimer's Disease
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
<b>Age Restrictions</b>	less than 40 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Donepezil HCl

---

## Products Affected

- *donepezil hcl oral tablet 10 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Alzheimer's Disease
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
<b>Age Restrictions</b>	less than 40 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dronabinol

---

## Products Affected

- *dronabinol*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Anorexia associated with weight loss in patients with AIDS, Chemotherapy-induced nausea and vomiting
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Anorexia associated with weight loss in patients with AIDS, or Chemotherapy-induced nausea and vomiting
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Drospirenone-Ethinyl Estradiol

---

## Products Affected

- *drospirenone-ethinyl estradiol oral tablet*  
3-0.03 mg

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Duavee

---

## Products Affected

- DUAVEE

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Duetact

---

## Products Affected

- DUETACT

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dulera

---

## Products Affected

- DULERA

<b>QL Criteria</b>	1 inhaler Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# DULoxetine HCl

---

## Products Affected

- *duloxetine hcl oral capsule delayed release particles 30 mg, 60 mg, 40 mg*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# DULoxetine HCl

---

## Products Affected

- *duloxetine hcl oral capsule delayed release particles 20 mg*

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Duragesic-100

---

## Products Affected

- DURAGESIC-100

<b>QL Criteria</b>	20 patches Per 30 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Duragesic-12

---

## Products Affected

- DURAGESIC-12

<b>QL Criteria</b>	20 patches Per 30 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Duragesic-25

---

## Products Affected

- DURAGESIC-25

<b>QL Criteria</b>	20 patches Per 30 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Duragesic-50

---

## Products Affected

- DURAGESIC-50

<b>QL Criteria</b>	20 patches Per 30 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Duragesic-75

---

## Products Affected

- DURAGESIC-75

<b>QL Criteria</b>	20 patches Per 30 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dutasteride

---

## Products Affected

- *dutasteride*

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dyanavel XR

## Products Affected

- DYANAVEL XR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Attention deficit hyperactivity disorder (ADHD)
<b>Exclusion Criteria</b>	Documentation of a diagnosis of either adult ADHD or of childhood ADHD onset with history of previous treatment and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment)
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	240 ML Per 30 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Dysport

---

## Products Affected

- DYSPOORT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/botulinum_toxin.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/botulinum_toxin.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Easy Plus II Glucose System

---

## Products Affected

- *easy plus ii glucose system*

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Easy Plus II Glucose Test

---

## Products Affected

- *easy plus ii glucose test*

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Easy Step Glucose Monitor

---

## Products Affected

- EASY STEP GLUCOSE MONITOR  
DEVICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Easy Step Test

---

## Products Affected

- EASY STEP TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Easy Talk Blood Glucose System

---

## Products Affected

- *easy talk blood glucose system device*

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Easy Talk Blood Glucose Test

---

## Products Affected

- *easy talk blood glucose test*

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Easy Touch Test

---

## Products Affected

- EASY TOUCH TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Easy Trak Blood Glucose Test

---

## Products Affected

- *easy trak blood glucose test*

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# EasyGluco

---

## Products Affected

- EASYGLUCO IN VITRO

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EasyMax 15 Test

---

## Products Affected

- EASYMAX 15 TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EasyMax L Blood Glucose

---

## Products Affected

- EASYMAX L BLOOD GLUCOSE DEVICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EasyMax N Blood Glucose

---

## Products Affected

- EASYMAX N BLOOD GLUCOSE  
DEVICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EasyMax NG Blood Glucose

---

## Products Affected

- EASYMAX NG BLOOD GLUCOSE DEVICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EASYMax Test

---

## Products Affected

- EASYMAX TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EasyMax V Blood Glucose

---

## Products Affected

- EASYMAX V BLOOD GLUCOSE DEVICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EasyMax V2 Blood Glucose

---

## Products Affected

- EASYMAX V2 BLOOD GLUCOSE DEVICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# EasyPlus Blood Glucose Test

---

## Products Affected

- *easyplus blood glucose test*

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EasyPRO Plus

---

## Products Affected

- EASYPRO PLUS IN VITRO

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Edarbi

---

## Products Affected

- EDARBI

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Edarbyclor

---

## Products Affected

- EDARBYCLOR

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Edurant

---

## Products Affected

- EDURANT

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Effexor XR

---

## Products Affected

- EFFEXOR XR ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 150  
MG

<b>QL Criteria</b>	2 caps Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Effexor XR

---

## Products Affected

- EFFEXOR XR ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 75  
MG, 37.5 MG

<b>QL Criteria</b>	1 caps Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Effient

## Products Affected

- EFFIENT

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acute coronary syndrome (ACS), which includes angina or myocardial infarction [MI].
<b>Exclusion Criteria</b>	History of Stroke or TIA
<b>Required Medical Information</b>	Member has a documented diagnosis of acute coronary syndrome (ACS), which includes angina or myocardial infarction [MI]) managed by percutaneous coronary intervention (PCI) AND Member has no prior history of stroke or transient ischemic attack (TIA)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Elaprase

---

## Products Affected

- ELAPRASE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Elelyso

---

## Products Affected

- ELELYSO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Element Plus

---

## Products Affected

- ELEMENT PLUS

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Element Test

---

## Products Affected

- ELEMENT TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Elestrin

---

## Products Affected

- ELESTRIN

<b>QL Criteria</b>	52 GM Per 30 days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Elidel

## Products Affected

- ELIDEL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of mild to moderate atopic dermatitis (eczema) in patients less than 2 years of age for short-term use (up to 3 months)(Note: requirement of a trial of topical corticosteroid is not required), or a documented diagnosis of atopic dermatitis (eczema) in an adult or child 2 years of age or older with one of the following: A documented contraindication, intolerance or allergy to one preferred alternative topical corticosteroid indicated for the patient's condition, or a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition, or treatment is in an area at high risk for skin atrophy such as face, eyelids, or genital areas.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Elinest

---

## Products Affected

- *elinest*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ella

---

## Products Affected

- ELLA

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Eloctate

---

## Products Affected

- ELOCTATE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Embeda

---

## Products Affected

- EMBEDA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Step Therapy
<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Embrace Blood Glucose Monitor

---

## Products Affected

- EMBRACE BLOOD GLUCOSE MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Embrace Blood Glucose Test

---

## Products Affected

- EMBRACE BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Emend

---

## Products Affected

- EMEND ORAL CAPSULE 40 MG, 125 MG, 80 MG

<b>QL Criteria</b>	9 capsules Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Emend

---

## Products Affected

- EMEND ORAL CAPSULE 80 & 125 MG

<b>QL Criteria</b>	3 tri-packs Per 30 months
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EMLA

## Products Affected

- EMLA

PA Criteria	Criteria Details
<b>Covered Uses</b>	***AUTHORIZATION IS NOT REQUIRED FOR LESS THAN 50 GRAMS OF LIDOCAINE EVERY 30 DAYS*** For quantities over 50 grams every 30 days, there must be a documented temporary need for topical anesthetic in either of the following situations: Normal, intact skin for local analgesia, or Genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia
<b>Exclusion Criteria</b>	Documentation of any of the following: Planned area of application includes non-intact skin, Sensitivity to amide-type local anesthetics or any other component of the product, Planned use on large surface area of the body or for a period of time over 3 hours as this can lead to increased toxicity, the medication is being used in conjunction with a cosmetic procedure (i.e. hair removal), Use in situations where the drug may migrate into the middle ear, beyond the tympanic membrane, History of methemoglobinemia, or if the product will be compounded with other products that would alter the total dose/dosage form being administered
<b>Required Medical Information</b>	A documented need for topical anesthetic in either of the following situations: Normal, intact skin for local analgesia, or Genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	*Topical lidocaine/prilocaine cream is used for temporary anesthesia. Prescription renewals for longer than 3 months require clinical documentation of medical necessity. Due to Safety Concerns higher quantities and prolonged use are not recommended. Renewal Duration: 3 months *Up to an additional 30 grams per 30 days. Higher additional quantities are not approvable.

<b>QL Criteria</b>	30 GM Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: October 03, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Emoquette

---

## Products Affected

- *emoquette*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Emsam

---

## Products Affected

- EMSAM

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Emtriva

---

## Products Affected

- EMTRIVA ORAL CAPSULE

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Enablex

---

## Products Affected

- ENABLEX

<b>QL Criteria</b>	1 tablet Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Enablex

---

## Products Affected

- ENABLEX

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Enbrel

---

## Products Affected

- ENBREL SUBCUTANEOUS\* 25  
MG/0.5ML

<b>QL Criteria</b>	4 syringes Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Enbrel

---

## Products Affected

- ENBREL SUBCUTANEOUS\* 50 MG/ML
- ENBREL SUBCUTANEOUS\* KIT

<b>QL Criteria</b>	8 syringes Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Enbrel SureClick

---

## Products Affected

- ENBREL SURECLICK  
SUBCUTANEOUS\*

<b>QL Criteria</b>	8 syringes Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Enjuvia

---

## Products Affected

- ENJUVIA ORAL TABLET 0.45 MG, 0.625 MG, 0.3 MG, 0.9 MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Enjuvia

---

## Products Affected

- ENJUVIA ORAL TABLET 1.25 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Enoxaparin Sodium

---

## Products Affected

- *enoxaparin sodium*

<b>QL Criteria</b>	2 syringes Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Enpresse-28

---

## Products Affected

- *enpresse-28*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Entecavir

---

## Products Affected

- *entecavir*

<b>QL Criteria</b>	1 EA Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Entecavir

---

## Products Affected

- *entecavir*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Entresto

---

## Products Affected

- ENTRESTO

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 08/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Entyvio

---

## Products Affected

- ENTYVIO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Epclusa

## Products Affected

- EPCLUSA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Epiduo Forte

---

## Products Affected

- EPIDUO FORTE

<b>QL Criteria</b>	45 grams Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EPINEPHrine

---

## Products Affected

- *epinephrine injection 0.15 mg/0.15ml, 0.3 mg/0.3ml*

<b>QL Criteria</b>	2 pens Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Epogen

## Products Affected

- EPOGEN INJECTION SOLUTION 20000 UNIT/ML, 4000 UNIT/ML, 10000 UNIT/ML, 2000 UNIT/ML, 3000 UNIT/ML

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Erythropoiesis_Stimulating_Agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Erythropoiesis_Stimulating_Agents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Eprosartan Mesylate

---

## Products Affected

- *eprosartan mesylate*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EQ Nicotine

---

## Products Affected

- *eq nicotine transdermal*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EQL Nicotine

---

## Products Affected

- *eql nicotine transdermal*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Erivedge

---

## Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 capsule Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Errin

---

## Products Affected

- *errin*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Esbriet

---

## Products Affected

- ESBRIET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Idiopathic_Pulmonary_Fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Idiopathic_Pulmonary_Fibrosis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	9 EA Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Escitalopram Oxalate

---

## Products Affected

- *escitalopram oxalate oral tablet 20 mg, 5 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Escitalopram Oxalate

---

## Products Affected

- *escitalopram oxalate oral solution*

<b>QL Criteria</b>	20 ml Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Escitalopram Oxalate

---

## Products Affected

- *escitalopram oxalate oral tablet 10 mg*

<b>QL Criteria</b>	1.5 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Esomeprazole Magnesium

---

## Products Affected

- *esomeprazole magnesium*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Estraderm

---

## Products Affected

- ESTRADERM

<b>QL Criteria</b>	8 patches Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Estradiol

---

## Products Affected

- *estradiol transdermal patch biweekly*

<b>QL Criteria</b>	8 patches Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Estradiol

---

## Products Affected

- *estradiol transdermal patch weekly 0.05 mg/24hr*

<b>QL Criteria</b>	4 patches Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Estradiol

---

## Products Affected

- *estradiol transdermal patch weekly 0.06 mg/24hr, 0.025 mg/24hr, 0.0375 mg/24hr, 0.1 mg/24hr, 0.075 mg/24hr*

<b>QL Criteria</b>	1 box (4 patches) Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Estradiol-Norethindrone Acet

---

## Products Affected

- *estradiol-norethindrone acet*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Estrogel

---

## Products Affected

- ESTROGEL

<b>QL Criteria</b>	50 grams Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Estrostep Fe

---

## Products Affected

- ESTROSTEP FE

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Eszopiclone

---

## Products Affected

- *eszopiclone*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Euflexxa

---

## Products Affected

- EUFLEXXA INTRA-ARTICULAR\*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Evamist

---

## Products Affected

- EVAMIST

<b>QL Criteria</b>	2 bottles Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Evekeo

---

## Products Affected

- EVEKEO

<b>QL Criteria</b>	120 tablets Per 30 Days
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EvenCare + Blood Glucose Test

---

## Products Affected

- EVENCARE + BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EvenCare Blood Glucose Test

---

## Products Affected

- EVENCARE BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EvenCare G2 Monitor

---

## Products Affected

- EVENCARE G2 MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EvenCare G2 Test

---

## Products Affected

- EVENCARE G2 TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EvenCare G3 Monitor

---

## Products Affected

- EVENCARE G3 MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# EvenCare G3 Test

---

## Products Affected

- EVENCARE G3 TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Evolution Autocode

---

## Products Affected

- EVOLUTION AUTOCODE IN VITRO

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Evolution Autocode

---

## Products Affected

- EVOLUTION AUTOCODE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Evoxac

---

## Products Affected

- EVOXAC

<b>QL Criteria</b>	3 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Exalgo

---

## Products Affected

- EXALGO ORAL 12 MG, 32 MG, 8 MG

<b>QL Criteria</b>	2 tablets Per 2 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Exalgo

---

## Products Affected

- EXALGO ORAL 16 MG

<b>QL Criteria</b>	4 tablets Per 2 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Exelon

---

## Products Affected

- EXELON TRANSDERMAL
- EXELON ORAL CAPSULE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Alzheimer's Disease
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
<b>Age Restrictions</b>	less than 40 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Exforge

---

## Products Affected

- EXFORGE

<b>QL Criteria</b>	1 TABS Per 1 DAY
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Exjade

---

## Products Affected

- EXJADE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Antidotes.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Antidotes.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Extavia

## Products Affected

- EXTAVIA SUBCUTANEOUS\* KIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 box (15 vials) Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Ez Smart Blood Glucose Test

---

## Products Affected

- EZ SMART BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ez Smart Monitoring System

---

## Products Affected

- EZ SMART MONITORING SYSTEM

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ez Smart Plus Glucose Test

---

## Products Affected

- EZ SMART PLUS GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ez Smart Plus Monitoring Sys

---

## Products Affected

- EZ SMART PLUS MONITORING SYS

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fabrazyme

---

## Products Affected

- FABRAZYME

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FaLessa

---

## Products Affected

- FALESSA ORAL KIT 20-1-0.1 MCG-MG

<b>QL Criteria</b>	1.5 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Falmina

---

## Products Affected

- *falmina*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Famciclovir

---

## Products Affected

- *famciclovir oral tablet 250 mg, 125 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Famciclovir

---

## Products Affected

- *famciclovir oral tablet 500 mg*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Famvir

---

## Products Affected

- FAMVIR ORAL TABLET 500 MG

<b>QL Criteria</b>	3 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Famvir

---

## Products Affected

- FAMVIR ORAL TABLET 250 MG, 125 MG

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fanapt

---

## Products Affected

- FANAPT

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fanapt Titration Pack

---

## Products Affected

- FANAPT TITRATION PACK

<b>QL Criteria</b>	0.27 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Farxiga

---

## Products Affected

- FARXIGA

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Farydak

---

## Products Affected

- FARYDAK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	12 EA Per 30 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FazaClo

---

## Products Affected

- FAZACLO ORAL TABLET  
DISPERSIBLE 200 MG

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# FazaClo

---

## Products Affected

- FAZACLO ORAL TABLET  
DISPERSIBLE 150 MG

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FazaClo

---

## Products Affected

- FAZACLO ORAL TABLET  
DISPERSIBLE 25 MG

<b>QL Criteria</b>	3 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FazaClo

---

## Products Affected

- FAZACLO ORAL TABLET  
DISPERSIBLE 12.5 MG

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FazaClo

---

## Products Affected

- FAZACLO ORAL TABLET  
DISPERSIBLE 100 MG

<b>QL Criteria</b>	9 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Feiba

---

## Products Affected

- FEIBA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Feiba NF

---

## Products Affected

- FEIBA NF

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Feiba VH Immuno

---

## Products Affected

- FEIBA VH IMMUNO

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Felodipine ER

---

## Products Affected

- *felodipine er*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Femcon Fe

---

## Products Affected

- FEMCON FE

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Femhrt Low Dose

---

## Products Affected

- FEMHRT LOW DOSE

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Femring

---

## Products Affected

- FEMRING

<b>QL Criteria</b>	1 ring Per 90 dayss
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fenofibrate

---

## Products Affected

- *fenofibrate oral tablet 48 mg, 54 mg, 145 mg, 160 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fenofibrate

---

## Products Affected

- *fenofibrate oral capsule*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fenofibrate Micronized

---

## Products Affected

- *fenofibrate micronized*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fenofibric Acid

---

## Products Affected

- *fenofibric acid oral tablet*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FentaNYL

---

## Products Affected

- *fentanyl*

<b>QL Criteria</b>	20 patches Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# FentaNYL Citrate

## Products Affected

- *fentanyl citrate buccal*

PA Criteria	Criteria Details
<b>Covered Uses</b>	For pain due to malignant diagnosis only
<b>Exclusion Criteria</b>	Use in non-malignant pain
<b>Required Medical Information</b>	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))

<b>QL Criteria</b>	4 lozenges Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: October 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fentora

---

## Products Affected

- FENTORA BUCCAL TABLET 200 MCG, 600 MCG, 800 MCG, 400 MCG, 100 MCG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	For pain due to malignant diagnosis only
<b>Exclusion Criteria</b>	Use in non-malignant pain
<b>Required Medical Information</b>	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))</p>
<b>QL Criteria</b>	4 tabs Per 1 DAYS
<b>Notes/References</b>	
<b>Revision Date</b>	<p>Prior Authorization: October 10, 2016  Step Therapy: August 25, 2015  Quantity Limits: August 25, 2015</p>

# Ferriprox

---

## Products Affected

- FERRIPROX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Antidotes.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Antidotes.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fetzima

---

## Products Affected

- FETZIMA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Major depressive disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of major depressive disorder
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 CP24 Per 1 DAYS
<b>Notes/References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: October 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fetzima Titration

---

## Products Affected

- FETZIMA TITRATION

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Major depressive disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of major depressive disorder
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 CP24 Per 1 DAYS
<b>Notes/References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: October 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fibricor

---

## Products Affected

- FIBRICOR

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Fifty50 Glucose Test 2.0

---

## Products Affected

- FIFTY50 GLUCOSE TEST 2.0

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Firazyr

## Products Affected

- FIRAZYR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/hereditary_angioedema.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/hereditary_angioedema.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 syringes Per 1 fill
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Flebogamma

---

## Products Affected

- FLEBOGAMMA INTRAVENOUS\*  
SOLUTION 0.5 GM/10ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Flebogamma DIF

## Products Affected

- FLEBOGAMMA DIF

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Flolan

---

## Products Affected

- FLOLAN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Flovent Diskus

---

## Products Affected

- FLOVENT DISKUS

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Asthma
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy. Medical Exception for Flovent Diskus and Flovent HFA: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
QL Criteria	2 diskus Per 1 month
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Flovent HFA

---

## Products Affected

- FLOVENT HFA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Asthma
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Asthma
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	Step Therapy. Medical Exception for Flovent Diskus and Flovent HFA: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Flunisolide

---

## Products Affected

- *flunisolide nasal solution 25 mcg/act (0.025%)*

<b>QL Criteria</b>	2 bottles Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# FLUoxetine HCl

---

## Products Affected

- *fluoxetine hcl oral capsule delayed release*

<b>QL Criteria</b>	4 capsules Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FLUoxetine HCl

---

## Products Affected

- *fluoxetine hcl oral tablet 10 mg*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FLUoxetine HCl

---

## Products Affected

- *fluoxetine hcl oral capsule 20 mg*

<b>QL Criteria</b>	4 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FLUoxetine HCl

---

## Products Affected

- *fluoxetine hcl oral capsule 40 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FLUoxetine HCl

---

## Products Affected

- *fluoxetine hcl oral tablet 60 mg*

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FLUoxetine HCl

---

## Products Affected

- *fluoxetine hcl oral capsule 10 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FLUoxetine HCl

---

## Products Affected

- *fluoxetine hcl oral tablet 20 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fluvastatin Sodium

---

## Products Affected

- *fluvastatin sodium*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Fluvastatin Sodium ER

---

## Products Affected

- *fluvastatin sodium er*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FluvoxaMINE Maleate

---

## Products Affected

- *fluvoxamine maleate oral tablet 25 mg, 50 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FluvoxaMINE Maleate

---

## Products Affected

- *fluvoxamine maleate oral tablet 100 mg*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fluvoxamine Maleate ER

---

## Products Affected

- *fluvoxamine maleate er*

<b>QL Criteria</b>	2 cap Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Focalin

---

## Products Affected

- FOCALIN

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Focalin XR

---

## Products Affected

- FOCALIN XR

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Follistim AQ

---

## Products Affected

- FOLLISTIM AQ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fondaparinux Sodium

---

## Products Affected

- *fondaparinux sodium*

<b>QL Criteria</b>	2 syringes Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# FORA D10 2-in-1 Monitor

---

## Products Affected

- FORA D10 2-IN-1 MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA D10 Blood Glucose Test

---

## Products Affected

- FORA D10 BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA D15g 2-in-1 Monitor

---

## Products Affected

- FORA D15G 2-IN-1 MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA D15g Blood Glucose Test

---

## Products Affected

- FORA D15G BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA D20 2-in-1 Monitor

---

## Products Affected

- FORA D20 2-IN-1 MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA D20 Blood Glucose Test

---

## Products Affected

- FORA D20 BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA G20 Blood Glucose Test

---

## Products Affected

- FORA G20 BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA G30a Blood Glucose System

---

## Products Affected

- FORA G30A BLOOD GLUCOSE SYSTEM

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# FORA G30a Blood Glucose Test

---

## Products Affected

- FORA G30A BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fora GD20 Blood Glucose System

---

## Products Affected

- FORA GD20 BLOOD GLUCOSE SYSTEM

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fora GD20 Test

---

## Products Affected

- FORA GD20 TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA V10 Blood Glucose System

---

## Products Affected

- FORA V10 BLOOD GLUCOSE SYSTEM

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA V10 Blood Glucose Test

---

## Products Affected

- FORA V10 BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA V12 Blood Glucose System

---

## Products Affected

- FORA V12 BLOOD GLUCOSE SYSTEM

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA V12 Blood Glucose Test

---

## Products Affected

- FORA V12 BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA V20 Blood Glucose System

---

## Products Affected

- FORA V20 BLOOD GLUCOSE SYSTEM

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# FORA V20 Blood Glucose Test

---

## Products Affected

- FORA V20 BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA V30a Blood Glucose System

---

## Products Affected

- FORA V30A BLOOD GLUCOSE SYSTEM DEVICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FORA V30a Blood Glucose Test

---

## Products Affected

- FORA V30A BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ForaCare GD40 Monitor

---

## Products Affected

- FORACARE GD40 MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ForaCare GD40 Test

---

## Products Affected

- FORACARE GD40 TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ForaCare premium V10

---

## Products Affected

- FORACARE PREMIUM V10

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ForaCare premium V10 Test

---

## Products Affected

- FORACARE PREMIUM V10 TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Foradil Aerolizer

---

## Products Affected

- FORADIL AEROLIZER

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Forteo

---

## Products Affected

- FORTEO SUBCUTANEOUS\*  
SOLUTION 600 MCG/2.4ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_disease_agents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fortical

---

## Products Affected

- *fortical*

<b>QL Criteria</b>	1 bottle Per 1 month
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fosamax

---

## Products Affected

- FOSAMAX ORAL TABLET 70 MG

<b>QL Criteria</b>	0.15 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fosamax Plus D

---

## Products Affected

- FOSAMAX PLUS D

<b>QL Criteria</b>	4 tablets Per 1 month
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fragmin

---

## Products Affected

- FRAGMIN

<b>QL Criteria</b>	2 syringes Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FreeStyle Flash System

## Products Affected

- FREESTYLE FLASH SYSTEM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYSS
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FreeStyle Freedom Lite

---

## Products Affected

- FREESTYLE FREEDOM LITE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FreeStyle InsuLinx System

## Products Affected

- FREESTYLE INSULINX SYSTEM

PA Criteria	Criteria Details
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# FreeStyle InsuLinx Test

---

## Products Affected

- FREESTYLE INSULINX TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FreeStyle Lite

## Products Affected

- FREESTYLE LITE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FreeStyle Lite Test

---

## Products Affected

- FREESTYLE LITE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# FreeStyle System

## Products Affected

- FREESTYLE SYSTEM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Frova

---

## Products Affected

- FROVA

<b>QL Criteria</b>	9 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Frovatriptan Succinate

---

## Products Affected

- *frovatriptan succinate*

<b>QL Criteria</b>	9 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fulyzaq

## Products Affected

- FULYZAQ

PA Criteria	Criteria Details
Covered Uses	Diarrhea
Exclusion Criteria	
Required Medical Information	Fulyzaq is covered for adult members who meet the following criteria: (1) Diagnosis of noninfectious diarrhea associated with HIV/AIDS infection that has lasted at least for one month, and (2) Currently taking antiviral therapy with adherence of at least 80%, and (3) Documentation of unsatisfactory effects with, intolerance to, or inability to take at least one anti-motility agent (loperamide, diphenoxylate/atropine, bismuth subsalicylate) or one or more watery bowel movements per day without regular ADM use.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	Annual Review: 03/2016
Revision Date	Prior Authorization: October 25, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Fycompa

---

## Products Affected

- FYCOMPA ORAL TABLET

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	Annual Review: 03/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Gabapentin

---

## Products Affected

- *gabapentin oral capsule*

<b>QL Criteria</b>	6 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gabapentin

---

## Products Affected

- *gabapentin oral solution 250 mg/5ml*

<b>QL Criteria</b>	40 ml Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gabapentin

---

## Products Affected

- *gabapentin oral tablet*

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gabril

---

## Products Affected

- GABITRIL ORAL TABLET 16 MG

<b>QL Criteria</b>	3 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gabitril

---

## Products Affected

- GABITRIL ORAL TABLET 12 MG, 4 MG

<b>QL Criteria</b>	4 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gabril

---

## Products Affected

- GABITRIL ORAL TABLET 2 MG

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Galantamine Hydrobromide

---

## Products Affected

- *galantamine hydrobromide oral tablet*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Alzheimer's Disease
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
<b>Age Restrictions</b>	less than 40 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gammagard

---

## Products Affected

- GAMMAGARD

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Gammagard S/D Less IgA

---

## Products Affected

- GAMMAGARD S/D LESS IGA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gammaked

---

## Products Affected

- GAMMAKED

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gammalex

## Products Affected

- GAMMAPLEX

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gamunex-C

---

## Products Affected

- GAMUNEX-C

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ganirelix Acetate

---

## Products Affected

- *ganirelix acetate*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gattex

---

## Products Affected

- GATTEX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Gattex.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Gattex.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 kit Per 1 month
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# GaviLyte-C

---

## Products Affected

- *gavilyte-c*

<b>QL Criteria</b>	4 liters Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# GaviLyte-G

---

## Products Affected

- *gavilyte-g*

<b>QL Criteria</b>	4 liters Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# GE100 Blood Glucose Test

---

## Products Affected

- *ge100 blood glucose test*

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gel-One

---

## Products Affected

- GEL-ONE INTRA-ARTICULAR\*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gelsyn-3

---

## Products Affected

- GELSYN-3

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Generess FE

---

## Products Affected

- GENERESS FE

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Genotropin

---

## Products Affected

- GENOTROPIN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Genotropin MiniQuick

---

## Products Affected

- GENOTROPIN MINIQUICK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Genvoya

---

## Products Affected

- GENVOYA

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Geodon

---

## Products Affected

- GEODON ORAL

<b>QL Criteria</b>	2 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Gianvi

---

## Products Affected

- *gianvi*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Giazo

---

## Products Affected

- GIAZO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Ulcerative colitis
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild to moderate ulcerative colitis in males. Note: Per Product Labeling, Giazo effectiveness was not demonstrated in female patients.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Step Therapy
<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gildagia

---

## Products Affected

- *gildagia*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Gildess 1.5/30

---

### Products Affected

- *gildess 1.5/30*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Gildess 1/20

---

### Products Affected

- *gildess 1/20*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Gildess FE 1.5/30

---

### Products Affected

- *gildess fe 1.5/30*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Gildess FE 1/20

---

### Products Affected

- *gildess fe 1/20*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gilenya

---

## Products Affected

- GILENYA

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Gilotrif

## Products Affected

- GILOTRIF

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gleevec

---

## Products Affected

- GLEEVEC ORAL TABLET 100 MG

<b>QL Criteria</b>	3 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gleevec

---

## Products Affected

- GLEEVEC ORAL TABLET 400 MG

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# GlucaGen Diagnostic

---

## Products Affected

- GLUCAGEN DIAGNOSTIC

<b>QL Criteria</b>	1 vial Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# GlucaGen HypoKit

---

## Products Affected

- GLUCAGEN HYPOKIT

<b>QL Criteria</b>	1 box Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Glucocard 01 Blood Glucose

---

## Products Affected

- GLUCOCARD 01 BLOOD GLUCOSE DEVICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Glucocard 01 Sensor Plus

---

## Products Affected

- GLUCOCARD 01 SENSOR PLUS

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Glucocard Expression Test

---

## Products Affected

- GLUCOCARD EXPRESSION TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Glucocard Vital Test

---

## Products Affected

- GLUCOCARD VITAL TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Glucocard X-Sensor

---

## Products Affected

- GLUCOCARD X-SENSOR

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# GlucoCom Blood Glucose Monitor

---

## Products Affected

- GLUCOCOM BLOOD GLUCOSE MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# GlucoCom Test

---

## Products Affected

- GLUCOCOM TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Glyxambi

---

## Products Affected

- GLYXAMBI

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gonal-f

---

## Products Affected

- GONAL-F

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gonal-f RFF

---

## Products Affected

- GONAL-F RFF

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gonal-f RFF Pen

---

## Products Affected

- GONAL-F RFF PEN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Gonal-f RFF Rediject

---

## Products Affected

- GONAL-F RFF REDIJECT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gralise

---

## Products Affected

- GRALISE ORAL TABLET 300 MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gralise

---

## Products Affected

- GRALISE ORAL TABLET 600 MG

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Gralise Starter

---

## Products Affected

- GRALISE STARTER

<b>QL Criteria</b>	1 starter pack Per 1 month
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Granisetron HCl

---

## Products Affected

- *granisetron hcl oral*

<b>QL Criteria</b>	10 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# GuanFACINE HCl ER

## Products Affected

- *guanfacine hcl er*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Attention deficit hyperactivity disorder (ADHD)Note: diagnosis criteria only applies to members greater than 18 years old. Step therapy requirement applies to all member regardless of age.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	18 or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: October 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Harvoni

---

## Products Affected

- HARVONI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Heather

---

## Products Affected

- *heather*

<b>QL Criteria</b>	1.5 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Helixate FS

---

## Products Affected

- HELIXATE FS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hemangeol

## Products Affected

- HEMANGEOL

PA Criteria	Criteria Details
Covered Uses	infantile hemangioma
Exclusion Criteria	
Required Medical Information	(1) Documented diagnosis of proliferating infantile hemangioma requiring systemic therapy, and (2) Documentation that the member was not born prematurely with a corrected age of less than 5 weeks, and (3) Documentation that the member does not weight less than 2kg, have sustained heart rate of less than 80 beats per minutes, have greater than first degree heart block, or have decompensated heart failure, and (4) Member does not have sustained blood pressure less than 50/30mmHg
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	Annual Review: 06/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hemofil M

---

## Products Affected

- HEMOFIL M INTRAVENOUS\*  
SOLUTION RECONSTITUTED 1000  
UNIT, 1700 UNIT, 500 UNIT, 1501-2000  
UNIT, 801-1500 UNIT, 220-400 UNIT,  
250 UNIT, 401-800 UNIT

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hepsera

---

## Products Affected

- HEPSERA

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hetlioz

## Products Affected

- HETLIOZ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Non-24 sleep wake-disorder
<b>Exclusion Criteria</b>	Documentation of concimant sleep disorders (sleep apnea, insomnia)
<b>Required Medical Information</b>	Documentation of non-24 sleep wake-disorder, and documentation of total-blindness with no light perception, and documentation of at least 3 months of difficulty initiating sleep, difficulty awakening in the morning, or excessive daytimes sleepiness.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hizentra

## Products Affected

- HIZENTRA SUBCUTANEOUS\*  
SOLUTION 1 GM/5ML, 4 GM/20ML, 10  
GM/50ML, 2 GM/10ML

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# HM Nicotine

---

## Products Affected

- *hm nicotine*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# HM Nicotine Polacrilex

---

## Products Affected

- *hm nicotine polacrilex mouth/throat lozenge 2 mg*

<b>QL Criteria</b>	20 EA Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Horizant

---

## Products Affected

- HORIZANT ORAL TABLET  
EXTENDEDRELEASE\* 300 MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Horizant

---

## Products Affected

- HORIZANT ORAL TABLET  
EXTENDEDRELEASE\* 600 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Humate-P

---

## Products Affected

- HUMATE-P INTRAVENOUS\*  
SOLUTION RECONSTITUTED  
1000-2400 UNIT, 250-600 UNIT,  
500-1200 UNIT

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Humatrope

---

## Products Affected

- HUMATROPE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Humira

---

## Products Affected

- HUMIRA SUBCUTANEOUS\* 40  
MG/0.8ML

<b>QL Criteria</b>	2 kit Per 1 kit (2 pens)
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Humira

---

## Products Affected

- HUMIRA SUBCUTANEOUS\* 20 MG/0.4ML, 10 MG/0.2ML

<b>QL Criteria</b>	2 injections Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Humira Pediatric Crohns Start

---

## Products Affected

- HUMIRA PEDIATRIC CROHNS START  
SUBCUTANEOUS\* 40 MG/0.8ML

<b>QL Criteria</b>	6 injections Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Humira Pen

---

## Products Affected

- HUMIRA PEN SUBCUTANEOUS\*

<b>QL Criteria</b>	2 kit Per 1 kit (2 pens)
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Humira Pen-Crohns Starter

---

## Products Affected

- HUMIRA PEN-CROHNS STARTER  
SUBCUTANEOUS\*

<b>QL Criteria</b>	6 injections Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Humira Pen-Psoriasis Starter

---

## Products Affected

- HUMIRA PEN-PSORIASIS STARTER  
SUBCUTANEOUS\*

<b>QL Criteria</b>	4 injections Per 21 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hyalgan

---

## Products Affected

- HYALGAN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hycamtin

## Products Affected

- HYCAMTIN ORAL

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hydrocod Polst-CPM Polst ER

---

## Products Affected

- *hydrocod polst-cpm polst er oral liquid extended release\**

<b>QL Criteria</b>	120 milliliters Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# HYDRORmorphone HCl ER

---

## Products Affected

- *hydromorphone hcl er oral 16 mg*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# HYDRomorphone HCl ER

---

## Products Affected

- *hydromorphone hcl er oral 32 mg, 8 mg, 12 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hymovis

---

## Products Affected

- HYMOVIS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Hyqvia

---

## Products Affected

- HYQVIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Hysingla ER

---

## Products Affected

- HYSINGLA ER

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ibandronate Sodium

---

## Products Affected

- *ibandronate sodium intravenous\* solution*  
3 mg/3ml

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_disease_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ibandronate Sodium

---

## Products Affected

- *ibandronate sodium oral*

<b>QL Criteria</b>	1 tablet Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ibrance

## Products Affected

- IBRANCE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	21 EA Per 28 Days
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Iclusig

## Products Affected

- ICLUSIG ORAL TABLET 45 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Iclusig

---

## Products Affected

- ICLUSIG ORAL TABLET 15 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Idelvion

---

## Products Affected

- IDELVION

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Ilaris

---

## Products Affected

- ILARIS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/immunomodulators_CAP.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/immunomodulators_CAP.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Imatinib Mesylate

---

## Products Affected

- *imatinib mesylate oral tablet 100 mg*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Imatinib Mesylate

## Products Affected

- *imatinib mesylate oral tablet 400 mg*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Imbruvica

---

## Products Affected

- IMBRUVICA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 EA Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Imiquimod

---

## Products Affected

- *imiquimod external*

<b>QL Criteria</b>	48 packets Per 112 dayss
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Imitrex

---

## Products Affected

- IMITREX SUBCUTANEOUS\*

<b>QL Criteria</b>	8 vials Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Imitrex

---

## Products Affected

- IMITREX NASAL

<b>QL Criteria</b>	6 sprays Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Imitrex

---

## Products Affected

- IMITREX ORAL

<b>QL Criteria</b>	9 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Imitrex STATdose Refill

---

## Products Affected

- IMITREX STATDOSE REFILL  
SUBCUTANEOUS\* 4 MG/0.5ML

<b>QL Criteria</b>	2 boxes Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Imitrex STATdose System

---

## Products Affected

- IMITREX STATDOSE SYSTEM  
SUBCUTANEOUS\* 6 MG/0.5ML

<b>QL Criteria</b>	2 boxes Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Impavido

---

## Products Affected

- IMPAVIDO

PA Criteria	Criteria Details
<b>Covered Uses</b>	Leishmaniasis
<b>Exclusion Criteria</b>	Known or suspected pregnancy
<b>Required Medical Information</b>	A documented diagnosis of any of the following leishmaniasis infections: Visceral leishmaniasis due to <i>Leishmania donovani</i> , Cutaneous leishmaniasis due to <i>Leishmania braziliensis</i> , <i>Leishmania guyanensis</i> , and <i>Leishmania panamensis</i> , or Mucosal leishmaniasis due to <i>Leishmania braziliensis</i>
<b>Age Restrictions</b>	12 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	28 days
<b>Other Criteria</b>	
<b>QL Criteria</b>	84 capsules Per 28 days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 16, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Implanon

---

## Products Affected

- IMPLANON

<b>QL Criteria</b>	1 implant Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Increlex

---

## Products Affected

- INCRELEX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/Increlex.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/Increlex.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Inderal XL

---

## Products Affected

- INDERAL XL ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 80 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Infinity Blood Glucose Test

---

## Products Affected

- INFINITY BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Inlyta

---

## Products Affected

- INLYTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# InnoPran XL

---

## Products Affected

- INNOPRAN XL ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 80 MG

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# InnoPran XL

---

## Products Affected

- INNOPRAN XL ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 120  
MG

<b>QL Criteria</b>	1 CP24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Intelligence

---

## Products Affected

- INTELENCE ORAL TABLET 200 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Intelligence

---

## Products Affected

- INTELENCE ORAL TABLET 25 MG,  
100 MG

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Intron A

---

## Products Affected

- INTRON A

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Introvale

---

## Products Affected

- *introvale*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Intuniv

---

## Products Affected

- INTUNIV

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Attention deficit hyperactivity disorder (ADHD)Note: diagnosis criteria only applies to members greater than 18 years old. Step therapy requirement applies to all member regardless of age.
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	18 or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 TABS Per 1 DAY
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: October 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Invega

---

## Products Affected

- INVEGA ORAL TABLET EXTENDED  
RELEASE 24 HR\* 1.5 MG, 3 MG, 9 MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Invega

---

## Products Affected

- INVEGA ORAL TABLET EXTENDED  
RELEASE 24 HR\* 6 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Invokamet

---

## Products Affected

- INVOKAMET

<b>QL Criteria</b>	2 tablets Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Invokamet XR

---

## Products Affected

- INVOKAMET XR

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Invokana

---

## Products Affected

- INVOKANA

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ipratropium Bromide

---

## Products Affected

- *ipratropium bromide nasal*

<b>QL Criteria</b>	1 bottle Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Iprivask

---

## Products Affected

- IPRIVASK

<b>QL Criteria</b>	2 syringes Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Irbesartan

---

## Products Affected

- *irbesartan*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Irbesartan-Hydrochlorothiazide

---

## Products Affected

- *irbesartan-hydrochlorothiazide*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Irenka

---

## Products Affected

- IRENKA

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Iressa

---

## Products Affected

- IRESSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Isentress

---

## Products Affected

- ISENTRESS ORAL TABLET

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Isentress

---

## Products Affected

- ISENTRESS ORAL TABLET  
CHEWABLE

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Itraconazole

---

## Products Affected

- *itraconazole oral*

<b>QL Criteria</b>	4 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ixinity

---

## Products Affected

- IXINITY INTRAVENOUS\* SOLUTION  
RECONSTITUTED 1500 UNIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jadenu

---

## Products Affected

- JADENU

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Antidotes.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Antidotes.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jakafi

---

## Products Affected

- JAKAFI ORAL TABLET 10 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Jakafi

## Products Affected

- JAKAFI ORAL TABLET 25 MG, 15 MG, 20 MG, 5 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Janumet

---

## Products Affected

- JANUMET

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Janumet XR

---

## Products Affected

- JANUMET XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 50-1000  
MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Janumet XR

---

## Products Affected

- JANUMET XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 50-500  
MG, 100-1000 MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Januvia

---

## Products Affected

- JANUVIA

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jardiance

---

## Products Affected

- JARDIANCE

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jentaduetto

---

## Products Affected

- JENTADUETO

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jentaduetto XR

---

## Products Affected

- JENTADUETO XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 5-1000  
MG

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Jentaduetto XR

---

## Products Affected

- JENTADUETO XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 2.5-1000  
MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jinteli

---

## Products Affected

- *jinteli*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jolessa

---

## Products Affected

- *jolessa*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jolivette

---

## Products Affected

- *jolivette*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Jublia

## Products Affected

- JUBLIA

PA Criteria	Criteria Details
Covered Uses	onychomycosis
Exclusion Criteria	
Required Medical Information	(1)Diagnosis of onychomycosis confirmed by either a positive KOH stain (potassium hydroxide), positive PAS stain (para-aminosalicylic acid), a positive DTM (dermatophyte test medium) or positive fungal culture (NOTE: This positive test should be within the last 3 - 6 months and associated with the current infection, and (2) A documented contraindication or intolerance or allergy or failure of an adequate trial of one systemic (oral) alternative such as terbinafine, itraconazole, griseofulvin, or fluconazole defined as (a) Failure of an adequate trial of one systemic (oral) alternative is terbinafine (6 weeks for fingernail infections, 12 weeks for toenail infections), griseofulvin (6 months), itraconazole (60 days (PulsePak) for fingernail infections, 90 days for toenail), or (b) Presence of hepatic dysfunction or increased risk for liver disease (for example, has a history of alcohol abuse or a history of hepatitis), or (c) Member is female and is pregnant and/or breastfeeding
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	Annual Review: 07/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Junel 1.5/30

---

### Products Affected

- *junel 1.5/30*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Junel 1/20

---

### Products Affected

- *junel 1/20*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Junel FE 1.5/30

---

### Products Affected

- *junel fe 1.5/30*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



## Junel FE 1/20

---

### Products Affected

- *junel fe 1/20*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Juxtapid

---

## Products Affected

- JUXTAPID ORAL CAPSULE 60 MG, 40 MG, 30 MG

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Juxtapid

---

## Products Affected

- JUXTAPID ORAL CAPSULE 10 MG, 5 MG

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kadian

---

## Products Affected

- KADIAN

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kalbitor

---

## Products Affected

- KALBITOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/hereditary_angioedema.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/hereditary_angioedema.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kalydeco

---

## Products Affected

- KALYDECO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/cystic_fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/cystic_fibrosis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 EA Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: December 21, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kalydeco

---

## Products Affected

- KALYDECO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/cystic_fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/cystic_fibrosis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: December 21, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kanuma

---

## Products Affected

- KANUMA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Kapvay

## Products Affected

- KAPVAY ORAL TABLET EXTENDED  
RELEASE 12 HR\*

PA Criteria	Criteria Details
Covered Uses	Attention deficit hyperactivity disorder (ADHD)Note: diagnosis criteria only applies to members greater than 18 years old. Step therapy requirement applies to all member regardless of age.
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 or older
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
QL Criteria	4 tabs Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: October 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kariva

---

## Products Affected

- *kariva*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kazano

---

## Products Affected

- KAZANO

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kelnor 1/35

---

## Products Affected

- *kelnor 1/35*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Keppra XR

---

## Products Affected

- KEPPRA XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 500 MG

<b>QL Criteria</b>	6 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Keppra XR

---

## Products Affected

- KEPPRA XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 750 MG

<b>QL Criteria</b>	4 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kerydin

## Products Affected

- KERYDIN

PA Criteria	Criteria Details
Covered Uses	onychomycosis
Exclusion Criteria	
Required Medical Information	(1)Diagnosis of onychomycosis confirmed by either a positive KOH stain (potassium hydroxide), positive PAS stain (para-aminosalicylic acid), a positive DTM (dermatophyte test medium) or positive fungal culture (NOTE: This positive test should be within the last 3 - 6 months and associated with the current infection, and (2) A documented contraindication or intolerance or allergy or failure of an adequate trial of one systemic (oral) alternative such as terbinafine, itraconazole, griseofulvin, or fluconazole defined as (a) Failure of an adequate trial of one systemic (oral) alternative is terbinafine (6 weeks for fingernail infections, 12 weeks for toenail infections), griseofulvin (6 months), itraconazole (60 days (PulsePak) for fingernail infections, 90 days for toenail), or (b) Presence of hepatic dysfunction or increased risk for liver disease (for example, has a history of alcohol abuse or a history of hepatitis), or (c) Member is female and is pregnant and/or breastfeeding
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Notes/References	Annual Review: 07/2016
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ketoconazole

---

## Products Affected

- *ketoconazole oral*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Ketorolac Tromethamine

---

## Products Affected

- *ketorolac tromethamine oral*

<b>QL Criteria</b>	20 tablets Per 28 dayss
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ketorolac Tromethamine

---

## Products Affected

- *ketorolac tromethamine ophthalmic*

<b>QL Criteria</b>	1 vial Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Keveyis

---

## Products Affected

- KEVEYIS

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Khedeza

---

## Products Affected

- KHEDEZLA

<b>QL Criteria</b>	1 TB24 Per 1 DAYS
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kineret

---

## Products Affected

- KINERET SUBCUTANEOUS\*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 syringe Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Koate-DVI

---

## Products Affected

- KOATE-DVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kogenate FS

---

## Products Affected

- KOGENATE FS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kogenate FS Bio-Set

---

## Products Affected

- KOGENATE FS BIO-SET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Kombiglyze XR

---

## Products Affected

- KOMBIGLYZE XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 5-500  
MG, 5-1000 MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kombiglyze XR

---

## Products Affected

- KOMBIGLYZE XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 2.5-1000  
MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Korlym

---

## Products Affected

- KORLYM

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kovaltry

---

## Products Affected

- KOVALTRY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kroger Blood Glucose

## Products Affected

- KROGER BLOOD GLUCOSE KIT  
W/DEVICE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kroger Blood Glucose Test

---

## Products Affected

- *kroger blood glucose test*

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kroger Premium Blood Glucose

## Products Affected

- KROGER PREMIUM BLOOD GLUCOSE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kroger Premium Glucose Test

---

## Products Affected

- *kroger premium glucose test*

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Kroger Test

---

## Products Affected

- *kroger test*

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kurvelo

---

## Products Affected

- *kurvelo*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kuvan

---

## Products Affected

- KUVAN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/metabolic_agents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 31, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Kynamro

---

## Products Affected

- KYNAMRO SUBCUTANEOUS\*

<b>QL Criteria</b>	4 SOLN Per 30 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LaMICtal ODT

---

## Products Affected

- LAMICTAL ODT ORAL TABLET  
DISPERSIBLE 50 MG

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LaMICtal ODT

---

## Products Affected

- LAMICTAL ODT ORAL TABLET  
DISPERSIBLE 200 MG, 100 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LaMICtal ODT

---

## Products Affected

- LAMICTAL ODT ORAL TABLET  
DISPERSIBLE 25 MG

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LaMICtal XR

---

## Products Affected

- LAMICTAL XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 300 MG,  
250 MG

<b>QL Criteria</b>	2 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# LaMICtal XR

---

## Products Affected

- LAMICTAL XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 50 MG,  
25 MG, 100 MG

<b>QL Criteria</b>	1 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LaMICtal XR

---

## Products Affected

- LAMICTAL XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 200 MG

<b>QL Criteria</b>	3 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamISIL

---

## Products Affected

- LAMISIL ORAL PACKET 125 MG

<b>QL Criteria</b>	2 packs Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamISIL

---

## Products Affected

- LAMISIL ORAL PACKET 187.5 MG

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamoTRIGine

---

## Products Affected

- *lamotrigine oral tablet dispersible 100 mg, 200 mg*

<b>QL Criteria</b>	2 TAB Per 1 DAILY
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamoTRIGine

---

## Products Affected

- *lamotrigine oral tablet dispersible 50 mg*

<b>QL Criteria</b>	3 TAB Per 1 DAILY
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamoTRIGine

---

## Products Affected

- *lamotrigine oral tablet dispersible 25 mg*

<b>QL Criteria</b>	6 TAB Per 1 DAILY
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamoTRIGine ER

---

## Products Affected

- *lamotrigine er oral tablet extended release*  
24 hr\* 300 mg, 250 mg

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# LamoTRIGine ER

---

## Products Affected

- *lamotrigine er oral tablet extended release*  
24 hr\* 200 mg

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamoTRIGine ER

---

## Products Affected

- *lamotrigine er oral tablet extended release*  
24 hr\* 100 mg, 25 mg

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LamoTRIGine ER

---

## Products Affected

- *lamotrigine er oral tablet extended release*  
24 hr\* 50 mg

<b>QL Criteria</b>	1 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lansoprazole

---

## Products Affected

- *lansoprazole oral capsule delayed release*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Larin Fe 1.5/30

---

## Products Affected

- LARIN FE 1.5/30

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Latuda

---

## Products Affected

- LATUDA ORAL TABLET 20 MG, 120 MG, 40 MG

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Latuda

---

## Products Affected

- LATUDA ORAL TABLET 80 MG

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lazanda

---

## Products Affected

- LAZANDA NASAL SOLUTION 300 MCG/ACT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	For pain due to malignant diagnosis only
<b>Exclusion Criteria</b>	Use in non-malignant pain
<b>Required Medical Information</b>	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months



PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))</p>
<b>QL Criteria</b>	4 bottles Per 30 days
<b>Notes/References</b>	
<b>Revision Date</b>	<p>Prior Authorization: October 10, 2016  Step Therapy: August 25, 2015  Quantity Limits: August 25, 2015</p>

# Lazanda

---

## Products Affected

- LAZANDA NASAL SOLUTION 400 MCG/ACT, 100 MCG/ACT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	For pain due to malignant diagnosis only
<b>Exclusion Criteria</b>	Use in non-malignant pain
<b>Required Medical Information</b>	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))</p>
<b>QL Criteria</b>	15 bottles Per 1 fill
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: October 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Leena

---

## Products Affected

- *leena*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Leflunomide

---

## Products Affected

- *leflunomide oral*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lemtrada

---

## Products Affected

- LEMTRADA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	6 ml Per 365 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lenvima 10 MG Daily Dose

---

## Products Affected

- LENVIMA 10 MG DAILY DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	30 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lenvima 14 MG Daily Dose

---

## Products Affected

- LENVIMA 14 MG DAILY DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	30 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Lenvima 18 MG Daily Dose

---

## Products Affected

- LENVIMA 18 MG DAILY DOSE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Prevention of acute or delayed nausea or vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	30 days Per 1 fill
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 23, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lenvima 20 MG Daily Dose

---

## Products Affected

- LENVIMA 20 MG DAILY DOSE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	30 EA Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lenvima 24 MG Daily Dose

---

## Products Affected

- LENVIMA 24 MG DAILY DOSE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	30 EA Per 1 Day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lenvima 8 MG Daily Dose

---

## Products Affected

- LENVIMA 8 MG DAILY DOSE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Prevention of acute or delayed nausea or vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	30 days Per 1 fill
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 23, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lescol XL

---

## Products Affected

- LESCOLO XL

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lessina

---

## Products Affected

- *lessina*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Leuprolide Acetate

---

## Products Affected

- *leuprolide acetate injection*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Levalbuterol Tartrate HFA

---

## Products Affected

- *levalbuterol tartrate hfa*

<b>QL Criteria</b>	2 inhalers Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# LevETIRAcetam ER

---

## Products Affected

- *levetiracetam er oral tablet extended release 24 hr\* 500 mg*

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# LevETIRAcetam ER

---

## Products Affected

- *levetiracetam er oral tablet extended release 24 hr\* 750 mg*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Levocetirizine Dihydrochloride

---

## Products Affected

- *levocetirizine dihydrochloride oral tablet*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Levonest

---

## Products Affected

- *levonest*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Levonorgest-Eth Estrad 91-Day

---

## Products Affected

- *levonorgest-eth estrad 91-day oral tablet*  
*0.1-0.02 & 0.01 mg, 0.15-0.03 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Levonorgestrel-Ethinyl Estrad

---

## Products Affected

- *levonorgestrel-ethinyl estrad oral tablet*  
*0.15-30 mg-mcg*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Levora 0.15/30 (28)

---

### Products Affected

- *levora 0.15/30 (28)*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lexapro

---

## Products Affected

- LEXAPRO ORAL SOLUTION

<b>QL Criteria</b>	20 ml Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Lexapro

---

## Products Affected

- LEXAPRO ORAL TABLET 20 MG, 5 MG

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lexapro

---

## Products Affected

- LEXAPRO ORAL TABLET 10 MG

<b>QL Criteria</b>	1.5 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lialda

---

## Products Affected

- LIALDA

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Liberty Blood Glucose Meter

---

## Products Affected

- *liberty blood glucose meter*

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Liberty Blood Glucose Monitor

---

## Products Affected

- *liberty blood glucose monitor*

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Liberty Next Generation Test

---

## Products Affected

- LIBERTY NEXT GENERATION TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Liberty Nxt Generation Monitor

---

## Products Affected

- LIBERTY NXT GENERATION MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Liberty Test

---

## Products Affected

- *liberty test*

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Lidocaine

## Products Affected

- *lidocaine external ointment*

PA Criteria	Criteria Details
<b>Covered Uses</b>	***AUTHORIZATION IS NOT REQUIRED FOR LESS THAN 50 GRAMS OF LIDOCAINE EVERY 30 DAYS*** For quantities over 50 grams every 30 days, there must be a documented temporary need for anesthesia for any of the following: Accessible mucous membranes of the oropharynx, skin and mucous membranes or stomatitis, or pain associated with a minor burns, including sunburn, abrasions of the skin, and insect bites.
<b>Exclusion Criteria</b>	Documentation of any of the following: Planned area of application includes non-intact skin, sensitivity to amide-type local anesthetics or any other component of the product, planned use on large surface area of the body as this can lead to increased toxicity, planned area of application includes severely traumatized skin (e.g., mucosal or skin abrasion, eczema, burns), the medication is being used in conjunction with a cosmetic procedure (i.e. hair removal), or if the product will be compounded with other products that would alter the total dose/dosage form being administered
<b>Required Medical Information</b>	A documented need for temporary anesthesia for any of the following: Accessible mucous membranes of the oropharynx, skin and mucous membranes or stomatitis, or pain associated with a minor burns, including sunburn, abrasions of the skin, and insect bites.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months

PA Criteria	Criteria Details
Other Criteria	<p>*Topical lidocaine ointment is used for temporary anesthesia. Prescription renewals for longer than 3 months require clinical documentation of medical necessity. Due to Safety Concerns higher quantities and prolonged use are not recommended. Renewal Duration: 3 months *Approval can made up to an additional 50gms per 30 days. Higher additional quantities are not approvable *FOR ADULTS: A single application should not exceed 5 g of Lidocaine Ointment 5%, containing 250 mg of lidocaine base (equivalent chemically to approximately 300 mg of lidocaine hydrochloride). This is roughly equivalent to squeezing a six (6) inch length of ointment from the tube. In a 70 kg adult this dose equals 3.6 mg/kg (1.6 mg/lb) lidocaine base. No more than one-half tube, approximately 17-20 g of ointment or 850-1000 mg lidocaine base, should be administered in any one day. FOR CHILDREN: For children less than ten years who have a normal lean body mass and a normal lean body development, the maximum dose may be determined by the application of one of the standard pediatric drug formulas (e.g., Clark's rule). For example a child of five years weighing 50 lbs., the dose of lidocaine should not exceed 75-100 mg when calculated according to Clark's rule. In any case, the maximum amount of lidocaine administered should not exceed 4.5 mg/kg (2.0 mg/lb) of body weight ***Lidocaine toxicity resulting from transcutaneous absorption is theoretically possible. Signs and symptoms of systemic lidocaine toxicity include CNS excitation and/or depression, nervousness, confusion, dizziness, tinnitus, blurred or double vision, vomiting, twitching, tremors, seizures, unconsciousness, respiratory depression, bradycardia, hypotension, and cardiopulmonary arrest. If there is suspicion of lidocaine-related systemic toxicity, check lidocaine blood concentrations</p>
QL Criteria	50 GM Per 30 Days
Notes/ References	
Revision Date	Prior Authorization: October 03, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lidocaine-Prilocaine

## Products Affected

- *lidocaine-prilocaine external cream*

PA Criteria	Criteria Details
<b>Covered Uses</b>	***AUTHORIZATION IS NOT REQUIRED FOR LESS THAN 50 GRAMS OF LIDOCAINE EVERY 30 DAYS*** For quantities over 50 grams every 30 days, there must be a documented temporary need for topical anesthetic in either of the following situations: Normal, intact skin for local analgesia, or Genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia
<b>Exclusion Criteria</b>	Documentation of any of the following: Planned area of application includes non-intact skin, Sensitivity to amide-type local anesthetics or any other component of the product, Planned use on large surface area of the body or for a period of time over 3 hours as this can lead to increased toxicity, the medication is being used in conjunction with a cosmetic procedure (i.e. hair removal), Use in situations where the drug may migrate into the middle ear, beyond the tympanic membrane, History of methemoglobinemia, or if the product will be compounded with other products that would alter the total dose/dosage form being administered
<b>Required Medical Information</b>	A documented need for topical anesthetic in either of the following situations: Normal, intact skin for local analgesia, or Genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	*Topical lidocaine/prilocaine cream is used for temporary anesthesia. Prescription renewals for longer than 3 months require clinical documentation of medical necessity. Due to Safety Concerns higher quantities and prolonged use are not recommended. Renewal Duration: 3 months *Up to an additional 30 grams per 30 days. Higher additional quantities are not approvable.

<b>QL Criteria</b>	30 GM Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: October 03, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lindane

---

## Products Affected

- *lindane external lotion*

<b>QL Criteria</b>	1 bottle Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Linezolid

---

## Products Affected

- *linezolid oral suspension reconstituted*

<b>QL Criteria</b>	150 ml Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Linezolid

---

## Products Affected

- *linezolid oral tablet*

<b>QL Criteria</b>	28 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Linzess

---

## Products Affected

- LINZESS

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Lipitor

---

## Products Affected

- LIPITOR

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lipofen

---

## Products Affected

- LIPOFEN

<b>QL Criteria</b>	1 CAPS Per 1 DAY
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Liptruzet

---

## Products Affected

- LIPTRUZET

<b>QL Criteria</b>	1 TAB Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Livalo

---

## Products Affected

- LIVALO

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lo Loestrin Fe

---

## Products Affected

- LO LOESTRIN FE

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Loestrin 1.5/30 (21)

---

### Products Affected

- LOESTRIN 1.5/30 (21)

<b>QL Criteria</b>	1.5 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Loestrin 1/20 (21)

---

### Products Affected

- LOESTRIN 1/20 (21)

<b>QL Criteria</b>	1.5 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Loestrin Fe 1.5/30

---

## Products Affected

- LOESTRIN FE 1.5/30

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Loestrin Fe 1/20

---

## Products Affected

- LOESTRIN FE 1/20

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lofibra

---

## Products Affected

- LOFIBRA

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lofibra

---

## Products Affected

- LOFIBRA

<b>QL Criteria</b>	1 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lomedia 24 FE

---

## Products Affected

- *lomedia 24 fe*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lonsurf

---

## Products Affected

- LONSURF ORAL TABLET 15-6.14 MG

<b>QL Criteria</b>	100 tablets Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lonsurf

---

## Products Affected

- LONSURF ORAL TABLET 20-8.19 MG

<b>QL Criteria</b>	80 tablets Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Loryna

---

## Products Affected

- *loryna*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Losartan Potassium

---

## Products Affected

- *losartan potassium oral tablet 50 mg, 25 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# LoSeasonique

---

## Products Affected

- LOSEASONIQUE

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lotronex

---

## Products Affected

- LOTRONEX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	severe diarrhea-predominant irritable bowel syndrome (IBS)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Patient is female, and has a documented diagnosis of severe diarrhea-predominant irritable bowel syndrome (IBS) including one or more of the following: frequent and severe abdominal pain/discomfort, frequent urgency or fecal incontinence or disability or restriction of daily activities due to IBS, AND patient has chronic IBS symptoms generally lasting 6 months or longer, AND anatomic or biochemical abnormalities of the gastrointestinal tract have been excluded
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Step Therapy
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lovastatin

---

## Products Affected

- *lovastatin*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lovaza

---

## Products Affected

- LOVAZA

<b>QL Criteria</b>	4 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lovenox

---

## Products Affected

- LOVENOX

<b>QL Criteria</b>	2 syringes Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Low-Ogestrel

---

## Products Affected

- *low-ogestrel*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lumigan

---

## Products Affected

- LUMIGAN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	open-angle glaucoma, ocular hypertension
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of glaucoma or ocular hypertension
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>Notes/References</b>	Annual Review: 03/2016
<b>Revision Date</b>	Prior Authorization: May 28, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lumizyme

---

## Products Affected

- LUMIZYME

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Lunesta

---

## Products Affected

- LUNESTA

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lutera

---

## Products Affected

- *lutera*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lynparza

---

## Products Affected

- LYNPARZA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	480 EA Per 30 Days
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lysteda

---

## Products Affected

- LYSTEDA

<b>QL Criteria</b>	30 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Lyza

---

## Products Affected

- LYZA

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Makena

---

## Products Affected

- MAKENA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/hydroxyprogesterone.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/hydroxyprogesterone.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Maprotiline HCl

---

## Products Affected

- *maprotiline hcl*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Marinol

---

## Products Affected

- MARINOL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Anorexia associated with weight loss in patients with AIDS, Chemotherapy-induced nausea and vomiting
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Anorexia associated with weight loss in patients with AIDS, or Chemotherapy-induced nausea and vomiting
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 CAPS Per 1 DAYS
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Marlissa

---

## Products Affected

- *marlissa*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Matzim LA

---

## Products Affected

- *matzim la oral tablet extended release 24 hr\* 180 mg, 360 mg, 300 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Matzim LA

---

## Products Affected

- *matzim la oral tablet extended release 24 hr\* 240 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Maxalt

---

## Products Affected

- MAXALT

<b>QL Criteria</b>	9 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Maxalt-MLT

---

## Products Affected

- MAXALT-MLT

<b>QL Criteria</b>	9 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Maxima Blood Glucose Test

---

## Products Affected

- MAXIMA BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# MedroxyPROGESTERone Acetate

---

## Products Affected

- *medroxyprogesterone acetate intramuscular\* suspension*

<b>QL Criteria</b>	1 syringe Per 90 dayss
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Meijer Blood Glucose

## Products Affected

- MEIJER BLOOD GLUCOSE

PA Criteria	Criteria Details
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Meijer Blood Glucose Test

---

## Products Affected

- *meijer blood glucose test*

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Meijer Premium Blood Glucose

## Products Affected

- MEIJER PREMIUM BLOOD GLUCOSE

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Meijer Premium Glucose Test

---

## Products Affected

- *meijer premium glucose test*

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Memantine HCl

---

## Products Affected

- *memantine hcl oral tablet 10 mg, 5 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Menopur

---

## Products Affected

- MENOPUR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Menostar

---

## Products Affected

- MENOSTAR

<b>QL Criteria</b>	1 box (4 patches) Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mesalamine

---

## Products Affected

- *mesalamine oral*

<b>QL Criteria</b>	6 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Metadate CD

---

## Products Affected

- METADATE CD ORAL CAPSULE  
EXTENDED RELEASE\* 10 MG, 60 MG,  
40 MG

<b>QL Criteria</b>	1 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Metadate CD

---

## Products Affected

- METADATE CD ORAL CAPSULE  
EXTENDED RELEASE\* 20 MG

<b>QL Criteria</b>	3 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Metadate CD

---

## Products Affected

- METADATE CD ORAL CAPSULE  
EXTENDED RELEASE\* 50 MG

<b>QL Criteria</b>	1 cap Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Metadate CD

---

## Products Affected

- METADATE CD ORAL CAPSULE  
EXTENDED RELEASE\* 30 MG

<b>QL Criteria</b>	2 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Metadate ER

---

## Products Affected

- METADATE ER ORAL TABLET  
EXTENDEDRELEASE\* 20 MG

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methadone HCl

---

## Products Affected

- *methadone hcl oral solution 10 mg/5ml*

<b>QL Criteria</b>	30 mg Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methadone HCl

---

## Products Affected

- *methadone hcl oral tablet soluble*
- *methadone hcl oral tablet*

<b>QL Criteria</b>	6 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methadone HCl

---

## Products Affected

- *methadone hcl oral solution 5 mg/5ml*

<b>QL Criteria</b>	60 mg Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methadose

---

## Products Affected

- *methadose oral tablet soluble*

<b>QL Criteria</b>	1.5 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Methamphetamine HCl

---

## Products Affected

- *methamphetamine hcl*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Attention deficit hyperactivity disorder (ADHD), Narcolepsy
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of ADHD or Narcolepsy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylin

---

## Products Affected

- METHYLIN ORAL SOLUTION 10  
MG/5ML

<b>QL Criteria</b>	30 soln Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylin

---

## Products Affected

- METHYLIN ORAL TABLET  
CHEWABLE

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylin

---

## Products Affected

- METHYLIN ORAL SOLUTION 5  
MG/5ML

<b>QL Criteria</b>	60 soln Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl

---

## Products Affected

- *methylphenidate hcl oral tablet*

<b>QL Criteria</b>	6 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl

---

## Products Affected

- *methylphenidate hcl oral solution 5 mg/5ml*

<b>QL Criteria</b>	60 milliliters Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl

---

## Products Affected

- *methylphenidate hcl oral solution 10 mg/5ml*

<b>QL Criteria</b>	30 milliliters Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER

---

## Products Affected

- *methylphenidate hcl er oral tablet extended release 24 hr\* 36 mg*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Methylphenidate HCl ER

---

## Products Affected

- *methylphenidate hcl er oral tablet extendedrelease\* 10 mg, 20 mg*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER

---

## Products Affected

- *methylphenidate hcl er oral tablet extendedrelease\* 27 mg, 18 mg, 54 mg*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER

---

## Products Affected

- *methylphenidate hcl er oral tablet  
extendedrelease\* 36 mg*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER (CD)

---

## Products Affected

- *methylphenidate hcl er (cd)*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER (LA)

---

## Products Affected

- *methylphenidate hcl er (la) oral capsule  
extended release 24 hour 30 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Methylphenidate HCl ER (LA)

---

## Products Affected

- *methylphenidate hcl er (la) oral capsule  
extended release 24 hour 40 mg, 20 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Metoprolol Succinate ER

---

## Products Affected

- *metoprolol succinate er oral tablet*  
*extended release 24 hr\* 100 mg, 50 mg*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Metoprolol Succinate ER

---

## Products Affected

- *metoprolol succinate er oral tablet  
extended release 24 hr\* 200 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Metoprolol Succinate ER

---

## Products Affected

- *metoprolol succinate er oral tablet  
extended release 24 hr\* 25 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mevacor

---

## Products Affected

- MEVACOR ORAL TABLET 40 MG

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Micardis

---

## Products Affected

- MICARDIS

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Micardis HCT

---

## Products Affected

- MICARDIS HCT

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Microdot Test

---

## Products Affected

- MICRODOT TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Microgestin 1.5/30

---

## Products Affected

- *microgestin 1.5/30*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Microgestin 1/20

---

## Products Affected

- *microgestin 1/20*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Microgestin FE 1.5/30

---

## Products Affected

- *microgestin fe 1.5/30*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Microgestin FE 1/20

---

## Products Affected

- *microgestin fe 1/20*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mimvey

---

## Products Affected

- *mimvey*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Minivelle

---

## Products Affected

- MINIVELLE

<b>QL Criteria</b>	8 patches Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mirapex ER

---

## Products Affected

- MIRAPEX ER

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mircera

## Products Affected

- MIRCERA INJECTION

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Erythropoiesis_Stimulating_Agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Erythropoiesis_Stimulating_Agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mircette

---

## Products Affected

- MIRCETTE

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Mirena (52 MG)

---

### Products Affected

- MIRENA (52 MG)

<b>QL Criteria</b>	1 IUD Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mirtazapine

---

## Products Affected

- *mirtazapine oral*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Mitigare

---

## Products Affected

- MITIGARE

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Modafinil

## Products Affected

- *modafinil oral tablet 200 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 Day

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Modafinil

## Products Affected

- *modafinil oral tablet 100 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Modicon (28)

---

### Products Affected

- MODICON (28)

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Monoclalte-P

---

## Products Affected

- MONOCLATE-P

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mono-Linyah

---

## Products Affected

- *mono-lynyah*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# MonoNessa

---

## Products Affected

- *mononessa*

<b>QL Criteria</b>	1.5 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mononine

---

## Products Affected

- MONONINE

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Monovisc

---

## Products Affected

- MONOVISC

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Montelukast Sodium

---

## Products Affected

- *montelukast sodium oral*

<b>QL Criteria</b>	1 pack Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Montelukast Sodium

---

## Products Affected

- *montelukast sodium oral*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Morphine Sulfate ER

---

## Products Affected

- *morphine sulfate er oral tablet  
extendedrelease\* 15 mg, 200 mg*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Morphine Sulfate ER

---

## Products Affected

- *morphine sulfate er oral tablet extended release\* 30 mg, 60 mg, 100 mg*
- *morphine sulfate er oral capsule extended release 24 hour*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Morphine Sulfate ER Beads

---

## Products Affected

- *morphine sulfate er beads*

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# MS Contin

---

## Products Affected

- MS CONTIN ORAL TABLET  
EXTENDEDRELEASE\*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Multaq

---

## Products Affected

- MULTAQ

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Myalept

## Products Affected

- MYALEPT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/Myalept.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/Myalept.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	0.5 VIAL Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# MyGlucoHealth Test

---

## Products Affected

- MYGLUCOHEALTH TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Myorisan

## Products Affected

- *myorisan oral capsule 10 mg, 40 mg, 20 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	severe recalcitrant nodular or cystic acne
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Member already has evidence of scarring and member is enrolled in the FDA iPLEDGE program (females of childbearing potential ONLY)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	5 months
<b>Other Criteria</b>	For coverage of additional quantities (greater than 2 capsules per day) member must meet the following criteria: Patient requires more than 2 capsules per day to reach the appropriate dose for weight, and this is the members FIRST course of therapy or member now requires a second course of therapy and it has been at least 8 weeks after the first course was initiated (2 month holiday), and member has recieved a cumulative dose of less than 120 mg/kg during a course of therapy lasting 20 weeks or less.
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Myozyme

---

## Products Affected

- MYOZYME

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Myrbetriq

---

## Products Affected

- MYRBETRIQ

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Mytesi

## Products Affected

- MYTESI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Diarrhea
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Covered for adult members who meet the following criteria: (1) Diagnosis of noninfectious diarrhea associated with HIV/AIDS infection that has lasted at least for one month, and (2) Currently taking antiviral therapy with adherence of at least 80%, and (3) Documentation of unsatisfactory effects with, intolerance to, or inability to take at least one anti-motility agent (loperamide, diphenoxylate/atropine, bismuth subsalicylate) or one or more watery bowel movements per day without regular ADM use.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: November 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Myzilra

---

## Products Affected

- *myzilra*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Naglazyme

---

## Products Affected

- NAGLAZYME

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Namenda

---

## Products Affected

- NAMENDA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Alzheimer's Disease
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
<b>Age Restrictions</b>	less than 40 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Namenda Titration Pak

---

## Products Affected

- NAMENDA TITRATION PAK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Alzheimer's Disease
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
<b>Age Restrictions</b>	less than 40 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Namenda XR

---

## Products Affected

- NAMENDA XR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Alzheimer's Disease
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
<b>Age Restrictions</b>	less than 40 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Namzanic

---

## Products Affected

- NAMZARIC ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 28-10  
MG, 14-10 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Alzheimer's Disease
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
<b>Age Restrictions</b>	less than 40 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Naratriptan HCl

---

## Products Affected

- *naratriptan hcl*

<b>QL Criteria</b>	9 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Natazia

---

## Products Affected

- NATAZIA

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Natesto

## Products Affected

- NATESTO

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Natpara

---

## Products Affected

- NATPARA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_diasease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_diasease_agents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 ctg Per 28 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Necon 0.5/35 (28)

---

### Products Affected

- *necon 0.5/35 (28)*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Necon 1/35 (28)

---

### Products Affected

- *necon 1/35 (28)*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Necon 1/50 (28)

---

### Products Affected

- *necon 1/50 (28)*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Necon 10/11 (28)

---

### Products Affected

- *necon 10/11 (28)*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nesina

---

## Products Affected

- NESINA

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Neupro

---

## Products Affected

- NEUPRO

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Neurontin

---

## Products Affected

- NEURONTIN ORAL CAPSULE

<b>QL Criteria</b>	6 cap Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Neurontin

---

## Products Affected

- NEURONTIN ORAL TABLET

<b>QL Criteria</b>	6 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Neurontin

---

## Products Affected

- NEURONTIN ORAL SOLUTION

<b>QL Criteria</b>	40 ml Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Neutek 2Tek Glucose/Pressure

---

## Products Affected

- NEUTEK 2TEK GLUCOSE/PRESSURE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Neutek 2Tek Test

---

## Products Affected

- NEUTEK 2TEK TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nevirapine ER

---

## Products Affected

- *nevirapine er oral tablet extended release*  
*24 hr\* 100 mg*

<b>QL Criteria</b>	3 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nevirapine ER

---

## Products Affected

- *nevirapine er oral tablet extended release*  
24 hr\* 400 mg

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NexAVAR

---

## Products Affected

- NEXAVAR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# NexIUM

---

## Products Affected

- NEXIUM ORAL CAPSULE DELAYED  
RELEASE 40 MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NexIUM

---

## Products Affected

- NEXIUM ORAL PACKET

<b>QL Criteria</b>	1 pack Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NexIUM 24HR

---

## Products Affected

- NEXIUM 24HR ORAL TABLET  
DELAYED RELEASE

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nexplanon

---

## Products Affected

- NEXPLANON

<b>QL Criteria</b>	1 implant Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Next Choice One Dose

---

## Products Affected

- *next choice one dose*

<b>QL Criteria</b>	1 tablet Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nicoderm CQ

---

## Products Affected

- NICODERM CQ

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nicorelief

---

## Products Affected

- *nicorelief mouth/throat gum*

<b>QL Criteria</b>	24 EA Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nicorette

---

## Products Affected

- NICORETTE MOUTH/THROAT GUM

<b>QL Criteria</b>	24 EA Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Nicotine

---

## Products Affected

- *nicotine transdermal patch 24 hr*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nicotine Step 1

---

## Products Affected

- *nicotine step 1*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Nicotine Step 2

---

### Products Affected

- *nicotine step 2*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nicotine Step 3

---

## Products Affected

- *nicotine step 3*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nicotrol

---

## Products Affected

- NICOTROL

<b>QL Criteria</b>	3 boxes-504 ctrtg Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nicotrol NS

---

## Products Affected

- NICOTROL NS

<b>QL Criteria</b>	4 bottles Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nifediac CC

---

## Products Affected

- *nifediac cc oral tablet extended release 24 hr\* 60 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nifediac CC

---

## Products Affected

- *nifediac cc oral tablet extended release 24 hr\* 30 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Nifedical XL

---

## Products Affected

- *nifedical xl oral tablet extended release 24 hr\* 30 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nifedical XL

---

## Products Affected

- *nifedical xl oral tablet extended release 24 hr\* 60 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NIFEdipine ER

---

## Products Affected

- *nifedipine er oral tablet extended release*  
24 hr\* 30 mg, 90 mg

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NIFEdipine ER

---

## Products Affected

- *nifedipine er oral tablet extended release*  
24 hr\* 60 mg

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NIFEdipine ER Osmotic Release

---

## Products Affected

- *nifedipine er osmotic release oral tablet*  
*extended release 24 hr\* 60 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NIFEdipine ER Osmotic Release

---

## Products Affected

- *nifedipine er osmotic release oral tablet*  
*extended release 24 hr\* 90 mg, 30 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nikki

---

## Products Affected

- NIKKI

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ninlaro

---

## Products Affected

- NINLARO

<b>QL Criteria</b>	3 capsules Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Nisoldipine ER

---

## Products Affected

- *nisoldipine er oral tablet extended release*  
24 hr\* 25.5 mg, 40 mg, 8.5 mg, 20 mg, 17 mg, 34 mg

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nisoldipine ER

---

## Products Affected

- *nisoldipine er oral tablet extended release*  
*24 hr\* 30 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nitroglycerin

---

## Products Affected

- *nitroglycerin translingual solution*

<b>QL Criteria</b>	12 grams Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nora-BE

---

## Products Affected

- *nora-be*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Norditropin FlexPro

---

## Products Affected

- NORDITROPIN FLEXPPO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Norethindrone

---

## Products Affected

- *norethindrone oral*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Norgestimate-Eth Estradiol

---

## Products Affected

- *norgestimate-eth estradiol oral tablet*  
*0.25-35 mg-mcg*

<b>QL Criteria</b>	1.5 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Norgestim-Eth Estrad Triphasic

---

## Products Affected

- *norgestim-eth estrad triphasic oral tablet*  
*0.18/0.215/0.25 mg-35 mcg*

<b>QL Criteria</b>	1.5 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Norinyl 1+35 (28)

---

## Products Affected

- NORINYL 1+35 (28)

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Norinyl 1+50 (28)

---

### Products Affected

- NORINYL 1+50 (28)

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Norlyroc

---

## Products Affected

- NORLYROC

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nor-QD

---

## Products Affected

- NOR-QD

<b>QL Criteria</b>	1.5 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Northera

---

## Products Affected

- NORTHERA ORAL CAPSULE 300 MG,  
200 MG

<b>QL Criteria</b>	6 EA Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Northera

---

## Products Affected

- NORTHERA ORAL CAPSULE 100 MG

<b>QL Criteria</b>	3 EA Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Nortrel 0.5/35 (28)

---

### Products Affected

- *nortrel 0.5/35 (28)*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Nortrel 1/35 (21)

---

### Products Affected

- *nortrel 1/35 (21)*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



## Nortrel 1/35 (28)

---

### Products Affected

- *nortrel 1/35 (28)*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nortrel 7/7/7

---

## Products Affected

- *nortrel 7/7/7*

<b>QL Criteria</b>	1.5 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nova Max Blood Glucose System

---

## Products Affected

- NOVA MAX BLOOD GLUCOSE SYSTEM DEVICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nova Max Glucose Test

---

## Products Affected

- NOVA MAX GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Novarel

---

## Products Affected

- *novarel*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Novoeight

---

## Products Affected

- NOVOEIGHT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NovoLOG PenFill

---

## Products Affected

- NOVOLOG PENFILL  
SUBCUTANEOUS\*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 or Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Type 1 or Type 2 Diabetes Mellitus
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Step therapy
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NovoSeven RT

---

## Products Affected

- NOVOSEVEN RT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Noxafil

---

## Products Affected

- NOXAFIL ORAL TABLET DELAYED RELEASE

<b>QL Criteria</b>	93 TBEC Per 30 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nucala

---

## Products Affected

- NUCALA

<b>QL Criteria</b>	1 injection Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nucynta

---

## Products Affected

- NUCYNTA

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nucynta ER

---

## Products Affected

- NUCYNTA ER

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	(1)Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment, (2)Diabetic peripheral neuropathy
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Chronic Pain or Diabetic peripheral neuropathy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Step Therapy
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nuedexta

---

## Products Affected

- NUEDEXTA

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nuplazid

---

## Products Affected

- NUPLAZID

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/Nuplazid.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/Nuplazid.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nutropin AQ NuSpin 10

---

## Products Affected

- NUTROPIN AQ NUSPIN 10

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nutropin AQ NuSpin 20

---

## Products Affected

- NUTROPIN AQ NUSPIN 20

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Nutropin AQ NuSpin 5

---

## Products Affected

- NUTROPIN AQ NUSPIN 5

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# NuvaRing

---

## Products Affected

- NUVARING

<b>QL Criteria</b>	1 ring Per 28 dayss
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nuvigil

## Products Affected

- NUVIGIL ORAL TABLET 200 MG, 150 MG, 250 MG

PA Criteria	Criteria Details
<b>Covered Uses</b>	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nuvigil

## Products Affected

- NUVIGIL ORAL TABLET 50 MG

PA Criteria	Criteria Details
<b>Covered Uses</b>	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 Day

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Nymalize

---

## Products Affected

- NYMALIZE

<b>QL Criteria</b>	135.2 ml Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ocaliva

## Products Affected

- OCALIVA ORAL TABLET 5 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/Primary_Biliary_Cholangitis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/Primary_Biliary_Cholangitis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
ST Criteria	<a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/Primary_Biliary_Cholangitis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/Primary_Biliary_Cholangitis.html</a>
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Ocella

---

## Products Affected

- *ocella*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Octagam

---

## Products Affected

- OCTAGAM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Odefsey

---

## Products Affected

- ODEFSEY

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Odomzo

---

## Products Affected

- ODOMZO

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ofev

---

## Products Affected

- OFEV

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Idiopathic_Pulmonary_Fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Idiopathic_Pulmonary_Fibrosis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 EA Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ogestrel

---

## Products Affected

- *ogestrel*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OLANZapine

---

## Products Affected

- *olanzapine oral tablet 20 mg, 5 mg, 7.5 mg, 10 mg, 15 mg*
- *olanzapine oral tablet dispersible*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OLANZapine

---

## Products Affected

- *olanzapine oral tablet 2.5 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# OLANZapine-FLUoxetine HCl

---

## Products Affected

- *olanzapine-fluoxetine hcl*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oleptro

---

## Products Affected

- OLEPTRO

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Olysio

---

## Products Affected

- OLYSIO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 CAPS Per 1 DAYS
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Omega-3-acid Ethyl Esters

---

## Products Affected

- *omega-3-acid ethyl esters*

<b>QL Criteria</b>	4 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# On Call Plus Blood Glucose

---

## Products Affected

- ON CALL PLUS BLOOD GLUCOSE

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# On Call Vivid Blood Glucose

---

## Products Affected

- ON CALL VIVID BLOOD GLUCOSE

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ondansetron

---

## Products Affected

- *ondansetron*

<b>QL Criteria</b>	12 tablets Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ondansetron HCl

---

## Products Affected

- *ondansetron hcl oral solution*

<b>QL Criteria</b>	1 bottle Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Ondansetron HCl

---

## Products Affected

- *ondansetron hcl oral tablet 8 mg*

<b>QL Criteria</b>	60 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ondansetron HCl

---

## Products Affected

- *ondansetron hcl oral tablet 4 mg, 24 mg*

<b>QL Criteria</b>	12 tablets Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OneTouch Test

---

## Products Affected

- ONETOUCH TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OneTouch Ultra 2

---

## Products Affected

- ONETOUCH ULTRA 2

<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OneTouch Ultra Blue

---

## Products Affected

- ONETOUCH ULTRA BLUE

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OneTouch Ultra Mini

---

## Products Affected

- ONETOUCH ULTRA MINI

<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OneTouch Verio

---

## Products Affected

- ONETOUCH VERIO IN VITRO STRIP

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OneTouch Verio IQ System

---

## Products Affected

- ONETOUCH VERIO IQ SYSTEM

<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Onfi

---

## Products Affected

- ONFI ORAL TABLET 20 MG, 10 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Onglyza

---

## Products Affected

- ONGLYZA

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Onsolis

## Products Affected

- ONSOLIS

PA Criteria	Criteria Details
<b>Covered Uses</b>	For pain due to malignant diagnosis only
<b>Exclusion Criteria</b>	Use in non-malignant pain
<b>Required Medical Information</b>	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: October 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Onzetra Xsail

---

## Products Affected

- ONZETRA XSAIL

<b>QL Criteria</b>	1 kit Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Opana ER

---

## Products Affected

- OPANA ER ORAL TABLET  
EXTENDED RELEASE 12 HR\* 20 MG, 5  
MG, 10 MG, 40 MG, 30 MG

PA Criteria	Criteria Details
<b>Covered Uses</b>	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Step Therapy
<b>Notes/References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Opana ER

---

## Products Affected

- OPANA ER ORAL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Step Therapy
<b>QL Criteria</b>	4 tablets Per 1 DAYS
<b>Notes/References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Opana ER

---

## Products Affected

- OPANA ER ORAL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Step Therapy
<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Opsumit

---

## Products Affected

- OPSUMIT

<b>QL Criteria</b>	1 EA Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oramorph SR

---

## Products Affected

- ORAMORPH SR ORAL TABLET  
EXTENDEDRELEASE\*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oravig

---

## Products Affected

- ORAVIG

<b>QL Criteria</b>	14 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Orencia

---

## Products Affected

- ORENCIA SUBCUTANEOUS\*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 syringes Per 28 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Orencia

---

## Products Affected

- ORENCIA INTRAVENOUS\*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Orencia ClickJect

---

## Products Affected

- ORENCIA CLICKJECT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 syringes Per 1 month
Notes/References	
Revision Date	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Orenitram

---

## Products Affected

- ORENITRAM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Orkambi

---

## Products Affected

- ORKAMBI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/cystic_fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/cystic_fibrosis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: December 21, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Orsythia

---

## Products Affected

- *orsythia*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ortho Diaphragm All-Flex

---

## Products Affected

- ORTHO DIAPHRAGM ALL-FLEX  
VAGINAL DIAPHRAGM 70 MM

<b>QL Criteria</b>	1 device Per 365 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ortho Micronor

---

## Products Affected

- ORTHO MICRONOR

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Ortho Tri-Cyclen (28)

---

### Products Affected

- ORTHO TRI-CYCLEN (28)

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ortho Tri-Cyclen Lo

---

## Products Affected

- ORTHO TRI-CYCLEN LO

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Ortho-Cept (28)

---

### Products Affected

- ORTHO-CEPT (28)

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Ortho-Cyclen (28)

---

### Products Affected

- ORTHO-CYCLEN (28)

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Ortho-Novum 1/35 (28)

---

### Products Affected

- ORTHO-NOVUM 1/35 (28)

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



## Ortho-Novum 7/7/7 (28)

---

### Products Affected

- ORTHO-NOVUM 7/7/7 (28)

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OrthoVisc

---

## Products Affected

- ORTHOVISC INTRA-ARTICULAR\*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oseni

---

## Products Affected

- OSENI

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Otezla

## Products Affected

- OTEZLA ORAL 10 & 20 & 30 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Otezla

## Products Affected

- OTEZLA ORAL TABLET

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 TABS Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Ovcon-35 (28)

---

### Products Affected

- OVCON-35 (28)

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ovidrel

---

## Products Affected

- OVIDREL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oxtellar XR

---

## Products Affected

- OXTELLAR XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 150 MG,  
300 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Oxtellar XR

---

## Products Affected

- OXTELLAR XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 600 MG

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oxybutynin Chloride

---

## Products Affected

- *oxybutynin chloride oral tablet*

<b>QL Criteria</b>	4 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OxyCODONE HCl ER

## Products Affected

- *oxycodone hcl er oral 10 mg, 80 mg, 40 mg, 20 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Step Therapy
<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oxycodone-Ibuprofen

---

## Products Affected

- *oxycodone-ibuprofen*

<b>QL Criteria</b>	28 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# OxyCONTIN

---

## Products Affected

- OXYCONTIN ORAL

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Oxymorphone HCl ER

---

## Products Affected

- *oxymorphone hcl er*

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Paliperidone ER

---

## Products Affected

- *paliperidone er oral tablet extended release*  
24 hr\* 3 mg, 1.5 mg, 6 mg

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Paliperidone ER

---

## Products Affected

- *paliperidone er oral tablet extended release*  
24 hr\* 9 mg

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Pamidronate Disodium

---

## Products Affected

- *pamidronate disodium*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_diasease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_diasease_agents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Paragard Intrauterine Copper

---

## Products Affected

- PARAGARD INTRAUTERINE COPPER

<b>QL Criteria</b>	1 IUD Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Paricalcitol

---

## Products Affected

- *paricalcitol oral*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PARoxetine HCl

---

## Products Affected

- *paroxetine hcl oral tablet 10 mg, 20 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PARoxetine HCl

---

## Products Affected

- *paroxetine hcl oral tablet 30 mg, 40 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PARoxetine HCl ER

---

## Products Affected

- *paroxetine hcl er oral tablet extended release 24 hr\* 12.5 mg, 37.5 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PARoxetine HCl ER

---

## Products Affected

- *paroxetine hcl er oral tablet extended release 24 hr\* 25 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Paxil

---

## Products Affected

- PAXIL ORAL SUSPENSION

<b>QL Criteria</b>	30 ml Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Paxil

---

## Products Affected

- PAXIL ORAL TABLET 40 MG, 30 MG

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Paxil

---

## Products Affected

- PAXIL ORAL TABLET 10 MG, 20 MG

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Paxil CR

---

## Products Affected

- PAXIL CR ORAL TABLET EXTENDED  
RELEASE 24 HR\* 12.5 MG

<b>QL Criteria</b>	6 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Paxil CR

---

## Products Affected

- PAXIL CR ORAL TABLET EXTENDED  
RELEASE 24 HR\* 25 MG

<b>QL Criteria</b>	3 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Paxil CR

---

## Products Affected

- PAXIL CR ORAL TABLET EXTENDED  
RELEASE 24 HR\* 37.5 MG

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PEG 3350/Electrolytes

---

## Products Affected

- *peg 3350/electrolytes*

<b>QL Criteria</b>	4 liters Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PEG-3350/Electrolytes

---

## Products Affected

- *peg-3350/electrolytes*

<b>QL Criteria</b>	4 liters Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pegasys

---

## Products Affected

- PEGASYS SUBCUTANEOUS\*  
SOLUTION

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Pegasys ProClick

---

## Products Affected

- PEGASYS PROCLICK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PegIntron

---

## Products Affected

- PEGINTRON

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Peg-Intron

---

## Products Affected

- PEG-INTRON

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Peg-Intron Redipen

## Products Affected

- PEG-INTRON REDIPEN  
SUBCUTANEOUS\* KIT 150  
MCG/0.5ML, 80 MCG/0.5ML, 50  
MCG/0.5ML

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Peg-Intron Redipen Pak 4

---

## Products Affected

- PEG-INTRON REDIPEN PAK 4  
SUBCUTANEOUS\* KIT 120  
MCG/0.5ML

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pennsaid

---

## Products Affected

- PENNSAID TRANSDERMAL SOLUTION 2 %

<b>QL Criteria</b>	4 ml Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pentasa

---

## Products Affected

- PENTASA ORAL CAPSULE  
EXTENDED RELEASE\* 250 MG

<b>QL Criteria</b>	16 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pentasa

---

## Products Affected

- PENTASA ORAL CAPSULE  
EXTENDED RELEASE\* 500 MG

<b>QL Criteria</b>	8 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Perforomist

---

## Products Affected

- PERFOROMIST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Chronic Obstructive Pulmonary Disorder (COPD)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Chronic obstructive pulmonary disease (COPD)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 milliliters Per 1 day
<b>Notes/References</b>	Annual Review: 07/2016
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pharmacist Choice Autocode

---

## Products Affected

- PHARMACIST CHOICE AUTOCODE

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Philith

---

## Products Affected

- *philith*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Picato

---

## Products Affected

- PICATO EXTERNAL GEL 0.05 %

<b>QL Criteria</b>	2 unit dose tubes Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Picato

---

## Products Affected

- PICATO EXTERNAL GEL 0.015 %

<b>QL Criteria</b>	3 unit dose tubes Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pioglitazone HCl

---

## Products Affected

- *pioglitazone hcl*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pioglitazone HCl-Glimepiride

---

## Products Affected

- *pioglitazone hcl-glimepiride*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pioglitazone HCl-Metformin HCl

---

## Products Affected

- *pioglitazone hcl-metformin hcl*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Plan B One-Step

---

## Products Affected

- PLAN B ONE-STEP

<b>QL Criteria</b>	1 tablet Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Plavix

---

## Products Affected

- PLAVIX ORAL TABLET 75 MG

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Plegridy

---

## Products Affected

- PLEGRIDY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 syringes Per 28 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Plegridy Starter Pack

---

## Products Affected

- PLEGRIDY STARTER PACK

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 syringes Per 28 Days
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PocketChem EZ Test

---

## Products Affected

- POCKETCHEM EZ TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pomalyst

---

## Products Affected

- POMALYST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Portia-28

---

## Products Affected

- *portia-28*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Potiga

---

## Products Affected

- POTIGA ORAL TABLET 400 MG, 300 MG, 200 MG

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Potiga

---

## Products Affected

- POTIGA ORAL TABLET 50 MG

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Praluent

---

## Products Affected

- PRALUENT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 syringes Per 28 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pramipexole Dihydrochloride ER

---

## Products Affected

- *pramipexole dihydrochloride er*

<b>QL Criteria</b>	1 TAB Per 1 DAILY
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pramipexole Dihydrochloride ER

---

## Products Affected

- *pramipexole dihydrochloride er*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PrandiMet

---

## Products Affected

- PRANDIMET

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pravachol

---

## Products Affected

- PRAVACHOL ORAL TABLET 20 MG, 80 MG, 40 MG

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pravastatin Sodium

---

## Products Affected

- *pravastatin sodium*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Precision PCx

---

## Products Affected

- PRECISION PCX

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Precision Xtra

---

## Products Affected

- PRECISION XTRA DEVICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Precision Xtra Blood Glucose

---

## Products Affected

- PRECISION XTRA BLOOD GLUCOSE

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Precision Xtra Monitor

---

## Products Affected

- PRECISION XTRA MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prefest

---

## Products Affected

- PREFEST

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pregnyl

---

## Products Affected

- *pregnyl*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Premarin

---

## Products Affected

- PREMARIN ORAL

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Premphase

---

## Products Affected

- PREMPHASE

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prempro

---

## Products Affected

- PREMPRO

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Prevacid

## Products Affected

- PREVACID ORAL CAPSULE  
DELAYED RELEASE 30 MG

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Gastroesophageal reflux disease, Complications related to GERD (e.g. esophageal strictures, Barrett's Esophagus), Peptic ulcer disease, Treatment and prevention of gastroduodenal ulcers associated with NSAIDs, Zollinger-Ellison Syndrome, or Helicobacter pylori eradication (Additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	1 capsule Per 1 day
Notes/References	
Revision Date	Prior Authorization: November 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prevacid 24HR

---

## Products Affected

- PREVACID 24HR

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prevacid SoluTab

## Products Affected

- PREVACID SOLUTAB

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications
Exclusion Criteria	
Required Medical Information	A documented diagnosis of one of the following: Gastroesophageal reflux disease, Complications related to GERD (e.g. esophageal strictures, Barrett's Esophagus), Peptic ulcer disease, Treatment and prevention of gastroduodenal ulcers associated with NSAIDs, Zollinger-Ellison Syndrome, or Helicobacter pylori eradication (Additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required). In addition for approval the following criteria must also be met: Documentation of an inability to swallow tablets/capsules.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	2 tablets Per 1 Day
Notes/References	Annual Review: 02/2016
Revision Date	Prior Authorization: November 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Previfem

---

## Products Affected

- *previfem*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prezista

---

## Products Affected

- PREZISTA ORAL TABLET 600 MG, 75 MG, 150 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prezista

---

## Products Affected

- PREZISTA ORAL TABLET 800 MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prezista

---

## Products Affected

- PREZISTA ORAL SUSPENSION

<b>QL Criteria</b>	12 milliliters Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pristiq

---

## Products Affected

- PRISTIQ

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Privigen

---

## Products Affected

- PRIVIGEN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/ivig.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Procardia XL

---

## Products Affected

- PROCARDIA XL ORAL TABLET  
EXTENDED RELEASE 24 HR\* 90 MG,  
60 MG

<b>QL Criteria</b>	2 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Procardia XL

---

## Products Affected

- PROCARDIA XL ORAL TABLET  
EXTENDED RELEASE 24 HR\* 30 MG

<b>QL Criteria</b>	1 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ProCentra

---

## Products Affected

- PROCENTRA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Attention deficit hyperactivity disorder (ADHD), Narcolepsy
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of ADHD or Narcolepsy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	40 milliliters Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Procrit

---

## Products Affected

- PROCIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Erythropoiesis_Stimulating_Agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Erythropoiesis_Stimulating_Agents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Procysbi

---

## Products Affected

- PROCYSBI ORAL CAPSULE DELAYED  
RELEASE 75 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	25 CAP Per 1 DAYS
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Procysbi

## Products Affected

- PROCYSBI ORAL CAPSULE DELAYED  
RELEASE 25 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	8 CAP Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prodigy AutoCode Blood Glucose

## Products Affected

- PRODIGY AUTOCODE BLOOD  
GLUCOSE KIT

PA Criteria	Criteria Details
Covered Uses	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Exclusion Criteria	
Required Medical Information	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years, 1 meter per year
Other Criteria	
QL Criteria	1 KIT Per 365 DAYs
Notes/References	
Revision Date	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Prodigy AutoCode Blood Glucose

---

## Products Affected

- PRODIGY AUTOCODE BLOOD  
GLUCOSE DEVICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prodigy No Coding Blood Gluc

---

## Products Affected

- PRODIGY NO CODING BLOOD GLUC

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Profilnine

---

## Products Affected

- PROFILNINE INTRAVENOUS\*  
SOLUTION RECONSTITUTED 1000  
UNIT

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Profilnine SD

---

## Products Affected

- PROFILNINE SD INTRAVENOUS\*  
SOLUTION RECONSTITUTED 500  
UNIT, 1500 UNIT

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Progesterone Micronized

---

## Products Affected

- *progesterone micronized oral*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Prolia

---

## Products Affected

- PROLIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_disease_agents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Promacta

---

## Products Affected

- PROMACTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/promacta.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/promacta.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Promacta

---

## Products Affected

- PROMACTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/promacta.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/promacta.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 EA Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Prometrium

---

## Products Affected

- PROMETRIUM

<b>QL Criteria</b>	2 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Propafenone HCl ER

---

## Products Affected

- *propafenone hcl er*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Protopic

## Products Affected

- PROTOPIC

PA Criteria	Criteria Details
<b>Covered Uses</b>	Atopic dermatitis, Vitiligo
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	FOR PROTOPIC 0.1%: A documented diagnosis of atopic dermatitis (eczema) or vitiligo in an adult or an adolescent 16 years of age or older with either a documented contraindication, intolerance or allergy to one preferred alternative topical corticosteroid indicated for the patient's condition, or a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition, or the treatment is in an area at high risk for skin atrophy such as face, eyelids, or genital areas. FOR PROTOPIC 0.03%: A documented diagnosis of mild to moderate atopic dermatitis (eczema) in patients less than 2 years of age for short-term use (up to 3 months)(Note: requirement of a trial of topical corticosteroid is not required) or a documented diagnosis of atopic dermatitis (eczema) or vitiligo in an adult or child 2 years of age or older and either a documented contraindication, intolerance or allergy to one preferred alternative topical corticosteroid indicated for the patient's condition, or a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition, or the treatment is in an area at high risk for skin atrophy such as face, eyelids, or genital areas.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	

<b>Revision Date</b>	Prior Authorization: October 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

# Provigil

## Products Affected

- PROVIGIL

PA Criteria	Criteria Details
Covered Uses	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
Exclusion Criteria	
Required Medical Information	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	
QL Criteria	2 tabs Per 1 DAYS

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Provigil

## Products Affected

- PROVIGIL

PA Criteria	Criteria Details
<b>Covered Uses</b>	Excessive daytime sleepiness associated with narcolepsy, Excessive daytime sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), Shift Work Sleep Disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	FOR NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of Narcolepsy, such as MSLT, clinical progress notes, etc. (Failure to adequately support the diagnosis of narcolepsy may result in denial of coverage). FOR OSAHS: The prescribing physician is a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a sleep specialist, and a Standard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSAHS, and the patient has received nasal continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) for at least 1 month, and CPAP or BIPAP therapy must be continued on a routine basis in combination with armodafinil therapy, and the daytime fatigue is significantly impacting, impairing, or compromising the patients ability to function normally, and the prescribing physician has established a patient care plan to treat the cause of OSAHS in conjunction with treating the daily fatigue, and patient must be compliant with recommendations for OSAHS treatment.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 Day

<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# PROzac

---

## Products Affected

- PROZAC ORAL CAPSULE 20 MG

<b>QL Criteria</b>	4 cap Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PROzac

---

## Products Affected

- PROZAC ORAL CAPSULE 40 MG

<b>QL Criteria</b>	2 cap Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PROzac

---

## Products Affected

- PROZAC ORAL CAPSULE 10 MG

<b>QL Criteria</b>	1 cap Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# PROzac Weekly

---

## Products Affected

- PROZAC WEEKLY

<b>QL Criteria</b>	0.15 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pulmicort

---

## Products Affected

- PULMICORT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Asthma
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For ages 5-8 documented inability to use metered dose inhalers
<b>Age Restrictions</b>	Less than 8 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Up to the age of 8
<b>Other Criteria</b>	No prior authorization required for children 1-4 years of age. Medical Exception for Pulmicort Respules: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
<b>Notes/References</b>	Annual Review: 07/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pulmicort Flexhaler

---

## Products Affected

- PULMICORT FLEXHALER

PA Criteria	Criteria Details
Covered Uses	Asthma
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Asthma
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy. Medical Exception for Flovent Diskus and Flovent HFA: Covered for topical steroid treatment of eosinophilic esophagitis for which other treatments have been unsatisfactory
QL Criteria	1 inhaler Per 1 month
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Pulmozyme

---

## Products Affected

- PULMOZYME

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/cystic_fibrosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/cystic_fibrosis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 ampules Per 1 day
Notes/References	
Revision Date	Prior Authorization: December 21, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Purixan

---

## Products Affected

- PURIXAN

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	3.5 ML Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Qbrelis

---

## Products Affected

- QBRELIS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Hypertension, Heart Failure, Myocardial Infarction
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of hypertension (Approved only for ages 6 and older), Heart failure, or Myocardial Infarction AND must have a documented inability to swallow tablets/capsules
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 09, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Quartette

---

## Products Affected

- QUARTETTE

<b>QL Criteria</b>	1.5 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Quasense

---

## Products Affected

- *quasense*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Qudexy XR

---

## Products Affected

- QUDEXY XR ORAL 100 MG, 25 MG, 50 MG

<b>QL Criteria</b>	1 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Qudexy XR

---

## Products Affected

- QUDEXY XR ORAL 200 MG, 150 MG

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# QUetiapine Fumarate

---

## Products Affected

- *quetiapine fumarate oral tablet 400 mg, 300 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# QUetiapine Fumarate

---

## Products Affected

- *quetiapine fumarate oral tablet 100 mg, 50 mg*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# QUetiapine Fumarate

---

## Products Affected

- *quetiapine fumarate oral tablet 200 mg*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# QUetiapine Fumarate

---

## Products Affected

- *quetiapine fumarate oral tablet 25 mg*

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# QuilliChew ER

---

## Products Affected

- QUILLICHEW ER ORAL 40 MG, 20 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Attention deficit hyperactivity disorder (ADHD)
<b>Exclusion Criteria</b>	Documentation of a diagnosis of either adult ADHD or of childhood ADHD onset with history of previous treatment and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment)
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# QuilliChew ER

---

## Products Affected

- QUILLICHEW ER ORAL 30 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Attention deficit hyperactivity disorder (ADHD)
<b>Exclusion Criteria</b>	Documentation of a diagnosis of either adult ADHD or of childhood ADHD onset with history of previous treatment and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment)
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Quillivant XR

## Products Affected

- QUILLIVANT XR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Attention deficit disorder, Attention deficit hyperactivity disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis of adult ADD or ADHD OR documentation of a diagnosis of childhood ADHD onset with history of previous treatment, and documentation of symptoms significantly impacting, impairing, or compromising the patient's ability to function normally (i.e., attend/maintain academic enrollment or employment), and documentation of intolerance to appropriately dosed and administered regular/immediate acting stimulants.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	12 milliliters Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# QuiNINE Sulfate

---

## Products Affected

- *quinine sulfate oral*

<b>QL Criteria</b>	42 capsule Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RA Blood Glucose Monitor

---

## Products Affected

- *ra blood glucose monitor*

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RA Nicotine

---

## Products Affected

- *ra nicotine transdermal*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RA TRUEtest Test

---

## Products Affected

- RA TRUETEST TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# RABEprazole Sodium

## Products Affected

- *rabeprazole sodium*

PA Criteria	Criteria Details
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of one of the following: Gastroesophageal reflux disease, Complications related to GERD (e.g. esophageal strictures, Barrett's Esophagus), Peptic ulcer disease, Treatment and prevention of gastroduodenal ulcers associated with NSAIDs, Zollinger-Ellison Syndrome, or Helicobacter pylori eradication (Additional documentation of two concurrent antibiotics (i.e. amoxicillin or clarithromycin or metronidazole or tetracycline) that will be used in the treatment regimen combined with the requested PPI as part of the therapy are required).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: November 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ranexa

---

## Products Affected

- RANEXA

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ravicti

## Products Affected

- RAVICTI

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	20 bottles Per 30 months
Notes/References	
Revision Date	Prior Authorization: August 31, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Razadyne

---

## Products Affected

- RAZADYNE ORAL TABLET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Alzheimer's Disease
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
<b>Age Restrictions</b>	less than 40 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rebetol

---

## Products Affected

- REBETOL ORAL SOLUTION

<b>QL Criteria</b>	5 bottles Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rebif

---

## Products Affected

- REBIF SUBCUTANEOUS\*

<b>QL Criteria</b>	12 syringes Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rebif Rebidose

---

## Products Affected

- REBIF REBIDOSE SUBCUTANEOUS\*

<b>QL Criteria</b>	12 syringes Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rebif Rebidoose Titration Pack

---

## Products Affected

- REBIF REBIDOSE TITRATION PACK  
SUBCUTANEOUS\*

<b>QL Criteria</b>	1 pack Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Rebif Titration Pack

---

## Products Affected

- REBIF TITRATION PACK  
SUBCUTANEOUS\*

<b>QL Criteria</b>	1 pack Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Reclast

---

## Products Affected

- RECLAST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_diasease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_diasease_agents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Reclipsen

---

## Products Affected

- *reclipsen*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Recombinate

---

## Products Affected

- RECOMBINATE

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rectiv

---

## Products Affected

- RECTIV

<b>QL Criteria</b>	1 tube Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RefuAH Plus Blood Glucose Test

---

## Products Affected

- REFUAH PLUS BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Relenza Diskhaler

---

## Products Affected

- RELENZA DISKHALER

<b>QL Criteria</b>	40 disks Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ReliOn Prime Monitor

---

## Products Affected

- RELION PRIME MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Relistor

---

## Products Affected

- RELISTOR ORAL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Opioid-induced constipation (OIC) in adults with chronic non-cancer pain
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of opioid induced constipation due to non-cancer pain and documented concomitant use of opioid therapy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Relistor

## Products Affected

- RELISTOR SUBCUTANEOUS\*  
SOLUTION 12 MG/0.6ML

PA Criteria	Criteria Details
Covered Uses	Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, OIC in adults with advanced illness
Exclusion Criteria	
Required Medical Information	A documented diagnosis of opioid induced constipation due to non-cancer pain, OR a documented diagnosis of an advanced illness (i.e., incurable cancer, end-stage COPD/emphysema, cardiovascular disease/heart failure, Alzheimer's disease/dementia, HIV/AIDS), receiving palliative care, and response to laxative therapy has not been sufficient and documented concomitant use of opioid therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
QL Criteria	0.6 ML Per 1 Day
Notes/References	
Revision Date	Prior Authorization: September 09, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Relistor

## Products Affected

- RELISTOR SUBCUTANEOUS\* KIT

PA Criteria	Criteria Details
<b>Covered Uses</b>	Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, OIC in adults with advanced illness
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of opioid induced constipation due to non-cancer pain, OR a documented diagnosis of an advanced illness (i.e., incurable cancer, end-stage COPD/emphysema, cardiovascular disease/heart failure, Alzheimer's disease/dementia, HIV/AIDS), receiving palliative care, and response to laxative therapy has not been sufficient and documented concomitant use of opioid therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	0.14 ml Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 09, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Relistor

## Products Affected

- RELISTOR SUBCUTANEOUS\*  
SOLUTION 8 MG/0.4ML

PA Criteria	Criteria Details
<b>Covered Uses</b>	Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, OIC in adults with advanced illness
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of opioid induced constipation due to non-cancer pain, OR a documented diagnosis of an advanced illness (i.e., incurable cancer, end-stage COPD/emphysema, cardiovascular disease/heart failure, Alzheimer's disease/dementia, HIV/AIDS), receiving palliative care, and response to laxative therapy has not been sufficient and documented concomitant use of opioid therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	0.4 ML Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 09, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Relpax

---

## Products Affected

- RELPAX

<b>QL Criteria</b>	6 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Remeron

---

## Products Affected

- REMERON

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Remeron SolTab

---

## Products Affected

- REMERON SOLTAB

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Remicade

---

## Products Affected

- REMICADE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Remodulin

---

## Products Affected

- REMODULIN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Repaglinide-Metformin HCl

---

## Products Affected

- *repaglinide-metformin hcl*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Repatha

---

## Products Affected

- REPATHA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 syringes Per 28 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Repatha Pushtronex System

## Products Affected

- REPATHA PUSHTRONEX SYSTEM

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxonmedicare/data/2016/MISC/PCSK9.html">http://www.aetna.com/products/rxonmedicare/data/2016/MISC/PCSK9.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 syringe Per 30 days
Notes/References	
Revision Date	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Repatha SureClick

---

## Products Affected

- REPATHA SURECLICK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/PCSK9.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 syringes Per 28 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Repronex

---

## Products Affected

- REPRONEX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/infertility.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Requip XL

---

## Products Affected

- REQUIP XL ORAL TABLET  
EXTENDED RELEASE 24 HR\* 4 MG, 6  
MG, 8 MG

<b>QL Criteria</b>	1 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Requip XL

---

## Products Affected

- REQUIP XL ORAL TABLET  
EXTENDED RELEASE 24 HR\* 12 MG

<b>QL Criteria</b>	2 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Rescula

---

## Products Affected

- RESCULA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	open-angle glaucoma, ocular hypertension
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of glaucoma or ocular hypertension
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>Notes/References</b>	Annual Review: 03/2016
<b>Revision Date</b>	Prior Authorization: May 28, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Restoril

---

## Products Affected

- RESTORIL ORAL CAPSULE 22.5 MG,  
7.5 MG

<b>QL Criteria</b>	1 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Retin-A

## Products Affected

- RETIN-A

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Retin-A Micro

## Products Affected

- RETIN-A MICRO

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Retin-A Micro Pump

## Products Affected

- RETIN-A MICRO PUMP

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Revatio

---

## Products Affected

- REVATIO ORAL SUSPENSION RECONSTITUTED
- REVATIO INTRAVENOUS\*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Revatio

---

## Products Affected

- REVATIO ORAL TABLET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	3 TABS Per 1 DAYS
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Reveal Blood Glucose Test

---

## Products Affected

- REVEAL BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Revlimid

## Products Affected

- REVLIMID

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 capsule Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rexall Blood Glucose Test

---

## Products Affected

- REXALL BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rexulti

---

## Products Affected

- REXULTI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Major depressive disorder, Schizophrenia
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of major depressive disorder or Schizophrenia
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Step Therapy
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/References</b>	Annual Review: 08/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Reyataz

---

## Products Affected

- REYATAZ ORAL CAPSULE 200 MG

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Reyataz

---

## Products Affected

- REYATAZ ORAL CAPSULE 300 MG,  
150 MG

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RiaSTAP

---

## Products Affected

- RIASTAP

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Rightest GS100 Blood Glucose

---

### Products Affected

- RIGHTEST GS100 BLOOD GLUCOSE

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rightest GS300 Blood Glucose

---

## Products Affected

- RIGHTEST GS300 BLOOD GLUCOSE

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



## Rightest GS550 Blood Glucose

---

### Products Affected

- RIGHTEST GS550 BLOOD GLUCOSE

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rilutek

---

## Products Affected

- RILUTEK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	amyotrophic lateral sclerosis (ALS)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of amyotrophic lateral sclerosis (ALS)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Riluzole

---

## Products Affected

- *riluzole*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	amyotrophic lateral sclerosis (ALS)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of amyotrophic lateral sclerosis (ALS)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Risedronate Sodium

---

## Products Affected

- *risedronate sodium oral tablet 35 mg*
- *risedronate sodium oral tablet delayed release*

<b>QL Criteria</b>	4 tablets Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Risedronate Sodium

---

## Products Affected

- *risedronate sodium oral tablet 5 mg, 30 mg*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Risedronate Sodium

---

## Products Affected

- *risedronate sodium oral tablet 150 mg*

<b>QL Criteria</b>	1 tablet Per 1 month
<b>Notes/ References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperDAL

---

## Products Affected

- RISPERDAL ORAL TABLET 3 MG, 1 MG, 2 MG, 0.5 MG, 0.25 MG

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperDAL

---

## Products Affected

- RISPERDAL ORAL TABLET 4 MG

<b>QL Criteria</b>	4 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# RisperDAL M-TAB

---

## Products Affected

- RISPERDAL M-TAB ORAL TABLET  
DISPERSIBLE 4 MG

<b>QL Criteria</b>	4 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperDAL M-TAB

---

## Products Affected

- RISPERDAL M-TAB ORAL TABLET  
DISPERSIBLE 2 MG, 1 MG, 0.5 MG

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperDAL M-TAB

---

## Products Affected

- RISPERDAL M-TAB ORAL TABLET  
DISPERSIBLE 3 MG

<b>QL Criteria</b>	3 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperiDONE

---

## Products Affected

- *risperidone oral tablet 1 mg, 2 mg, 0.25 mg, 0.5 mg*
- *risperidone oral tablet dispersible 0.5 mg, 1 mg, 2 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperiDONE

---

## Products Affected

- *risperidone oral tablet 3 mg*
- *risperidone oral tablet dispersible 3 mg*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperiDONE

---

## Products Affected

- *risperidone oral tablet dispersible 4 mg*
- *risperidone oral tablet 4 mg*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperiDONE M-TAB

---

## Products Affected

- RISPERIDONE M-TAB ORAL TABLET  
DISPERSIBLE 2 MG, 0.5 MG, 1 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# RisperiDONE M-TAB

---

## Products Affected

- RISPERIDONE M-TAB ORAL TABLET  
DISPERSIBLE 3 MG

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# RisperiDONE M-TAB

---

## Products Affected

- RISPERIDONE M-TAB ORAL TABLET  
DISPERSIBLE 4 MG

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ritalin

---

## Products Affected

- RITALIN

<b>QL Criteria</b>	6 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ritalin LA

---

## Products Affected

- RITALIN LA ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 30  
MG, 10 MG

<b>QL Criteria</b>	2 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ritalin LA

---

## Products Affected

- RITALIN LA ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 40  
MG, 20 MG

<b>QL Criteria</b>	1 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ritalin LA

---

## Products Affected

- RITALIN LA ORAL CAPSULE  
EXTENDED RELEASE 24 HOUR 60 MG

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rivastigmine

---

## Products Affected

- *rivastigmine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Alzheimer's Disease
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
<b>Age Restrictions</b>	less than 40 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rivastigmine Tartrate

---

## Products Affected

- *rivastigmine tartrate*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Alzheimer's Disease
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of mild, moderate, severe Alzheimer's Disease
<b>Age Restrictions</b>	less than 40 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rixubis

---

## Products Affected

- RIXUBIS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Rizatriptan Benzoate

---

## Products Affected

- *rizatriptan benzoate*

<b>QL Criteria</b>	9 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ROPINIRole HCl ER

---

## Products Affected

- *ropinirole hcl er oral tablet extended release 24 hr\* 6 mg, 8 mg, 4 mg, 2 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ROPINIRole HCl ER

---

## Products Affected

- *ropinirole hcl er oral tablet extended release 24 hr\* 12 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rosuvastatin Calcium

---

## Products Affected

- *rosuvastatin calcium*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rozerem

---

## Products Affected

- ROZEREM

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ruconest

---

## Products Affected

- RUCONEST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/hereditary_angioedema.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/hereditary_angioedema.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Rythmol SR

---

## Products Affected

- RYTHMOL SR

<b>QL Criteria</b>	2 CP12 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sabril

---

## Products Affected

- SABRIL

<b>QL Criteria</b>	6 packets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Sabril

---

## Products Affected

- SABRIL

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Safyral

---

## Products Affected

- SAFYRAL

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Saizen

---

## Products Affected

- SAIZEN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Samsca

---

## Products Affected

- SAMSCA ORAL TABLET 30 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CV/samsca.htm">http://www.aetna.com/products/rxnonmedicare/data/2016/CV/samsca.htm</a> 1
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Samsca

---

## Products Affected

- SAMSCA ORAL TABLET 15 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CV/samsca.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CV/samsca.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sancuso

---

## Products Affected

- SANCUSO

<b>QL Criteria</b>	1 patch Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Saphris

---

## Products Affected

- SAPHRIS

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Savella

---

## Products Affected

- SAVELLA

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 03/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Savella Titration Pack

---

## Products Affected

- SAVELLA TITRATION PACK

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	Annual Review: 03/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Seasonique

---

## Products Affected

- SEASONIQUE

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Seebri Neohaler

---

## Products Affected

- SEEBRI NEOHALER

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Selzentry

---

## Products Affected

- SELZENTRY ORAL TABLET 150 MG

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sensipar

---

## Products Affected

- SENSIPAR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Documented diagnosis of hyperparathyroidism & parathyroid carcinoma or other FDA approved indication
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Step Therapy
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Serevent Diskus

---

## Products Affected

- SEREVENT DISKUS

<b>QL Criteria</b>	2 blisters Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SEROquel

---

## Products Affected

- SEROQUEL ORAL TABLET 25 MG

<b>QL Criteria</b>	6 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SEROquel

---

## Products Affected

- SEROQUEL ORAL TABLET 300 MG,  
400 MG

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# SEROquel

---

## Products Affected

- SEROQUEL ORAL TABLET 200 MG

<b>QL Criteria</b>	4 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SEROquel

---

## Products Affected

- SEROQUEL ORAL TABLET 50 MG, 100 MG

<b>QL Criteria</b>	3 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SEROquel XR

---

## Products Affected

- SEROQUEL XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 150 MG,  
200 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Major depressive disorder, Bipolar disorder or schizophrenia
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of Major Depressive Disorder, Bipolar Disorder or Schizophrenia
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	Step Therapy
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SEROquel XR

## Products Affected

- SEROQUEL XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 300 MG,  
400 MG, 50 MG

PA Criteria	Criteria Details
Covered Uses	Major depressive disorder, Bipolar disorder or schizophrenia
Exclusion Criteria	
Required Medical Information	A documented diagnosis of Major Depressive Disorder, Bipolar Disorder or Schizophrenia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 years
Other Criteria	Step Therapy
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Serostim

## Products Affected

- SEROSTIM SUBCUTANEOUS\*  
SOLUTION RECONSTITUTED 4 MG, 6  
MG, 5 MG

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sertraline HCl

---

## Products Affected

- *sertraline hcl oral concentrate*

<b>QL Criteria</b>	10 ml Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sertraline HCl

---

## Products Affected

- *sertraline hcl oral tablet 50 mg*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sertraline HCl

---

## Products Affected

- *sertraline hcl oral tablet 100 mg*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Sertraline HCl

---

## Products Affected

- *sertraline hcl oral tablet 25 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sharobel

---

## Products Affected

- SHAROBEL

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Signifor

## Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/Signifor.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/Signifor.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 SOLN Per 1 DAYS
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Signifor LAR

---

## Products Affected

- SIGNIFOR LAR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/Signifor.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/Signifor.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 EA Per 28 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sildenafil Citrate

---

## Products Affected

- *sildenafil citrate oral*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Simcor

---

## Products Affected

- SIMCOR ORAL TABLET EXTENDED  
RELEASE 24 HR\* 1000-40 MG, 500-40  
MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Simcor

---

## Products Affected

- SIMCOR ORAL TABLET EXTENDED  
RELEASE 24 HR\* 500-20 MG, 750-20  
MG, 1000-20 MG

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Simponi

## Products Affected

- SIMPONI SUBCUTANEOUS\*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 syringe Per 1 month
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Simponi Aria

---

## Products Affected

- SIMPONI ARIA

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 vial Per 1 month
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Simvastatin

---

## Products Affected

- *simvastatin oral*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Singular

---

## Products Affected

- SINGULAIR ORAL PACKET

<b>QL Criteria</b>	1 PACK Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sirturo

---

## Products Affected

- SIRTURO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Multi-drug resistant tuberculosis
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	18 years or greater
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	
<b>QL Criteria</b>	188 EA Per 365 Days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Skyla

---

## Products Affected

- SKYLA

<b>QL Criteria</b>	1 IUD Per 365 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SM Nicotine

---

## Products Affected

- *sm nicotine transdermal*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Smartest Blood Glucose Test

---

## Products Affected

- SMARTEST BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Smartest Eject

---

## Products Affected

- SMARTEST EJECT

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Smartest Protege

---

## Products Affected

- SMARTEST PROTEGE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sodium Phenylbutyrate

---

## Products Affected

- *sodium phenylbutyrate oral powder 3 gm/tsp*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/metabolic_agents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
Notes/References	
Revision Date	Prior Authorization: August 31, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Solia

---

## Products Affected

- *solia*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Soliris

---

## Products Affected

- SOLIRIS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/soliris.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/soliris.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Solus V2 Test

---

## Products Affected

- SOLUS V2 TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Somavert

---

## Products Affected

- SOMAVERT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sonata

---

## Products Affected

- SONATA ORAL CAPSULE 10 MG

<b>QL Criteria</b>	2 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sonata

---

## Products Affected

- SONATA ORAL CAPSULE 5 MG

<b>QL Criteria</b>	3 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Soriatane

---

## Products Affected

- SORIATANE ORAL CAPSULE 10 MG, 17.5 MG, 25 MG

<b>QL Criteria</b>	2 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sovaldi

---

## Products Affected

- SOVALDI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Spiriva HandiHaler

---

## Products Affected

- SPIRIVA HANDIHALER

<b>QL Criteria</b>	1 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Spiriva Respimat

---

## Products Affected

- SPIRIVA RESPIMAT

<b>QL Criteria</b>	1 inhaler Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sporanox

---

## Products Affected

- SPORANOX ORAL CAPSULE

<b>QL Criteria</b>	1 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sporanox Pulsepak

---

## Products Affected

- SPORANOX PULSEPAK

<b>QL Criteria</b>	1 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sprintec 28

---

## Products Affected

- *sprintec 28*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Spritam

---

## Products Affected

- SPRITAM

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Sprix

---

## Products Affected

- SPRIX

<b>QL Criteria</b>	5 UD sprays Per 30 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sprycel

## Products Affected

- SPRYCEL ORAL TABLET 140 MG, 100 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 tablet Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sprycel

## Products Affected

- SPRYCEL ORAL TABLET 20 MG, 80 MG, 50 MG, 70 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	2 tablets Per 1 day
Notes/References	
Revision Date	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sronyx

---

## Products Affected

- *sronyx*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Stelara

## Products Affected

- STELARA INTRAVENOUS\*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/Stelara.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/Stelara.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 vials Per 30 days
Notes/References	
Revision Date	Prior Authorization: November 08, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Stelara

---

## Products Affected

- STELARA SUBCUTANEOUS\*

<b>QL Criteria</b>	1 syringe Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Stiolto Respimat

---

## Products Affected

- STIOLTO RESPIMAT

<b>QL Criteria</b>	1 inhaler Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Stivarga

---

## Products Affected

- STIVARGA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Strattera

---

## Products Affected

- STRATTERA

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Stribild

---

## Products Affected

- STRIBILD

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Suboxone

## Products Affected

- SUBOXONE SUBLINGUAL FILM 8-2  
MG, 4-1 MG, 2-0.5 MG

PA Criteria	Criteria Details
<b>Covered Uses</b>	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
<b>Exclusion Criteria</b>	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
<b>Required Medical Information</b>	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months = current enrollement

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
Updated 12/2016

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at <a href="http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx">http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx</a> . Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
<b>QL Criteria</b>	3 films Per 1 day
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Suboxone

## Products Affected

- SUBOXONE SUBLINGUAL TABLET  
SUBLINGUAL

PA Criteria	Criteria Details
<b>Covered Uses</b>	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
<b>Exclusion Criteria</b>	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
<b>Required Medical Information</b>	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months = current enrollement

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
Updated 12/2016

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at <a href="http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jsp">http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jsp</a> . Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Suboxone

## Products Affected

- SUBOXONE SUBLINGUAL FILM 12-3 MG

PA Criteria	Criteria Details
<b>Covered Uses</b>	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
<b>Exclusion Criteria</b>	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
<b>Required Medical Information</b>	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months = current enrollement

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
Updated 12/2016

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at <a href="http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx">http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx</a>. Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
<b>QL Criteria</b>	2 films Per 1 day
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Subsys

## Products Affected

- SUBSYS

PA Criteria	Criteria Details
<b>Covered Uses</b>	For pain due to malignant diagnosis only
<b>Exclusion Criteria</b>	Use in non-malignant pain
<b>Required Medical Information</b>	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))

<b>QL Criteria</b>	8 sprays Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: October 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Subsys

## Products Affected

- SUBSYS

PA Criteria	Criteria Details
<b>Covered Uses</b>	For pain due to malignant diagnosis only
<b>Exclusion Criteria</b>	Use in non-malignant pain
<b>Required Medical Information</b>	A documented diagnosis of cancer with concomitant use of around the clock long acting opioid therapy for cancer pain, requiring management of breakthrough pain and meet step therapy requirements, or the patient is terminally ill.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	For additional quantities, the member must have a documented diagnosis of cancer and prescription is written by an oncologist or pain specialist, or the member is enrolled in a hospice program or meets hospice criteria, or the member is terminally ill, or the patient has signed an opioid agreement in support of clinical guidelines by the American Pain Society and the American Academy of Pain Medicine. In addition, there must be documentation of one of the following: (1) A Healthcare Provider verbal confirmation that an agreement has been signed by the patient meets the criteria requirement (exceptions to requiring the signed opioid agreement for additional quantities are only for those patients that have a diagnosis of cancer or that are enrolled in a hospice program), or (2) the member has current diagnosis of cancer(see exception to opioid agreement above) as the primary cause of the pain and is currently on long-acting opioid and is being titrated on the long-acting opioid by physician, and the member has tried and failed an adequate trial of two weeks of a single entity or combination pain medication containing an immediate release acting opioid (ex. oxycodone, morphine sulfate oral(Roxanol), oxymorphone(Opana), hydromorphone(Dilaudid), oxycodone/apap(Percocet))

<b>QL Criteria</b>	8 sprays Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: October 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sular

---

## Products Affected

- SULAR ORAL TABLET EXTENDED RELEASE 24 HR\* 17 MG, 8.5 MG, 34 MG

<b>QL Criteria</b>	1 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SulfaSALazine

---

## Products Affected

- *sulfasalazine oral*

<b>QL Criteria</b>	8 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sulfazine

---

## Products Affected

- *sulfazine*

<b>QL Criteria</b>	8 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sulfazine EC

---

## Products Affected

- SULFAZINE EC

<b>QL Criteria</b>	8 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# SUMAtriptan

---

## Products Affected

- *sumatriptan nasal*

<b>QL Criteria</b>	6 sprays Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SUMAtriptan Succinate

---

## Products Affected

- *sumatriptan succinate oral*

<b>QL Criteria</b>	9 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SUMAtriptan Succinate

---

## Products Affected

- *sumatriptan succinate subcutaneous\** 6 mg/0.5ml, 4 mg/0.5ml
- *sumatriptan succinate subcutaneous\** solution 4 mg/0.5ml

<b>QL Criteria</b>	2 boxes (4 doses) Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SUMAtriptan Succinate

---

## Products Affected

- *sumatriptan succinate subcutaneous\**  
*solution 6 mg/0.5ml*

<b>QL Criteria</b>	8 vials Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SUMAtriptan Succinate Refill

---

## Products Affected

- *sumatriptan succinate refill subcutaneous\**

<b>QL Criteria</b>	2 boxes (4 doses) Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Supartz

---

## Products Affected

- SUPARTZ INTRA-ARTICULAR\*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sure Edge Glucose Monitor

---

## Products Affected

- SURE EDGE GLUCOSE MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sure Edge Test

---

## Products Affected

- SURE EDGE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# SureChek Blood Glucose Monitor

---

## Products Affected

- SURECHEK BLOOD GLUCOSE MONITOR DEVICE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SureChek Blood Glucose Test

---

## Products Affected

- SURECHEK BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sure-Test EasyPlus Mini Meter

---

## Products Affected

- SURE-TEST EASYPLUS MINI METER

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sure-Test EasyPlus Mini Test

---

## Products Affected

- SURE-TEST EASYPLUS MINI TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sutent

---

## Products Affected

- SUTENT

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Syeda

---

## Products Affected

- *syeda*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Sylatron

---

## Products Affected

- SYLATRON SUBCUTANEOUS\* KIT  
200 MCG, 4 X 200 MCG, 300 MCG, 600 MCG, 4 X 300 MCG

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Symbicort

---

## Products Affected

- SYMBICORT

<b>QL Criteria</b>	1 inhaler Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Symbyax

---

## Products Affected

- SYMBYAX ORAL CAPSULE 12-25 MG, 6-25 MG, 6-50 MG, 12-50 MG

<b>QL Criteria</b>	1 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Symlin

## Products Affected

- SYMLIN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes, Type 2 Diabetes
<b>Exclusion Criteria</b>	Poor compliance with current insulin regimen, poor compliance with prescribed self-blood glucose monitoring, an A1C greater than 9%, recurrent severe hypoglycemia requiring assistance during the previous 6 months, presence of hypoglycemia unawareness, confirmed diagnosis of gastroparesis, need for medications that stimulate GI motility, patient is less than 18 years old, concurrent use with other oral antidiabetic medications (except metformin and sulfonylureas) or drugs that alter gastrointestinal motility
<b>Required Medical Information</b>	A documented diagnosis of type I or type II diabetes and concurrent use of a rapid or short-acting insulin i.e., Humalog or regular insulin
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 Months (initial)
<b>Other Criteria</b>	12 month extended approval if patient has demonstrated expected reduction in HbA1c since starting therapy.
<b>Notes/References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SymLinPen 120

## Products Affected

- SYMLINPEN 120 SUBCUTANEOUS\*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Type 1 Diabetes, Type 2 Diabetes
<b>Exclusion Criteria</b>	Poor compliance with current insulin regimen, poor compliance with prescribed self-blood glucose monitoring, an A1C greater than 9%, recurrent severe hypoglycemia requiring assistance during the previous 6 months, presence of hypoglycemia unawareness, confirmed diagnosis of gastroparesis, need for medications that stimulate GI motility, patient is less than 18 years old, concurrent use with other oral antidiabetic medications (except metformin and sulfonylureas) or drugs that alter gastrointestinal motility
<b>Required Medical Information</b>	A documented diagnosis of type I or type II diabetes and concurrent use of a rapid or short-acting insulin i.e., Humalog or regular insulin
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 Months (initial)
<b>Other Criteria</b>	12 month extended approval if patient has demonstrated expected reduction in HbA1c since starting therapy.
<b>Notes/References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# SymLinPen 60

## Products Affected

- SYMLINPEN 60 SUBCUTANEOUS\*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Type 1 Diabetes, Type 2 Diabetes
<b>Exclusion Criteria</b>	Poor compliance with current insulin regimen, poor compliance with prescribed self-blood glucose monitoring, an A1C greater than 9%, recurrent severe hypoglycemia requiring assistance during the previous 6 months, presence of hypoglycemia unawareness, confirmed diagnosis of gastroparesis, need for medications that stimulate GI motility, patient is less than 18 years old, concurrent use with other oral antidiabetic medications (except metformin and sulfonylureas) or drugs that alter gastrointestinal motility
<b>Required Medical Information</b>	A documented diagnosis of type I or type II diabetes and concurrent use of a rapid or short-acting insulin i.e., Humalog or regular insulin
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 Months (initial)
<b>Other Criteria</b>	12 month extended approval if patient has demonstrated expected reduction in HbA1c since starting therapy.
<b>Notes/References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Synagis

---

## Products Affected

- SYNAGIS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Synagis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/Synagis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Synjardy

---

## Products Affected

- SYNJARDY

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Synribo

---

## Products Affected

- SYNRIBO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Synvisc

---

## Products Affected

- SYNVISIC INTRA-ARTICULAR\*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Synvisc One

---

## Products Affected

- SYNVISIC ONE INTRA-ARTICULAR\*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/viscosupplements.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: June 01, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tacrolimus

## Products Affected

- *tacrolimus external*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Atopic dermatitis, Vitiligo
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	FOR PROTOPIC 0.1%: A documented diagnosis of atopic dermatitis (eczema) or vitiligo in an adult or an adolescent 16 years of age or older with either a documented contraindication, intolerance or allergy to one preferred alternative topical corticosteroid indicated for the patient's condition, or a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition, or the treatment is in an area at high risk for skin atrophy such as face, eyelids, or genital areas. FOR PROTOPIC 0.03%: A documented diagnosis of mild to moderate atopic dermatitis (eczema) in patients less than 2 years of age for short-term use (up to 3 months)(Note: requirement of a trial of topical corticosteroid is not required) or a documented diagnosis of atopic dermatitis (eczema) or vitiligo in an adult or child 2 years of age or older and either a documented contraindication, intolerance or allergy to one preferred alternative topical corticosteroid indicated for the patient's condition, or a documented failure of an adequate trial of 2 weeks (14 days) of one preferred alternative topical corticosteroid indicated for the patient's condition, or the treatment is in an area at high risk for skin atrophy such as face, eyelids, or genital areas.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
Updated 12/2016

<b>Revision Date</b>	Prior Authorization: October 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

# Tafinlar

---

## Products Affected

- TAFINLAR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 EA Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tagrisso

---

## Products Affected

- TAGRISSO

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Take Action

---

## Products Affected

- *take action*

<b>QL Criteria</b>	1 tablet Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Taltz

---

## Products Affected

- TALTZ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tamiflu

---

## Products Affected

- TAMIFLU ORAL CAPSULE

<b>QL Criteria</b>	20 capsules Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Tamiflu

---

## Products Affected

- TAMIFLU ORAL SUSPENSION  
RECONSTITUTED 6 MG/ML

<b>QL Criteria</b>	1 bottle Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tanzeum

---

## Products Affected

- TANZEUM

<b>QL Criteria</b>	4 pens Per 1 month
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tarceva

---

## Products Affected

- TARCEVA

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tasigna

---

## Products Affected

- TASIGNA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 capsules Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Taytulla

---

## Products Affected

- TAYTULLA

<b>QL Criteria</b>	1.5 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Taztia XT

---

## Products Affected

- *taztia xt oral capsule extended release 24 hour 120 mg, 180 mg, 360 mg, 300 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Taztia XT

---

## Products Affected

- *taztia xt oral capsule extended release 24 hour 240 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tecfidera

---

## Products Affected

- TECFIDERA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 CPDR Per 1 DAYS
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Tecfidera

---

## Products Affected

- TECFIDERA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 EA Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Technivie

---

## Products Affected

- TECHNIVIE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 EA Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tekamlo

---

## Products Affected

- TEKAMLO

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tekturna

---

## Products Affected

- TEKTURNA

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tekturna HCT

---

## Products Affected

- TEKTURNA HCT

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Telcare Blood Glucose Test

---

## Products Affected

- TELCARE BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Telmisartan

---

## Products Affected

- *telmisartan*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Telmisartan-Amlodipine

---

## Products Affected

- *telmisartan-amlodipine*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Telmisartan-HCTZ

---

## Products Affected

- *telmisartan-hctz*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Temazepam

---

## Products Affected

- *temazepam oral capsule 7.5 mg, 22.5 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Testim

## Products Affected

- TESTIM

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	10 grams Per 1 fill
<b>Notes/References</b>	Annual Review: 02/2016

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

# Testosterone

## Products Affected

- *testosterone transdermal gel 10 mg/act (2%), 50 mg/5gm (1%), 25 mg/2.5gm (1%), 12.5 mg/act (1%)*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	10 grams Per 1 fill
<b>Notes/References</b>	

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

# Testosterone Cypionate

---

## Products Affected

- *testosterone cypionate intramuscular\**  
*solution 250 mg/ml*

<b>QL Criteria</b>	4 ml Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Testosterone Cypionate

---

## Products Affected

- *testosterone cypionate intramuscular\**  
*solution 100 mg/ml*

<b>QL Criteria</b>	10 vials Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Testosterone Cypionate

---

## Products Affected

- *testosterone cypionate intramuscular\**  
*solution 200 mg/ml*

<b>QL Criteria</b>	10 ml Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tetrabenazine

---

## Products Affected

- *tetrabenazine oral tablet 25 mg*

<b>QL Criteria</b>	4 EA Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tetrabenazine

---

## Products Affected

- *tetrabenazine oral tablet 12.5 mg*

<b>QL Criteria</b>	8 EA Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Teveten HCT

---

## Products Affected

- TEVETEN HCT ORAL TABLET 600-25  
MG

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tev-Tropin

---

## Products Affected

- TEV-TROPIN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TGT Blood Glucose Monitoring

## Products Affected

- TGT BLOOD GLUCOSE MONITORING

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TGT Nicotine Step One

---

## Products Affected

- *tgt nicotine step one*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TGT Nicotine Step Three

---

## Products Affected

- *tgt nicotine step three*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# TGT Nicotine Step Two

---

## Products Affected

- *tgt nicotine step two*

<b>QL Criteria</b>	1 patch Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Thrive

---

## Products Affected

- *thrive mouth/throat gum 2 mg*

<b>QL Criteria</b>	24 EA Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TiaGABine HCl

---

## Products Affected

- *tiagabine hcl oral tablet 4 mg*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TiaGABine HCl

---

## Products Affected

- *tiagabine hcl oral tablet 2 mg*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tiazac

---

## Products Affected

- TIAZAC ORAL CAPSULE EXTENDED  
RELEASE 24 HOUR 240 MG

<b>QL Criteria</b>	2 CP24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tiazac

---

## Products Affected

- TIAZAC ORAL CAPSULE EXTENDED  
RELEASE 24 HOUR 360 MG, 180 MG,  
420 MG, 120 MG, 300 MG

<b>QL Criteria</b>	1 CP24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tilia Fe

---

## Products Affected

- *tilia fe*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tirosint

---

## Products Affected

- TIROSINT

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Tivicay

---

## Products Affected

- TIVICAY

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tivicay

---

## Products Affected

- TIVICAY

<b>QL Criteria</b>	2 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tivorbex

---

## Products Affected

- TIVORBEX

<b>QL Criteria</b>	3 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tobi

---

## Products Affected

- TOBI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ID/Aminoglycosides.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ID/Aminoglycosides.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	56 ML Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: February 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tobi Podhaler

---

## Products Affected

- TOBI PODHALER

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ID/Aminoglycosides.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ID/Aminoglycosides.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 CAPS Per 28 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: February 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tobramycin

---

## Products Affected

- *tobramycin inhalation*

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ID/Aminoglycosides.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ID/Aminoglycosides.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	10 ml Per 1 day
Notes/References	
Revision Date	Prior Authorization: February 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tolterodine Tartrate ER

---

## Products Affected

- *tolterodine tartrate er*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Topamax Sprinkle

---

## Products Affected

- TOPAMAX SPRINKLE

<b>QL Criteria</b>	4 CPSP Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Topiramate

---

## Products Affected

- *topiramate oral capsule sprinkle*

<b>QL Criteria</b>	4 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Toprol XL

---

## Products Affected

- TOPROL XL ORAL TABLET  
EXTENDED RELEASE 24 HR\* 200 MG

<b>QL Criteria</b>	2 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Toprol XL

---

## Products Affected

- TOPROL XL ORAL TABLET  
EXTENDED RELEASE 24 HR\* 25 MG

<b>QL Criteria</b>	1 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Toprol XL

---

## Products Affected

- TOPROL XL ORAL TABLET  
EXTENDED RELEASE 24 HR\* 100 MG,  
50 MG

<b>QL Criteria</b>	1.5 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Toujeo SoloStar

---

## Products Affected

- TOUJEO SOLOSTAR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 or Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Type 1 or Type 2 Diabetes Mellitus
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Step therapy
<b>Notes/References</b>	Annual Review: 03/2016
<b>Revision Date</b>	Prior Authorization: April 22, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Toviaz

---

## Products Affected

- TOVIAZ

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tradjenta

---

## Products Affected

- TRADJENTA

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TraMADol HCl ER

---

## Products Affected

- *tramadol hcl er oral tablet extended release 24 hr\**

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# TraMADol HCl ER (Biphasic)

---

## Products Affected

- *tramadol hcl er (biphasic)*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tramadol-Acetaminophen

---

## Products Affected

- *tramadol-acetaminophen*

<b>QL Criteria</b>	8 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tranexamic Acid

---

## Products Affected

- *tranexamic acid oral*

<b>QL Criteria</b>	30 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tretinoin

## Products Affected

- *tretinoin external gel 0.01 %*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tretinoin

## Products Affected

- *tretinoin external cream*
- *tretinoin external gel 0.025 %*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	50 grams Per 1 fill
<b>Notes/References</b>	

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

# Tretinoin

---

## Products Affected

- *tretinoin external gel 0.05 %*

<b>QL Criteria</b>	50 grams Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tretinoin Microsphere

## Products Affected

- *tretinoin microsphere*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Tretinoin Microsphere Pump

## Products Affected

- *tretinoin microsphere pump*

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tretin-X

## Products Affected

- TRETIN-X EXTERNAL CREAM

PA Criteria	Criteria Details
<b>Covered Uses</b>	Acne Vulgaris (including comedonal, cystic, nodular and papular acne), actinic keratoses with lesions, hypertrophic scars or keloids, keratosis follicularis (e.g., Darier's disease, Darier-White disease), facial flat warts, multiple flat warts (e.g., common warts, plantar warts)
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For members greater than 35 years old, the following criteria must be met: Documented diagnosis of acne vulgaris (includes comedonal, cystic, nodular & papular acne), or Documented diagnosis of actinic keratoses and lesions are on the face, or Lesions are not on the face and therapy includes the use of 5-fluorouracil in conjunction with tretinoin, or • Documented diagnosis of hypertrophic scars or keloids AND intralesional injection of corticosteroids was ineffective or not tolerated, or Documented diagnosis of keratosis follicularis (Darier's disease, Darier-White disease), or Documented diagnosis of facial flat warts, or Documented diagnosis of multiple flat warts (includes common warts and plantar warts)
<b>Age Restrictions</b>	Prior authorization only applies for members greater than 35 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tretten

---

## Products Affected

- TRETEN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tribenzor

---

## Products Affected

- TRIBENZOR

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tricor

---

## Products Affected

- TRICOR

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tri-Legest Fe

---

## Products Affected

- *tri-legest fe*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tri-Linyah

---

## Products Affected

- *tri-linyah*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Trilipix

---

## Products Affected

- TRILIPIX

<b>QL Criteria</b>	1 CPDR Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# TriNessa (28)

---

## Products Affected

- *trinessa (28)*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Tri-Norinyl (28)

---

### Products Affected

- TRI-NORINYL (28)

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Trintellix

---

## Products Affected

- TRINTELLIX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Major depressive disorder
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of major depressive disorder
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: October 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tri-Previfem

---

## Products Affected

- *tri-previfem*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tri-Sprintec

---

## Products Affected

- *tri-sprintec*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Triumeq

---

## Products Affected

- TRIUMEQ

<b>QL Criteria</b>	1 EA Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Trivora (28)

---

### Products Affected

- *trivora (28)*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Trokendi XR

---

## Products Affected

- TROKENDI XR

<b>QL Criteria</b>	1 CP24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Trospium Chloride

---

## Products Affected

- *trospium chloride*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Trospium Chloride ER

---

## Products Affected

- *trospium chloride er*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TRUE2go Blood Glucose Monitor

---

## Products Affected

- TRUE2GO BLOOD GLUCOSE MONITOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TRUEresult Blood Glucose

## Products Affected

- TRUERESULT BLOOD GLUCOSE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TRUEtest Test

---

## Products Affected

- TRUETEST TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TrueTrack Blood Glucose

## Products Affected

- TRUETRACK BLOOD GLUCOSE KIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TrueTrack Smart System

---

## Products Affected

- TRUETRACK SMART SYSTEM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a physical limitation that makes utilization of a Lifescan product unsafe, inaccurate or otherwise not feasible. Such limitations may include, but are not limited to, manual dexterity or visual impairment issues not accommodated by the features and capabilities of the Lifescan product line, or the member has hematocrit levels which are chronically less than 30% or greater than 55%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years, 1 meter per year
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 KIT Per 365 DAYs
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TrueTrack Test

---

## Products Affected

- TRUETRACK TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Trulicity

---

## Products Affected

- TRULICITY

<b>QL Criteria</b>	4 injections Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tudorza Pressair

---

## Products Affected

- TUDORZA PRESSAIR INHALATION  
AEROSOL POWDER, BREATH  
ACTIVATED 400 MCG/ACT

<b>QL Criteria</b>	1 inhaler Per 30 fills
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# TussiCaps

---

## Products Affected

- TUSSICAPS

<b>QL Criteria</b>	20 capsules Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Twynsta

---

## Products Affected

- TWYNSTA

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tybost

---

## Products Affected

- TYBOST

<b>QL Criteria</b>	1 EA Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tykerb

---

## Products Affected

- TYKERB

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tysabri

---

## Products Affected

- TYSABRI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tyvaso

---

## Products Affected

- TYVASO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 SOLN Per 1 DAYS
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Tyvaso Refill

---

## Products Affected

- TYVASO REFILL

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 ML Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tyvaso Starter

---

## Products Affected

- TYVASO STARTER

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	1 ML Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Tyzeka

---

## Products Affected

- TYZEKA

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Uceris

---

## Products Affected

- UCERIS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Active mild to moderate ulcerative colitis
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	A documented diagnosis of ACTIVE mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge, requiring induction of remission.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 canisters Per 1 month
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Uceris

---

## Products Affected

- UCERIS ORAL

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ulesfia

---

## Products Affected

- ULESFIA

<b>QL Criteria</b>	3 bottles Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Uloric

---

## Products Affected

- ULORIC

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ultima Test

---

## Products Affected

- ULTIMA TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Ultracet

---

## Products Affected

- ULTRACET

<b>QL Criteria</b>	8 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ultram ER

---

## Products Affected

- ULTRAM ER ORAL TABLET  
EXTENDED RELEASE 24 HR\* 300 MG,  
100 MG

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ultram ER

---

## Products Affected

- ULTRAM ER ORAL TABLET  
EXTENDED RELEASE 24 HR\* 200 MG

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# UltraTRAK Active

---

## Products Affected

- ULTRATRAK ACTIVE

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# UltraTRAK PRO

---

## Products Affected

- ULTRATRAK PRO

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# UltraTRAK PRO Test

---

## Products Affected

- ULTRATRAK PRO TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# UltraTRAK Ultimate Monitor

---

## Products Affected

- ULTRATRAK ULTIMATE MONITOR

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# UltraTRAK Ultimate Test

---

## Products Affected

- ULTRATRAK ULTIMATE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Uptravi

---

## Products Affected

- UPTRAVI ORAL TABLET 1200 MCG, 400 MCG, 600 MCG, 1600 MCG, 1000 MCG, 1400 MCG, 800 MCG

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Uptravi

## Products Affected

- UPTRAVI ORAL TABLET 200 MCG
- UPTRAVI ORAL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Utibron Neohaler

---

## Products Affected

- UTIBRON NEOHALER

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Valchlor

---

## Products Affected

- VALCHLOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 GM Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Valcyte

---

## Products Affected

- VALCYTE ORAL TABLET

<b>QL Criteria</b>	102 EA Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ValGANciclovir HCl

---

## Products Affected

- *valganciclovir hcl oral tablet*

<b>QL Criteria</b>	102 TABS Per 30 DAYs
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ValGANciclovir HCl

---

## Products Affected

- *valganciclovir hcl oral solution reconstituted*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviraltopical.html">http://www.aetna.com/products/rxnonmedicare/data/2017/ID/antiviraltopical.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Valsartan

---

## Products Affected

- *valsartan*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Valsartan-Hydrochlorothiazide

---

## Products Affected

- *valsartan-hydrochlorothiazide*

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Varubi

---

## Products Affected

- VARUBI

<b>QL Criteria</b>	4 tablets Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vascepa

---

## Products Affected

- VASCEPA ORAL CAPSULE 1 GM

<b>QL Criteria</b>	4 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vecamyl

---

## Products Affected

- VECAMYL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	All FDA approved indications
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of trial and failure with four antihypertensive drugs from at least three different therapeutic subclasses, and documentation of moderately severe to severe hypertension (blood pressure greater than or equal to 160/100 mmHg) or documentation of malignant hypertension without complications (blood pressure greater or equal to 180/120 mmHg) with retinal hemorrhages, exudates, or papilledema
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year

PA Criteria	Criteria Details
Other Criteria	<p>Examples of antihypertensive drugs listed by therapeutic subclasses:DIURETICS: HydroDiuril, Microzide (hydrochlorothiazide), Hygroton (chlorthalidone), Diuril (chlorthiazide), Lasix (furosemide), Midamor (amiloride), Dyazide, Maxzide (triamterene-hydrochlorothiazide). BETA BLOCKERS: Tenormin (atenolol), Toprol XL (metoprolol succinate), Lopressor (metoprolol tartrate), Zebeta (bisoprolol), Coreg (carvedilol), Inderal LA (propranolol). CALCIUM CHANNEL BLOCKERS: Adalat CC, Procardia XL (nifedipine), Calan, Isoptin, Verelan (verapamil), Cardizem, Cartia (diltiazem), Norvasc (amlodipine), Sular (nisoldipine), Plendil (felodipine). ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEI) &amp; ACEI COMBINATIONS: Prinivil, Zestril (lisinopril), Lotensin/Lotensin HCT/Lotrel (benazepril), Vasotec (enalapril), Accupril (quinapril), Mavik (trandolapril),Univasc (moexipril). ANGIOTENSION RECEPTOR BLOCKER (ARB) &amp; ARB COMBINATIONS: Cozaar/Hyzaar (losartan), Benicar/Benicar HCT (olmesartan), Micardis/Micardis HCT (telmisartan) , Diovan/Diovan HCT (valsartan), Avapro/Avalide (irbesartan), Atacand/Atacand HCT (candesartan), Teveten /Teveten HCT (eprosartan), Edarbi/Edarbyclor (azilsartan)</p>
QL Criteria	10 tabs Per 1 DAYS
Notes/ References	
Revision Date	<p>Prior Authorization: October 05, 2015  Step Therapy: August 25, 2015  Quantity Limits: August 25, 2015</p>

# Veletri

---

## Products Affected

- VELETRI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Velivet

---

## Products Affected

- *velivet*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Veltassa

---

## Products Affected

- VELTASSA

<b>QL Criteria</b>	1 packet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Venclexta

## Products Affected

- VENCLEXTA ORAL TABLET 100 MG

PA Criteria	Criteria Details
Covered Uses	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOP L/Venclexta.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOP L/Venclexta.html</a>
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Refer to the clinical policy bulletin above for details.
Other Criteria	
QL Criteria	4 tablets Per 1 Day
Notes/References	
Revision Date	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venclexta

---

## Products Affected

- VENCLEXTA ORAL TABLET 10 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOP L/Venclexta.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOP L/Venclexta.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	40 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venclexta

---

## Products Affected

- VENCLEXTA ORAL TABLET 50 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOP L/Venclexta.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOP L/Venclexta.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	8 tablets Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venclexta Starting Pack

---

## Products Affected

- VENCLEXTA STARTING PACK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOP L/Venclexta.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOP L/Venclexta.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 pack Per 28 days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl

---

## Products Affected

- *venlafaxine hcl oral tablet 25 mg, 100 mg*

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl

---

## Products Affected

- *venlafaxine hcl oral tablet 50 mg*

<b>QL Criteria</b>	6 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl

---

## Products Affected

- *venlafaxine hcl oral tablet 37.5 mg*

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl

---

## Products Affected

- *venlafaxine hcl oral tablet 75 mg*

<b>QL Criteria</b>	5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Venlafaxine HCl ER

---

## Products Affected

- *venlafaxine hcl er oral tablet extended release 24 hr\* 225 mg, 37.5 mg, 75 mg*

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl ER

---

## Products Affected

- *venlafaxine hcl er oral capsule extended release 24 hour 37.5 mg, 75 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl ER

---

## Products Affected

- *venlafaxine hcl er oral capsule extended release 24 hour 150 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Venlafaxine HCl ER

---

## Products Affected

- *venlafaxine hcl er oral tablet extended release 24 hr\* 150 mg*

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ventavis

---

## Products Affected

- VENTAVIS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CV/pulmonaryhypertensionagents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Verapamil HCl ER

---

## Products Affected

- *verapamil hcl er oral capsule extended release 24 hour 200 mg*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Verapamil HCl ER

---

## Products Affected

- *verapamil hcl er oral capsule extended release 24 hour 100 mg, 300 mg*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# VESicare

---

## Products Affected

- VESICARE

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Vestura

---

## Products Affected

- *vestura*

<b>QL Criteria</b>	1.5 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Viberzi

---

## Products Affected

- VIBERZI

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Victory AGM-4000 Test

---

## Products Affected

- VICTORY AGM-4000 TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Victory Blood Glucose System

---

## Products Affected

- VICTORY BLOOD GLUCOSE SYSTEM

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Victoza

---

## Products Affected

- VICTOZA SUBCUTANEOUS\*

<b>QL Criteria</b>	1 box-2 or 3 pens Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Victrelis

---

## Products Affected

- VICTRELIS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	10 capsules Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Viekira Pak

---

## Products Affected

- VIEKIRA PAK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Viekira XR

---

## Products Affected

- VIEKIRA XR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	3 tablets Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Viibryd

---

## Products Affected

- VIIBRYD ORAL TABLET

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Viibryd

---

## Products Affected

- VIIBRYD ORAL TABLET

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	Annual Review: 05/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vimizim

---

## Products Affected

- VIMIZIM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vimpat

---

## Products Affected

- VIMPAT ORAL SOLUTION

<b>QL Criteria</b>	40 ML Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vimpat

---

## Products Affected

- VIMPAT ORAL TABLET

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Viorele

---

## Products Affected

- *viorele*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Viramune XR

---

## Products Affected

- VIRAMUNE XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 100 MG

<b>QL Criteria</b>	3 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Viramune XR

---

## Products Affected

- VIRAMUNE XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 400 MG

<b>QL Criteria</b>	1 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Viread

---

## Products Affected

- VIREAD ORAL TABLET

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vistogard

---

## Products Affected

- VISTOGARD

<b>QL Criteria</b>	20 packs Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vivelle

---

## Products Affected

- VIVELLE

<b>QL Criteria</b>	8 patches Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vivelle-Dot

---

## Products Affected

- VIVELLE-DOT

<b>QL Criteria</b>	8 patches Per 28 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vivlodex

---

## Products Affected

- VIVLODEX

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vocal Point Blood Glucose Test

---

## Products Affected

- VOCAL POINT BLOOD GLUCOSE TEST

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vogelxo

## Products Affected

- VOGELXO TRANSDERMAL GEL 50 MG/5GM (1%)

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	10 grams Per 1 DAYS
<b>Notes/References</b>	Annual Review: 02/2016

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--



# Vogelxo Pump

## Products Affected

- VOGELXO PUMP

PA Criteria	Criteria Details
<b>Covered Uses</b>	Primary hypogonadism or hypogonadotropic hypogonadism, gender dysphoria, gender reassignment
<b>Exclusion Criteria</b>	patient with carcinoma of the breast or suspected carcinoma of the prostate, patient will be using therapy for muscle building purposes
<b>Required Medical Information</b>	Documented diagnosis of primary hypogonadism or hypogonadotropic hypogonadism as defined by either one of the following: (1) Member has undergone bilateral orchiectomy (no total fasting serum testosterone levels required), or (2) Having two consecutive low total fasting serum testosterone levels (below the testing laboratory's reference range or below 300ng/dl if reference ranges are not available), or for persons with low normal total testosterone levels (above 300 ng/dL but below 400 ng/dL), two consecutive low free or bioavailable fasting serum testosterone levels (below the testing laboratory's reference range or less than 225 picomoles per liter (pmol/L) (6 ng/dL) if reference ranges are not available)(Note: Two morning samples drawn between 7:00 a.m. and 10:00 a.m. obtained on two different days is required for NEW starts only), or (3) Member has a documented diagnosis of gender dysphoria or documentation of undergoing gender reassignment surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>QL Criteria</b>	10 grams Per 1 DAYS
<b>Notes/References</b>	Annual Review: 02/2016

<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015
----------------------	--

# Voltaren

---

## Products Affected

- VOLTAREN TRANSDERMAL

<b>QL Criteria</b>	200 GM Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vonvendi

---

## Products Affected

- VONVENDI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2017/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 21, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Votrient

---

## Products Affected

- VOTRIENT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vpriv

---

## Products Affected

- VPRIV

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vraylar

---

## Products Affected

- VRAYLAR ORAL CAPSULE 4.5 MG, 6 MG

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vraylar

---

## Products Affected

- VRAYLAR ORAL CAPSULE 1.5 MG

<b>QL Criteria</b>	4 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Vraylar

---

## Products Affected

- VRAYLAR ORAL CAPSULE 3 MG

<b>QL Criteria</b>	2 capsule Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vytorin

---

## Products Affected

- VYTORIN

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Vyvanse

---

## Products Affected

- VYVANSE

<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# WaveSense KeyNote Pro Meter

---

## Products Affected

- WAVESENSE KEYNOTE PRO METER

<b>QL Criteria</b>	1 meter Per 1 year
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# WaveSense Presto

---

## Products Affected

- WAVESENSE PRESTO

<b>QL Criteria</b>	300 strips Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wellbutrin

---

## Products Affected

- WELLBUTRIN

<b>QL Criteria</b>	6 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wellbutrin SR

---

## Products Affected

- WELLBUTRIN SR

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wera

---

## Products Affected

- *wera*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Wide-Seal Diaphragm 60

---

## Products Affected

- WIDE-SEAL DIAPHRAGM 60

<b>QL Criteria</b>	1 diaphragm Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wide-Seal Diaphragm 65

---

## Products Affected

- WIDE-SEAL DIAPHRAGM 65

<b>QL Criteria</b>	1 diaphragm Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wide-Seal Diaphragm 70

---

## Products Affected

- WIDE-SEAL DIAPHRAGM 70

<b>QL Criteria</b>	1 diaphragm Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wide-Seal Diaphragm 75

---

## Products Affected

- WIDE-SEAL DIAPHRAGM 75

<b>QL Criteria</b>	1 diaphragm Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wide-Seal Diaphragm 80

---

## Products Affected

- WIDE-SEAL DIAPHRAGM 80

<b>QL Criteria</b>	1 diaphragm Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wide-Seal Diaphragm 85

---

## Products Affected

- WIDE-SEAL DIAPHRAGM 85

<b>QL Criteria</b>	1 diaphragm Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wide-Seal Diaphragm 90

---

## Products Affected

- WIDE-SEAL DIAPHRAGM 90

<b>QL Criteria</b>	1 diaphragm Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wide-Seal Diaphragm 95

---

## Products Affected

- WIDE-SEAL DIAPHRAGM 95

<b>QL Criteria</b>	1 diaphragm Per 1 year
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Wilate

---

## Products Affected

- WILATE INTRAVENOUS\* KIT
- WILATE INTRAVENOUS\* SOLUTION RECONSTITUTED 500-500 UNIT, 1000-1000 UNIT

PA Criteria	Criteria Details
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Wymzya Fe

---

## Products Affected

- *wymzya fe*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xalatan

---

## Products Affected

- XALATAN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	open-angle glaucoma, ocular hypertension
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of glaucoma or ocular hypertension
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 28, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xalkori

---

## Products Affected

- XALKORI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xanax XR

---

## Products Affected

- XANAX XR

<b>QL Criteria</b>	2 TB24 Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xartemis XR

---

## Products Affected

- XARTEMIS XR

<b>QL Criteria</b>	4 tablets Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xeljanz

---

## Products Affected

- XELJANZ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xeljanz XR

---

## Products Affected

- XELJANZ XR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Xeloda

---

## Products Affected

- XELODA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xenazine

---

## Products Affected

- XENAZINE ORAL TABLET 12.5 MG

<b>QL Criteria</b>	8 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xenazine

---

## Products Affected

- XENAZINE ORAL TABLET 25 MG

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xeomin

---

## Products Affected

- XEOMIN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/botulinum_toxin.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/botulinum_toxin.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xgeva

---

## Products Affected

- XGEVA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_diasease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_diasease_agents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xifaxan

---

## Products Affected

- XIFAXAN ORAL TABLET 200 MG

<b>QL Criteria</b>	9 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xifaxan

---

## Products Affected

- XIFAXAN ORAL TABLET 550 MG

<b>QL Criteria</b>	3 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xigduo XR

---

## Products Affected

- XIGDUO XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 10-1000  
MG, 10-500 MG, 5-500 MG

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Xigduo XR

---

## Products Affected

- XIGDUO XR ORAL TABLET  
EXTENDED RELEASE 24 HR\* 5-1000  
MG

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xolair

---

## Products Affected

- XOLAIR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/immunologicalagents_rheumatoid_arthritis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xopenex HFA

---

## Products Affected

- XOPENEX HFA

<b>QL Criteria</b>	2 inhalers Per 180 Days
<b>Notes/ References</b>	Annual Review: 03/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xtampza ER

---

## Products Affected

- XTAMPZA ER

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Step Therapy
<b>QL Criteria</b>	2 capsules Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xtandi

---

## Products Affected

- XTANDI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 capsules Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xulane

---

## Products Affected

- XULANE

<b>QL Criteria</b>	1 box (3 patches) Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xuriden

---

## Products Affected

- XURIDEN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/metabolic_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/metabolic_agents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 packets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 31, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xyntha

---

## Products Affected

- XYNTHA INTRAVENOUS\* KIT 500 UNIT, 250 UNIT, 2000 UNIT, 1000 UNIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Xyntha Solofuse

---

## Products Affected

- XYNTHA SOLOFUSE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MISC/bloodproducts_coagulants.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xyrem

## Products Affected

- XYREM

PA Criteria	Criteria Details
<b>Covered Uses</b>	Excessive daytime sleepiness associated with narcolepsy, Cataplexy associated with narcolepsy
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN ASSOCIATION WITH NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of narcolepsy, such as MSLT, clinical progress notes, and documentation of failure of an adequate trial of at least two of the immediate release stimulants (Dexedrine, Ritalin, Adderall), and documentation of failure of an adequate trial of Nuvigil. FOR THE TREATMENT OF CATAPLEXY IN ASSOCIATION WITH NARCOLEPSY: Documentation of diagnostic testing and clinical notations supporting diagnosis of narcolepsy, such as MSLT, clinical progress notes, and documentation of failure of an adequate trial of at least two of the immediate release stimulants (Dexedrine, Ritalin, Adderall), and documentation of failure of an adequate trial of an antidepressant.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Sleep specialist, pulmonologist, neurologist, or psychiatrist
<b>Coverage Duration</b>	3 months, extended approval based on therapeutic response
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: October 05, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Xyzal

---

## Products Affected

- XYZAL ORAL TABLET

<b>QL Criteria</b>	1 TABS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Yasmin 28

---

## Products Affected

- YASMIN 28

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# YAZ

---

## Products Affected

- YAZ

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Yervoy

---

## Products Affected

- YERVOY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/yervoy.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/yervoy.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: September 28, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zaleplon

---

## Products Affected

- *zaleplon*

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zarah

---

## Products Affected

- *zarah*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Zavesca

---

## Products Affected

- ZAVESCA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/lysosomal_storage.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	3 capsules Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zecuity

---

## Products Affected

- ZECUITY

<b>QL Criteria</b>	4 patches Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zegerid OTC

---

## Products Affected

- ZEGERID OTC

<b>QL Criteria</b>	1 capsule Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zelapar

---

## Products Affected

- ZELAPAR

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zelboraf

---

## Products Affected

- ZELBORAF

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	8 tablets Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zembrace SymTouch

---

## Products Affected

- ZEMBRACE SYMTOUCH

<b>QL Criteria</b>	8 syringes Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zemplar

---

## Products Affected

- ZEMPLAR ORAL CAPSULE 2 MCG, 1 MCG

<b>QL Criteria</b>	1 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zenatane

## Products Affected

- *zenatane oral capsule 20 mg, 10 mg, 40 mg*

PA Criteria	Criteria Details
<b>Covered Uses</b>	severe recalcitrant nodular or cystic acne
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Member already has evidence of scarring and member is enrolled in the FDA iPLEDGE program (females of childbearing potential ONLY)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	5 months
<b>Other Criteria</b>	For coverage of additional quantities (greater than 2 capsules per day) member must meet the following criteria: Patient requires more than 2 capsules per day to reach the appropriate dose for weight, and this is the members FIRST course of therapy or member now requires a second course of therapy and it has been at least 8 weeks after the first course was initiated (2 month holiday), and member has recieved a cumulative dose of less than 120 mg/kg during a course of therapy lasting 20 weeks or less.
<b>QL Criteria</b>	2 capsules Per 1 DAYS
<b>Notes/References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Zenatane

---

## Products Affected

- ZENATANE ORAL CAPSULE 30 MG

<b>QL Criteria</b>	2 tablets Per 1 Day
<b>Notes/ References</b>	Annual Review: 02/2016
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zenchant

---

## Products Affected

- *zenchant*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zenchant FE

---

## Products Affected

- *zenchant fe*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zepatier

## Products Affected

- ZEPATIER

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html">http://www.aetna.com/products/rxnonmedicare/data/2016/GI/hepatitis_c.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zetia

---

## Products Affected

- ZETIA

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zinbryta

---

## Products Affected

- ZINBRYTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html">http://www.aetna.com/products/rxnonmedicare/data/2016/CNS/multiple_sclerosis.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	1 injection Per 30 days
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 10, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zioptan

---

## Products Affected

- ZIOPTAN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	open-angle glaucoma, ocular hypertension
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of glaucoma or ocular hypertension
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	
<b>Notes/References</b>	Annual Review: 03/2016
<b>Revision Date</b>	Prior Authorization: May 28, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Ziprasidone HCl

---

## Products Affected

- *ziprasidone hcl*

<b>QL Criteria</b>	2 capsules Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Zocor

---

## Products Affected

- ZOCOR

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zohydro ER

---

## Products Affected

- ZOHYDRO ER

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Chronic pain due to malignant condition or severe pain requiring daily, around the clock, long term opioid treatment
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Step Therapy
<b>Notes/References</b>	Annual Review: 06/2016
<b>Revision Date</b>	Prior Authorization: April 11, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zoledronic Acid

---

## Products Affected

- *zoledronic acid*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_diasease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_diasease_agents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zolinza

---

## Products Affected

- ZOLINZA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	4 capsules Per 1 day
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ZOLMitriptan

---

## Products Affected

- *zolmitriptan oral*

<b>QL Criteria</b>	6 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zoloft

---

## Products Affected

- ZOLOFT ORAL CONCENTRATE

<b>QL Criteria</b>	10 ml Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zoloft

---

## Products Affected

- ZOLOFT ORAL TABLET 50 MG

<b>QL Criteria</b>	1.5 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zoloft

---

## Products Affected

- ZOLOFT ORAL TABLET 100 MG

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Zoloft

---

## Products Affected

- ZOLOFT ORAL TABLET 25 MG

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zolpidem Tartrate

---

## Products Affected

- *zolpidem tartrate oral*

<b>QL Criteria</b>	2 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zolpidem Tartrate ER

---

## Products Affected

- *zolpidem tartrate er*

<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zometa

---

## Products Affected

- ZOMETA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_disease_agents.html">http://www.aetna.com/products/rxnonmedicare/data/2016/MUSC/bone_disease_agents.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zomig

---

## Products Affected

- ZOMIG NASAL SOLUTION 5 MG

<b>QL Criteria</b>	1 box (6 doses) Per 1 month
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zomig

---

## Products Affected

- ZOMIG ORAL

<b>QL Criteria</b>	6 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zomig ZMT

---

## Products Affected

- ZOMIG ZMT

<b>QL Criteria</b>	6 tablets Per 30 Days
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zorbtive

---

## Products Affected

- ZORBTIVE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ENDO/growthhormone.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# Zorvolex

---

## Products Affected

- ZORVOLEX

<b>QL Criteria</b>	3 CAPS Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Zovia 1/35E (28)

---

### Products Affected

- *zovia 1/35e (28)*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

## Zovia 1/50E (28)

---

### Products Affected

- *zovia 1/50e (28)*

<b>QL Criteria</b>	1.5 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zubsolv

## Products Affected

- ZUBSOLV SUBLINGUAL TABLET  
SUBLINGUAL 1.4-0.36 MG, 5.7-1.4 MG

PA Criteria	Criteria Details
<b>Covered Uses</b>	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
<b>Exclusion Criteria</b>	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
<b>Required Medical Information</b>	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months = current enrollement

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
Updated 12/2016

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at <a href="http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx">http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx</a> . Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
<b>QL Criteria</b>	3 Tabs Per 1 DAYS
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zubsolv

## Products Affected

- ZUBSOLV SUBLINGUAL TABLET  
SUBLINGUAL 2.9-0.71 MG

PA Criteria	Criteria Details
<b>Covered Uses</b>	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
<b>Exclusion Criteria</b>	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
<b>Required Medical Information</b>	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months = current enrollement

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
Updated 12/2016

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at <a href="http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx">http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx</a> . Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
<b>QL Criteria</b>	3 tablets Per 1 Day
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zubsolv

## Products Affected

- ZUBSOLV SUBLINGUAL TABLET  
SUBLINGUAL 8.6-2.1 MG

PA Criteria	Criteria Details
<b>Covered Uses</b>	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
<b>Exclusion Criteria</b>	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
<b>Required Medical Information</b>	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months = current enrollement

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
Updated 12/2016



PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at <a href="http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jsp">http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jsp</a> . Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zubsolv

## Products Affected

- ZUBSOLV SUBLINGUAL TABLET  
SUBLINGUAL 11.4-2.9 MG

PA Criteria	Criteria Details
<b>Covered Uses</b>	Opioid dependence. NOTE: Prior Authorization does not apply to members residing in Massachusetts.
<b>Exclusion Criteria</b>	Medical literature does not support the concurrent use of opioids/Tramadol as part of opioid drug dependence treatment. Abstinence of opioids/Tramadol is required both during and following therapy with Suboxone/Subutex/Zubsolv/Bunavail/buprenorphine, and will only be covered when determined to be medically necessary (defined as short-term use during and following opioid dependence treatment for the treatment of acute pain related to surgery, dental procedure, or an emergency situation or for long-term use following opioid dependence treatment for the treatment of chronic pain. For long term use, the member must be treated by a single provider of their choice, opioids will only be covered when prescribed by this single provider, and this single provider is aware of past buprenorphine use for opioid dependence treatment in which an opioid dependence diagnosis). Physicians can contact (855) 746-0013 with any information related to the medical necessity for opioid/Tramadol therapy.
<b>Required Medical Information</b>	Prescriber provides verbal verification of patient's current and ongoing enrollment in an outpatient drug addiction treatment program/ counseling. If the member is currently enrolled, the approval will be 6 months. If the member is NOT enrolled (answer=no) and prescriber provides verbal verification of patient's agreed commitment to become enrolled in an acceptable drug addiction treatment program counseling, the approval will be for 2 months (Note: 1 time approval ONLY). If after 2 months member does not enroll in a program, then all future requests will be denied until member enrolls in a program.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months = current enrollement

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
Updated 12/2016

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For coverage of additional quantities, the following conditions must be met: FOR BUPRENORPHONE SL: Member is pregnant or breastfeeding (Up to 120 tablets in 30 days) or member has a documented contraindication, intolerance, or allergy to buprenorphine-naloxone sublingual tablet or Suboxone (will allow up to 90 tablets per month for max length of approval of 6 months). FOR SUBOXONE OR BUPRENORPHINE-NALOXONE SUBLINGUAL TABLET 2mg/0.5mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 12 mg/daily for total of 42 tablets/films in 7 days). FOR ZUBSOLBV 1.4mg/0.36mg: Member's dose is being titrated by physician for 7 day induction therapy (max dose 8.4 mg/daily for total of 42 tablets/films in 7 days). Note: Aetna considers the following as acceptable programs: Outpatient drug addiction treatment programs and/or counseling, 12- step programs focused on "drug" addiction such as Narcotics Anonymous (N.A.), Other accepted programs can be found at <a href="http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx">http://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx</a> . Aetna considers the following as non-acceptable programs: On-line programs such as Here to Help, 12-step programs that are not focused on "drug" addiction (ex: Alcoholics Anonymous).</p>
<b>QL Criteria</b>	1 tablet Per 1 Day
<b>Notes/References</b>	Annual Review: 04/2016
<b>Revision Date</b>	Prior Authorization: April 20, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zurampic

---

## Products Affected

- ZURAMPIC

<b>QL Criteria</b>	1 tablet Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zyban

---

## Products Affected

- ZYBAN

<b>QL Criteria</b>	2 tablet Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zydelig

---

## Products Affected

- ZYDELIG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	2 CAP Per 1 DAYS
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zykadia

---

## Products Affected

- ZYKADIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Covered Uses</b>	Refer to the clinical policy bulletin for details: <a href="http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html">http://www.aetna.com/products/rxnonmedicare/data/2016/ANEOPL/Antineoplastics.html</a>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Refer to the clinical policy bulletin above for details.
<b>Other Criteria</b>	
<b>QL Criteria</b>	5 CAP Per 1 DAYS
<b>Notes/References</b>	
<b>Revision Date</b>	Prior Authorization: May 27, 2016 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ZyPREXA

---

## Products Affected

- ZYPREXA ORAL TABLET 15 MG, 5 MG, 7.5 MG, 10 MG, 20 MG

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015



# ZyPREXA

---

## Products Affected

- ZYPREXA ORAL TABLET 2.5 MG

<b>QL Criteria</b>	2 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# ZyPREXA Zydys

---

## Products Affected

- ZYPREXA ZYDIS

<b>QL Criteria</b>	1 tabs Per 1 DAYS
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zytiga

---

## Products Affected

- ZYTIGA

<b>QL Criteria</b>	4 tablets Per 1 day
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

# Zyvox

---

## Products Affected

- ZYVOX ORAL TABLET

<b>QL Criteria</b>	28 tablets Per 1 fill
<b>Notes/ References</b>	
<b>Revision Date</b>	Prior Authorization: August 25, 2015 Step Therapy: August 25, 2015 Quantity Limits: August 25, 2015

**Index**

ABILIFY DISCMELT .....	3	ADVAIR DISKUS INHALATION	
ABILIFY ORAL SOLUTION .....	2	AEROSOL POWDER, BREATH	
ABILIFY ORAL TABLET .....	1	ACTIVATED 100-50 MCG/DOSE, 250-50	
ABSTRAL .....	4	MCG/DOSE .....	41
<i>acamprosate calcium</i> .....	6	ADVAIR DISKUS INHALATION	
ACCU-CHEK ACTIVE .....	7	AEROSOL POWDER, BREATH	
ACCU-CHEK AVIVA IN VITRO STRIP .....	8	ACTIVATED 500-50 MCG/DOSE .....	42
ACCU-CHEK AVIVA PLUS .....	9	ADVAIR HFA .....	43
ACCU-CHEK AVIVA PLUS IN VITRO .....	10	ADVANCE INTUITION METER .....	44
ACCU-CHEK COMPACT PLUS .....	11	ADVANCE INTUITION TEST .....	45
ACCU-CHEK COMPACT PLUS CARE .....	12	ADVATE .....	46
ACCU-CHEK MULTICLIX LANCET DEV		ADVICOR ORAL TABLET EXTENDED	
.....	13	RELEASE 24 HR* 1000-20 MG .....	47
ACCU-CHEK NANO SMARTVIEW .....	14	ADVICOR ORAL TABLET EXTENDED	
ACCU-CHEK SMARTVIEW .....	15	RELEASE 24 HR* 1000-40 MG, 500-20 MG	
ACCU-CHEK VOICEMATE .....	16	.....	48
ACCUTREND GLUCOSE .....	17	ADVICOR ORAL TABLET EXTENDED	
ACIPHEX .....	18	RELEASE 24 HR* 750-20 MG .....	49
ACIPHEX SPRINKLE .....	19	ADVOCATE BLOOD GLUCOSE MONITOR	
<i>acitretin</i> .....	20	.....	50
ACTEMRA INTRAVENOUS* .....	22	ADVOCATE DUO DEVICE .....	51
ACTEMRA SUBCUTANEOUS* .....	21	ADVOCATE REDI-CODE DEVICE .....	52
ACTIQ .....	23	ADVOCATE REDI-CODE IN VITRO .....	53
ACTIVELLA .....	25	ADVOCATE REDI-CODE+ .....	54
ACTONEL ORAL TABLET 150 MG .....	26	ADVOCATE REDI-CODE+ TEST .....	55
ACTONEL ORAL TABLET 30 MG, 5 MG		ADVOCATE TEST .....	56
.....	27	ADZENYS XR-ODT .....	57
ACTONEL ORAL TABLET 35 MG .....	28	AEROSPAN .....	58
ACTOPLUS MET .....	29	<i>afeditab cr oral tablet extended release 24 hr*</i>	
ACTOPLUS MET XR .....	30	<i>30 mg</i> .....	59
ACTOS .....	31	<i>afeditab cr oral tablet extended release 24 hr*</i>	
ACURA BLOOD GLUCOSE TEST .....	32	<i>60 mg</i> .....	60
ADALAT CC ORAL TABLET EXTENDED		AFINITOR .....	61
RELEASE 24 HR* 30 MG, 90 MG .....	33	AFINITOR DISPERZ .....	62
ADALAT CC ORAL TABLET EXTENDED		AFREZZA .....	63
RELEASE 24 HR* 60 MG .....	34	AFREZZA .....	64
ADCIRCA .....	35	AFSTYLA .....	65
ADDERALL .....	36	AGAMATRIX AMP TEST .....	66
ADDERALL XR .....	37	AGAMATRIX JAZZ TEST .....	67
<i>adefovir dipivoxil</i> .....	38	AGAMATRIX KEYNOTE TEST .....	68
ADEMPAS .....	39	AGAMATRIX PRESTO .....	69
ADRENACLICK INJECTION .....	40	AGAMATRIX PRESTO PRO METER .....	70
		AGAMATRIX PRESTO TEST .....	71
		AKYNZEO .....	72
		ALDARA .....	73

ALDURAZYME .....	74	ANDROGEL TRANSDERMAL GEL 40.5	
ALECENSA .....	75	MG/2.5GM (1.62%) .....	116
<i>alendronate sodium oral tablet 40 mg, 10 mg,</i>		ANDROGEL TRANSDERMAL GEL 50	
<i>5 mg</i> .....	77	MG/5GM (1%) .....	110
<i>alendronate sodium oral tablet 70 mg, 35 mg</i>		ANGELIQ .....	122
.....	76	ANORO ELLIPTA .....	123
<i>alfuzosin hcl er</i> .....	78	ANTARA ORAL CAPSULE 30 MG, 90 MG	
<i>almotriptan malate</i> .....	79	.....	124
<i>alogliptin benzoate</i> .....	80	ANZEMET ORAL .....	125
<i>alogliptin-metformin hcl</i> .....	81	<i>apap-caff-dihydrocodeine oral capsule</i> .....	126
<i>alogliptin-pioglitazone</i> .....	82	<i>apri</i> .....	127
ALORA .....	83	APRISO .....	128
<i>alose tron hcl</i> .....	84	APTENSIO XR .....	129
ALPHANATE/VWF COMPLEX/HUMAN		APTIOM ORAL TABLET 600 MG, 200 MG	
.....	85	.....	130
ALPHANINE SD .....	86	APTIOM ORAL TABLET 800 MG, 400 MG	
<i>alprazolam er</i> .....	87	.....	131
<i>alprazolam xr</i> .....	88	<i>aranelle</i> .....	132
ALPROLIX .....	89	ARANESP (ALBUMIN FREE) INJECTION	
<i>altavera</i> .....	90	.....	133
ALTOPREV .....	91	ARANESP (ALBUMIN FREE) INJECTION	
ALVESCO .....	92	SOLUTION 25 MCG/ML, 300 MCG/ML, 40	
<i>alyacen 1/35</i> .....	93	MCG/ML, 100 MCG/ML, 200 MCG/ML, 150	
<i>alyacen 7/7/7</i> .....	94	MCG/0.75ML, 10 MCG/0.4ML, 60 MCG/ML	
AMBIEN CR .....	97	.....	133
AMBIEN ORAL TABLET 10 MG .....	95	ARAVA .....	134
AMBIEN ORAL TABLET 5 MG .....	96	ARCALYST .....	135
AMERGE .....	98	ARCAPTA NEOHALER .....	136
<i>amethia</i> .....	99	ARICEPT .....	137
<i>amethia lo</i> .....	100	ARICEPT ODT .....	138
<i>amethyst</i> .....	101	<i>aripiprazole oral solution</i> .....	140
AMITIZA .....	102	<i>aripiprazole oral tablet</i> .....	139
<i>amlodipine besylate-valsartan</i> .....	103	<i>aripiprazole oral tablet dispersible</i> .....	139
<i>amlodipine-atorvastatin</i> .....	104	ARIXTRA .....	141
<i>amnesteem</i> .....	105	<i>armodafinil oral tablet 200 mg, 150 mg, 250</i>	
<i>amphetamine-dextroamphet er</i> .....	106	<i>mg</i> .....	142
<i>amphetamine-dextroamphetamine</i> .....	107	<i>armodafinil oral tablet 50 mg</i> .....	144
AMPYRA .....	108	ARNUITY ELLIPTA .....	146
AMTURNIDE .....	109	ASACOL HD .....	147
ANDROGEL PUMP TRANSDERMAL GEL		ASCENSIA AUTODISC TEST .....	148
12.5 MG/ACT (1%) .....	118	ASSURE 3 TEST .....	149
ANDROGEL PUMP TRANSDERMAL GEL		ASSURE 4 METER .....	150
20.25 MG/ACT (1.62%) .....	120	ASSURE 4 TEST .....	151
ANDROGEL TRANSDERMAL GEL 20.25		ASSURE PLATINUM .....	152
MG/1.25GM (1.62%) .....	114	ASSURE PLATINUM METER .....	153
ANDROGEL TRANSDERMAL GEL 25		ASSURE PRO BLOOD GLUCOSE METER	
MG/2.5GM (1%) .....	112	.....	154

ASSURE PRO TEST .....	155	BAYER CONTOUR LINK MONITOR .....	192
ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 0.5 MG .....	156	BAYER CONTOUR MONITOR DEVICE .....	193
ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 1 MG .....	157	BAYER CONTOUR MONITOR KIT .....	194
ATACAND HCT ORAL TABLET 16-12.5 MG .....	161	BAYER CONTOUR NEXT EZ .....	195
ATACAND HCT ORAL TABLET 32-25 MG, 32-12.5 MG .....	160	BAYER CONTOUR NEXT LINK .....	196
ATACAND ORAL TABLET 32 MG .....	158	BAYER CONTOUR NEXT MONITOR .....	197
ATACAND ORAL TABLET 4 MG, 16 MG, 8 MG .....	159	BAYER CONTOUR NEXT TEST .....	198
AELVIA .....	162	BAYER CONTOUR NEXT USB MONITOR .....	199
<i>atorvastatin calcium oral</i> .....	163	BAYER CONTOUR TEST .....	200
ATRIPLA .....	164	BAYER CONTOUR USB .....	201
AUBAGIO .....	165	BEBULIN .....	202
AUVI-Q INJECTION .....	166	BEBULIN VH .....	203
AVALIDE ORAL TABLET 150-12.5 MG .....	167	BELBUCA .....	204
AVALIDE ORAL TABLET 300-12.5 MG .....	168	BELSOMRA .....	205
AVANDAMET ORAL TABLET 2-1000 MG .....	169	BENEFIX INTRAVENOUS* SOLUTION RECONSTITUTED .....	206
AVANDIA .....	170	BENICAR .....	207
AVAPRO .....	171	BENICAR HCT .....	208
<i>aviane</i> .....	172	BENLYSTA .....	209
AVINZA .....	173	BERINERT .....	210
<i>avita external cream</i> .....	175	BETASERON SUBCUTANEOUS* KIT ...	211
<i>avita external gel</i> .....	174	BETHKIS .....	212
AVODART .....	177	BEVESPI AEROSPHERE .....	213
AVONEX .....	178	BEYAZ .....	214
AVONEX PEN INTRAMUSCULAR* .....	179	BG STAR TEST .....	215
AVONEX PREFILLED INTRAMUSCULAR* .....	180	<i>bicalutamide</i> .....	216
AXERT .....	181	<i>bimatoprost ophthalmic</i> .....	217
AZILECT .....	182	BIVIGAM .....	218
AZOR .....	183	BONIVA ORAL TABLET 150 MG .....	219
AZULFIDINE .....	184	BOSULIF ORAL TABLET 100 MG .....	220
AZULFIDINE EN-TABS .....	185	BOSULIF ORAL TABLET 500 MG .....	221
<i>azurette</i> .....	186	BOTOX .....	222
<i>balsalazide disodium</i> .....	187	BOTOX COSMETIC INTRAMUSCULAR* SOLUTION RECONSTITUTED 50 UNIT .....	223
<i>balziva</i> .....	188	BRAVELLE .....	224
BANZEL ORAL TABLET .....	189	BREEZE 2 BLOOD GLUCOSE SYSTEM .....	225
BARACLUDE ORAL TABLET .....	190	BREO ELLIPTA INHALATION AEROSOL POWDER, BREATH ACTIVATED 100-25 MCG/INH .....	226
BAYER BREEZE 2 TEST .....	191	BREO ELLIPTA INHALATION AEROSOL POWDER, BREATH ACTIVATED 200-25 MCG/INH .....	227
		BREVICON (28) .....	228

<i>briellyn</i> .....	229	CAPRELSA ORAL TABLET 300 MG.....	270
BRILINTA.....	230	CARBAGLU.....	271
BRINTELLIX.....	231	CARDIZEM LA ORAL TABLET EXTENDED RELEASE 24 HR* 120 MG, 360 MG.....	273
BRISDELLE.....	232	CARDIZEM LA ORAL TABLET EXTENDED RELEASE 24 HR* 240 MG .....	272
BRIVIACT ORAL SOLUTION.....	233	CARDURA XL.....	274
BRIVIACT ORAL TABLET.....	234	CARESENS N GLUCOSE SYSTEM.....	275
BROVANA.....	235	CARESENS N GLUCOSE TEST.....	276
<i>budesonide inhalation</i> .....	236	CARIMUNE NF INTRAVENOUS* SOLUTION RECONSTITUTED 6 GM, 12 GM.....	277
<i>budesonide inhalation</i> .....	237	<i>cartia xt oral capsule extended release 24 hour 180 mg, 120 mg, 300 mg</i> .....	278
BUNAVAIL.....	238	<i>cartia xt oral capsule extended release 24 hour 240 mg</i> .....	279
BUPHENYL ORAL POWDER 3 GM/TSP .....	240	CASODEX.....	280
BUPHENYL ORAL TABLET.....	240	CAYSTON.....	281
<i>buprenorphine hcl sublingual tablet sublingual 2 mg</i> .....	241	<i>caziant</i> .....	282
<i>buprenorphine hcl sublingual tablet sublingual 8 mg</i> .....	243	CELEBREX.....	283
<i>buprenorphine hcl-naloxone hcl</i> .....	245	<i>celecoxib oral</i> .....	284
<i>buproban</i> .....	247	CELEXA ORAL TABLET.....	285
<i>bupropion hcl er (smoking det)</i> .....	249	CENESTIN ORAL TABLET 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG.....	286
<i>bupropion hcl er (sr)</i> .....	250	CENESTIN ORAL TABLET 1.25 MG.....	287
<i>bupropion hcl er (xl)</i> .....	251	CERDELGA.....	288
<i>bupropion hcl oral</i> .....	248	CEREZYME INTRAVENOUS* SOLUTION RECONSTITUTED 400 UNIT.....	289
<i>butorphanol tartrate nasal</i> .....	252	CESAMET.....	290
BUTRANS.....	253	<i>cesia</i> .....	291
BYDUREON SUBCUTANEOUS* 2 MG .....	255	CETROTIDE SUBCUTANEOUS* KIT 0.25 MG.....	292
BYDUREON SUBCUTANEOUS* SUSPENSION RECONSTITUTED.....	254	<i>cevimeline hcl</i> .....	293
BYETTA 10 MCG PEN SUBCUTANEOUS* .....	256	CHANTIX.....	294
BYETTA 5 MCG PEN SUBCUTANEOUS* .....	257	CHANTIX CONTINUING MONTH PAK .....	295
BYSTOLIC ORAL TABLET 10 MG, 2.5 MG, 5 MG.....	258	CHANTIX STARTING MONTH PAK.....	296
BYSTOLIC ORAL TABLET 20 MG.....	259	<i>chateal</i> .....	297
BYVALSON.....	260	CHENODAL.....	298
CABOMETYX.....	261	CHOLBAM.....	300
<i>calcitonin (salmon)</i> .....	262	<i>chorionic gonadotropin intramuscular*</i> .....	301
<i>camila</i> .....	263	CIALIS ORAL TABLET 5 MG.....	302
<i>camrese</i> .....	264	CIMZIA PREFILLED.....	304
<i>camrese lo</i> .....	265	CIMZIA STARTER KIT.....	305
CANASA.....	266		
<i>candesartan cilexetil oral tablet 8 mg, 4 mg, 16 mg</i> .....	267		
<i>candesartan cilexetil-hctz</i> .....	268		
CAPRELSA ORAL TABLET 100 MG.....	269		



CIMZIA SUBCUTANEOUS* KIT 2 X 200 MG .....	303	COMETRIQ (140 MG DAILY DOSE) .....	342
CINQAIR .....	306	COMETRIQ (60 MG DAILY DOSE) .....	343
CINRYZE .....	307	COMPLERA .....	344
<i>citalopram hydrobromide oral tablet 10 mg, 20 mg</i> .....	308	CONCERTA ORAL TABLET EXTENDEDRELEASE* 27 MG, 54 MG, 18 MG .....	345
<i>citalopram hydrobromide oral tablet 40 mg</i> .....	309	CONCERTA ORAL TABLET EXTENDEDRELEASE* 36 MG .....	346
<i>claravis</i> .....	310	CONTROL AST .....	347
CLARINEX ORAL TABLET .....	311	CONTROL TEST .....	348
CLARINEX-D 12 HOUR .....	312	COPAXONE SUBCUTANEOUS* .....	349
CLEVER CHEK AUTO-CODE .....	313	CORDRAN EXTERNAL TAPE .....	350
CLEVER CHEK AUTO-CODE SYSTEM .....	314	COREG CR .....	351
CLEVER CHEK AUTO-CODE TEST .....	315	CORIFACT .....	352
CLEVER CHEK AUTO-CODE VOICE .....	316	CORLANOR .....	353
CLEVER CHEK AUTO-CODE VOICE IN VITRO .....	317	COSENTYX .....	354
CLEVER CHEK TEST .....	318	COSENTYX SENSOREADY PEN SUBCUTANEOUS* 150 MG/ML .....	355
CLEVER CHOICE AUTO-CODE SYSTEM .....	319	COTELLIC .....	356
CLEVER CHOICE AUTO-CODE TEST .....	320	COZAAR ORAL TABLET 50 MG, 25 MG .....	357
CLEVER CHOICE MICRO SYSTEM .....	321	CRESTOR .....	358
CLEVER CHOICE MICRO TEST .....	322	<i>cryselle-28</i> .....	359
CLEVER CHOICE MINI SYSTEM .....	323	<i>cvs nicotine polacrilex mouth/throat lozenge 4 mg</i> .....	361
CLIMARA .....	324	<i>cvs nicotine transdermal patch 24 hr 7 mg/24hr, 14 mg/24hr</i> .....	360
CLIMARA PRO .....	325	<i>cvs nts step 1</i> .....	362
<i>clonidine hcl er</i> .....	326	<i>cyclafem 1/35</i> .....	363
<i>clopidogrel bisulfate</i> .....	327	<i>cyclafem 7/7/7</i> .....	364
<i>clozapine oral tablet 100 mg</i> .....	329	CYCLESSA .....	365
<i>clozapine oral tablet 200 mg</i> .....	332	CYCLOSET .....	366
<i>clozapine oral tablet 25 mg, 50 mg</i> .....	330	CYMBALTA ORAL CAPSULE DELAYED RELEASE PARTICLES 20 MG .....	368
<i>clozapine oral tablet dispersible 100 mg</i> .....	329	CYMBALTA ORAL CAPSULE DELAYED RELEASE PARTICLES 30 MG .....	367
<i>clozapine oral tablet dispersible 12.5 mg</i> .....	331	CYMBALTA ORAL CAPSULE DELAYED RELEASE PARTICLES 60 MG .....	369
<i>clozapine oral tablet dispersible 150 mg</i> .....	333	CYSTAGON .....	370
<i>clozapine oral tablet dispersible 200 mg</i> .....	328	CYSTARAN .....	371
<i>clozapine oral tablet dispersible 25 mg</i> .....	330	DAKLINZA .....	372
CLOZARIL ORAL TABLET 100 MG .....	334	DAKLINZA .....	373
CLOZARIL ORAL TABLET 25 MG .....	335	DALIRESP .....	374
COLAZAL .....	336	<i>darifenacin hydrobromide er</i> .....	375
<i>colchicine oral tablet</i> .....	337	<i>dasetta 1/35</i> .....	376
COLCRYS .....	338	<i>dasetta 7/7/7</i> .....	377
COLYTE WITH FLAVOR PACKS ORAL SOLUTION RECONSTITUTED 227.1 GM .....	339	<i>daysee</i> .....	378
COMBIPATCH .....	340		
COMETRIQ (100 MG DAILY DOSE) .....	341		

DAYTRANA .....	379	<i>diltiazem hcl er oral capsule extended release</i>	
DEBLITANE .....	380	<i>12 hour 120 mg</i> .....	407
DELZICOL .....	381	<i>diltiazem hcl er oral capsule extended release</i>	
DEPO-PROVERA INTRAMUSCULAR* SUSPENSION 150 MG/ML .....	382	<i>24 hour 120 mg, 180 mg</i> .....	407
DEPO-SUBQ PROVERA 104 SUBCUTANEOUS* SUSPENSION .....	383	<i>diltiazem hcl er oral capsule extended release</i>	
DESCOVY .....	384	<i>24 hour 240 mg</i> .....	408
<i>desloratadine</i> .....	385	<i>dilt-xr oral capsule extended release 24 hour</i>	
DESOGEN .....	386	<i>120 mg, 180 mg</i> .....	413
DESOXYN .....	387	<i>dilt-xr oral capsule extended release 24 hour</i>	
<i>desvenlafaxine fumarate er</i> .....	388	<i>240 mg</i> .....	414
DETROL LA .....	389	DIOVAN .....	415
DEXEDRINE ORAL CAPSULE EXTENDED RELEASE 24 HOUR .....	390	DIOVAN HCT .....	416
<i>dexedrine oral tablet</i> .....	391	DIPENTUM .....	417
DEXILANT .....	392	DITROPAN XL .....	418
<i>dexmethylphenidate hcl</i> .....	393	DOLOPHINE .....	419
<i>dexmethylphenidate hcl er oral capsule</i> <i>extended release 24 hour 20 mg</i> .....	395	<i>donepezil hcl oral tablet 10 mg</i> .....	421
<i>dexmethylphenidate hcl er oral capsule</i> <i>extended release 24 hour 30 mg, 10 mg, 5 mg,</i> <i>15 mg, 40 mg</i> .....	394	<i>donepezil hcl oral tablet 5 mg, 23 mg</i> .....	420
<i>dextroamphetamine sulfate er</i> .....	398	<i>donepezil hcl oral tablet dispersible</i> .....	420
<i>dextroamphetamine sulfate oral solution</i> .....	397	<i>dronabinol</i> .....	422
<i>dextroamphetamine sulfate oral tablet</i> .....	396	<i>drospirenone-ethinyl estradiol oral tablet</i> <i>3-0.03 mg</i> .....	423
<i>diazepam gel</i> .....	399	DUAVEE .....	424
DICLEGIS .....	400	DUETACT .....	425
<i>diclofenac sodium transdermal gel 1 %</i> .....	401	DULERA .....	426
<i>diclofenac sodium transdermal solution</i> .....	402	<i>duloxetine hcl oral capsule delayed release</i> <i>particles 20 mg</i> .....	428
DIFICID .....	403	<i>duloxetine hcl oral capsule delayed release</i> <i>particles 30 mg, 60 mg, 40 mg</i> .....	427
<i>dihydroergotamine mesylate nasal</i> .....	404	DURAGESIC-100 .....	429
<i>diltiazem cd oral capsule extended release 24</i> <i>hour 180 mg, 120 mg</i> .....	405	DURAGESIC-12 .....	430
<i>diltiazem cd oral capsule extended release 24</i> <i>hour 240 mg</i> .....	406	DURAGESIC-25 .....	431
<i>diltiazem hcl er beads oral capsule extended</i> <i>release 24 hour 120 mg, 180 mg, 300 mg, 360</i> <i>mg, 420 mg</i> .....	409	DURAGESIC-50 .....	432
<i>diltiazem hcl er beads oral capsule extended</i> <i>release 24 hour 240 mg</i> .....	410	DURAGESIC-75 .....	433
<i>diltiazem hcl er coated beads oral capsule</i> <i>extended release 24 hour 240 mg</i> .....	412	<i>dutasteride</i> .....	434
<i>diltiazem hcl er coated beads oral capsule</i> <i>extended release 24 hour 360 mg, 180 mg, 300</i> <i>mg, 120 mg</i> .....	411	DYANAVEL XR .....	435
		DYSPORT .....	436
		<i>easy plus ii glucose system</i> .....	437
		<i>easy plus ii glucose test</i> .....	438
		EASY STEP GLUCOSE MONITOR DEVICE .....	439
		EASY STEP TEST .....	440
		<i>easy talk blood glucose system device</i> .....	441
		<i>easy talk blood glucose test</i> .....	442
		EASY TOUCH TEST .....	443
		<i>easy trak blood glucose test</i> .....	444
		EASYGLUCO IN VITRO .....	445
		EASYMAX 15 TEST .....	446

EASYMAX L BLOOD GLUCOSE DEVICE	447	ENBREL SUBCUTANEOUS* 25 MG/0.5ML	482
EASYMAX N BLOOD GLUCOSE DEVICE	448	ENBREL SUBCUTANEOUS* 50 MG/ML	483
EASYMAX NG BLOOD GLUCOSE DEVICE	449	ENBREL SUBCUTANEOUS* KIT	483
EASYMAX TEST	450	ENBREL SURECLICK SUBCUTANEOUS*	484
EASYMAX V BLOOD GLUCOSE DEVICE	451	ENJUVIA ORAL TABLET 0.45 MG, 0.625 MG, 0.3 MG, 0.9 MG	485
EASYMAX V2 BLOOD GLUCOSE DEVICE	452	ENJUVIA ORAL TABLET 1.25 MG	486
<i>easyplus blood glucose test</i>	453	<i>enoxaparin sodium</i>	487
EASYPRO PLUS IN VITRO	454	<i>enpresse-28</i>	488
EDARBI	455	<i>entecavir</i>	489
EDARBYCLOR	456	<i>entecavir</i>	490
EDURANT	457	ENTRESTO	491
EFFEXOR XR ORAL CAPSULE		ENTYVIO	492
EXTENDED RELEASE 24 HOUR 150 MG	458	EPCLUSA	493
EFFEXOR XR ORAL CAPSULE		EPIDUO FORTE	494
EXTENDED RELEASE 24 HOUR 75 MG, 37.5 MG	459	<i>epinephrine injection 0.15 mg/0.15ml, 0.3 mg/0.3ml</i>	495
EFFIENT	460	EPOGEN INJECTION SOLUTION 20000 UNIT/ML, 4000 UNIT/ML, 10000 UNIT/ML, 2000 UNIT/ML, 3000 UNIT/ML	496
ELAPRASE	461	<i>eprosartan mesylate</i>	497
ELELYSO	462	<i>eq nicotine transdermal</i>	498
ELEMENT PLUS	463	<i>eql nicotine transdermal</i>	499
ELEMENT TEST	464	ERIVEDGE	500
ELESTRIN	465	<i>errin</i>	501
ELIDEL	466	ESBRIET	502
<i>elinest</i>	467	<i>escitalopram oxalate oral solution</i>	504
ELLA	468	<i>escitalopram oxalate oral tablet 10 mg</i>	505
ELOCTATE	469	<i>escitalopram oxalate oral tablet 20 mg, 5 mg</i>	503
EMBEDA	470	<i>esomeprazole magnesium</i>	506
EMBRACE BLOOD GLUCOSE MONITOR	471	ESTRADERM	507
EMBRACE BLOOD GLUCOSE TEST	472	<i>estradiol transdermal patch biweekly</i>	508
EMEND ORAL CAPSULE 40 MG, 125 MG, 80 MG	473	<i>estradiol transdermal patch weekly 0.05 mg/24hr</i>	509
EMEND ORAL CAPSULE 80 & 125 MG	474	<i>estradiol transdermal patch weekly 0.06 mg/24hr, 0.025 mg/24hr, 0.0375 mg/24hr, 0.1 mg/24hr, 0.075 mg/24hr</i>	510
EMLA	475	<i>estradiol-norethindrone acet</i>	511
<i>emoquette</i>	477	ESTROGEL	512
EMSAM	478	ESTROSTEP FE	513
EMTRIVA ORAL CAPSULE	479	<i>eszopiclone</i>	514
ENABLEX	480	EUFLEXXA INTRA-ARTICULAR*	515
ENABLEX	481	EVAMIST	516

EVEKEO .....	517	FEIBA VH IMMUNO .....	555
EVENCARE + BLOOD GLUCOSE TEST .....	518	<i>felodipine er</i> .....	556
EVENCARE BLOOD GLUCOSE TEST .....	519	FEMCON FE .....	557
EVENCARE G2 MONITOR .....	520	FEMHRT LOW DOSE .....	558
EVENCARE G2 TEST .....	521	FEMRING .....	559
EVENCARE G3 MONITOR .....	522	<i>fenofibrate micronized</i> .....	562
EVENCARE G3 TEST .....	523	<i>fenofibrate oral capsule</i> .....	561
EVOLUTION AUTOCODE .....	525	<i>fenofibrate oral tablet 48 mg, 54 mg, 145 mg, 160 mg</i> .....	560
EVOLUTION AUTOCODE IN VITRO .....	524	<i>fenofibric acid oral tablet</i> .....	563
EVOXAC .....	526	<i>fentanyl</i> .....	564
EXALGO ORAL 12 MG, 32 MG, 8 MG .....	527	<i>fentanyl citrate buccal</i> .....	565
EXALGO ORAL 16 MG .....	528	FENTORA BUCCAL TABLET 200 MCG, 600 MCG, 800 MCG, 400 MCG, 100 MCG .....	567
EXELON ORAL CAPSULE .....	529	FERRIPROX .....	569
EXELON TRANSDERMAL .....	529	FETZIMA .....	570
EXFORGE .....	530	FETZIMA TITRATION .....	571
EXJADE .....	531	FIBRICOR .....	572
EXTAVIA SUBCUTANEOUS* KIT .....	532	FIFTY50 GLUCOSE TEST 2.0 .....	573
EZ SMART BLOOD GLUCOSE TEST .....	533	FIRAZYR .....	574
EZ SMART MONITORING SYSTEM .....	534	FLEBOGAMMA DIF .....	576
EZ SMART PLUS GLUCOSE TEST .....	535	FLEBOGAMMA INTRAVENOUS* .....	575
EZ SMART PLUS MONITORING SYS .....	536	SOLUTION 0.5 GM/10ML .....	577
FABRAZYME .....	537	FLOLAN .....	577
FALESSA ORAL KIT 20-1-0.1 MCG-MG .....	538	FLOVENT DISKUS .....	578
<i>falmina</i> .....	539	FLOVENT HFA .....	579
<i>famciclovir oral tablet 250 mg, 125 mg</i> .....	540	<i>flunisolide nasal solution 25 mcg/act (0.025%)</i> .....	580
<i>famciclovir oral tablet 500 mg</i> .....	541	<i>fluoxetine hcl oral capsule 10 mg</i> .....	586
FAMVIR ORAL TABLET 250 MG, 125 MG .....	543	<i>fluoxetine hcl oral capsule 20 mg</i> .....	583
.....	543	<i>fluoxetine hcl oral capsule 40 mg</i> .....	584
FAMVIR ORAL TABLET 500 MG .....	542	<i>fluoxetine hcl oral capsule delayed release</i> .....	581
FANAPT .....	544	<i>fluoxetine hcl oral tablet 10 mg</i> .....	582
FANAPT TITRATION PACK .....	545	<i>fluoxetine hcl oral tablet 20 mg</i> .....	587
FARXIGA .....	546	<i>fluoxetine hcl oral tablet 60 mg</i> .....	585
FARYDAK .....	547	<i>fluvastatin sodium</i> .....	588
FAZACLO ORAL TABLET DISPERSIBLE .....	552	<i>fluvastatin sodium er</i> .....	589
100 MG .....	552	<i>fluvoxamine maleate er</i> .....	592
FAZACLO ORAL TABLET DISPERSIBLE .....	551	<i>fluvoxamine maleate oral tablet 100 mg</i> .....	591
12.5 MG .....	551	<i>fluvoxamine maleate oral tablet 25 mg, 50 mg</i> .....	590
FAZACLO ORAL TABLET DISPERSIBLE .....	549	FOCALIN .....	593
150 MG .....	549	FOCALIN XR .....	594
FAZACLO ORAL TABLET DISPERSIBLE .....	548	FOLLISTIM AQ .....	595
200 MG .....	548	<i>fondaparinux sodium</i> .....	596
FAZACLO ORAL TABLET DISPERSIBLE .....	550		
25 MG .....	550		
FEIBA .....	553		
FEIBA NF .....	554		

FORA D10 2-IN-1 MONITOR .....	597	<i>gabapentin oral capsule</i> .....	637
FORA D10 BLOOD GLUCOSE TEST .....	598	<i>gabapentin oral solution 250 mg/5ml</i> .....	638
FORA D15G 2-IN-1 MONITOR .....	599	<i>gabapentin oral tablet</i> .....	639
FORA D15G BLOOD GLUCOSE TEST .....	600	GABITRIL ORAL TABLET 12 MG, 4 MG .....	641
FORA D20 2-IN-1 MONITOR .....	601	GABITRIL ORAL TABLET 16 MG .....	640
FORA D20 BLOOD GLUCOSE TEST .....	602	GABITRIL ORAL TABLET 2 MG .....	642
FORA G20 BLOOD GLUCOSE TEST .....	603	<i>galantamine hydrobromide oral tablet</i> .....	643
FORA G30A BLOOD GLUCOSE SYSTEM .....	604	GAMMAGARD .....	644
FORA G30A BLOOD GLUCOSE TEST .....	605	GAMMAGARD S/D LESS IGA .....	645
FORA GD20 BLOOD GLUCOSE SYSTEM .....	606	GAMMAKED .....	646
FORA GD20 TEST .....	607	GAMMAPLEX .....	647
FORA V10 BLOOD GLUCOSE SYSTEM .....	608	GAMUNEX-C .....	648
FORA V10 BLOOD GLUCOSE TEST .....	609	<i>ganirelix acetate</i> .....	649
FORA V12 BLOOD GLUCOSE SYSTEM .....	610	GATTEX .....	650
FORA V12 BLOOD GLUCOSE TEST .....	611	<i>gavilyte-c</i> .....	651
FORA V20 BLOOD GLUCOSE SYSTEM .....	612	<i>gavilyte-g</i> .....	652
FORA V20 BLOOD GLUCOSE TEST .....	613	<i>ge100 blood glucose test</i> .....	653
FORA V30A BLOOD GLUCOSE SYSTEM .....	614	GEL-ONE INTRA-ARTICULAR* .....	654
FORA V30A BLOOD GLUCOSE TEST .....	615	GELSYN-3 .....	655
FORACARE GD40 MONITOR .....	616	GENERESS FE .....	656
FORACARE GD40 TEST .....	617	GENOTROPIN .....	657
FORACARE PREMIUM V10 .....	618	GENOTROPIN MINIQUICK .....	658
FORACARE PREMIUM V10 TEST .....	619	GENVOYA .....	659
FORADIL AEROLIZER .....	620	GEODON ORAL .....	660
FORTEO SUBCUTANEOUS* SOLUTION .....	621	<i>gianvi</i> .....	661
600 MCG/2.4ML .....	622	GIAZO .....	662
<i>fortical</i> .....	623	<i>gildagia</i> .....	663
FOSAMAX ORAL TABLET 70 MG .....	624	<i>gildess 1.5/30</i> .....	664
FOSAMAX PLUS D .....	625	<i>gildess 1/20</i> .....	665
FRAGMIN .....	626	<i>gildess fe 1.5/30</i> .....	666
FREESTYLE FLASH SYSTEM .....	627	<i>gildess fe 1/20</i> .....	667
FREESTYLE FREEDOM LITE .....	628	GILENYA .....	668
FREESTYLE INSULINX SYSTEM .....	629	GILOTRIF .....	669
FREESTYLE INSULINX TEST .....	630	GLEEVEC ORAL TABLET 100 MG .....	670
FREESTYLE LITE .....	631	GLEEVEC ORAL TABLET 400 MG .....	671
FREESTYLE LITE TEST .....	632	GLUCAGEN DIAGNOSTIC .....	672
FREESTYLE SYSTEM .....	633	GLUCAGEN HYPOKIT .....	673
FROVA .....	634	GLUCOCARD 01 BLOOD GLUCOSE .....	674
<i>frovatriptan succinate</i> .....	635	DEVICE .....	675
FULYZAQ .....	636	GLUCOCARD 01 SENSOR PLUS .....	676
FYCOMPA ORAL TABLET .....	637	GLUCOCARD EXPRESSION TEST .....	677
		GLUCOCARD VITAL TEST .....	678
		GLUCOCARD X-SENSOR .....	679
		GLUCOCOM BLOOD GLUCOSE .....	680
		MONITOR .....	
		GLUCOCOM TEST .....	



GLYXAMBI.....	681	HYCAMTIN ORAL.....	712
GONAL-F.....	682	<i>hydrocod polst-cpm polst er oral liquid</i>	
GONAL-F RFF.....	683	<i>extendedrelease*</i>	713
GONAL-F RFF PEN.....	684	<i>hydromorphone hcl er oral 16 mg</i>	714
GONAL-F RFF REDIJECT.....	685	<i>hydromorphone hcl er oral 32 mg, 8 mg, 12</i>	
GRALISE ORAL TABLET 300 MG.....	686	<i>mg</i>	715
GRALISE ORAL TABLET 600 MG.....	687	HYMOVIS.....	716
GRALISE STARTER.....	688	HYQVIA.....	717
<i>granisetron hcl oral</i> .....	689	HYSINGLA ER.....	718
<i>guanfacine hcl er</i> .....	690	<i>ibandronate sodium intravenous* solution 3</i>	
HARVONI.....	691	<i>mg/3ml</i> .....	719
<i>heather</i> .....	692	<i>ibandronate sodium oral</i> .....	720
HELIXATE FS.....	693	IBRANCE.....	721
HEMANGEOL.....	694	ICLUSIG ORAL TABLET 15 MG.....	723
HEMOFIL M INTRAVENOUS* SOLUTION		ICLUSIG ORAL TABLET 45 MG.....	722
RECONSTITUTED 1000 UNIT, 1700 UNIT,		IDELVION.....	724
500 UNIT, 1501-2000 UNIT, 801-1500 UNIT,		ILARIS.....	725
220-400 UNIT, 250 UNIT, 401-800 UNIT	695	<i>imatinib mesylate oral tablet 100 mg</i>	726
.....		<i>imatinib mesylate oral tablet 400 mg</i>	727
HEPSERA.....	696	IMBRUVICA.....	728
HETLIOZ.....	697	<i>imiquimod external</i> .....	729
HIZENTRA SUBCUTANEOUS* SOLUTION		IMITREX NASAL.....	731
1 GM/5ML, 4 GM/20ML, 10 GM/50ML, 2		IMITREX ORAL.....	732
GM/10ML.....	698	IMITREX STATDOSE REFILL	
<i>hm nicotine</i> .....	699	SUBCUTANEOUS* 4 MG/0.5ML.....	733
<i>hm nicotine polacrilex mouth/throat lozenge 2</i>		IMITREX STATDOSE SYSTEM	
<i>mg</i> .....	700	SUBCUTANEOUS* 6 MG/0.5ML.....	734
HORIZANT ORAL TABLET		IMITREX SUBCUTANEOUS*.....	730
EXTENDEDRELEASE* 300 MG.....	701	IMPAVIDO.....	735
HORIZANT ORAL TABLET		IMPLANON.....	736
EXTENDEDRELEASE* 600 MG.....	702	INCRELEX.....	737
HUMATE-P INTRAVENOUS* SOLUTION		INDERAL XL ORAL CAPSULE	
RECONSTITUTED 1000-2400 UNIT,		EXTENDED RELEASE 24 HOUR 80 MG	
250-600 UNIT, 500-1200 UNIT.....	703	.....	738
HUMATROPE.....	704	INFINITY BLOOD GLUCOSE TEST.....	739
HUMIRA PEDIATRIC CROHNS START		INLYTA.....	740
SUBCUTANEOUS* 40 MG/0.8ML.....	707	INNOPRAN XL ORAL CAPSULE	
HUMIRA PEN SUBCUTANEOUS*.....	708	EXTENDED RELEASE 24 HOUR 120 MG	
HUMIRA PEN-CROHNS STARTER		.....	742
SUBCUTANEOUS*.....	709	INNOPRAN XL ORAL CAPSULE	
HUMIRA PEN-PSORIASIS STARTER		EXTENDED RELEASE 24 HOUR 80 MG	
SUBCUTANEOUS*.....	710	.....	741
HUMIRA SUBCUTANEOUS* 20		INTELENCE ORAL TABLET 200 MG.....	743
MG/0.4ML, 10 MG/0.2ML.....	706	INTELENCE ORAL TABLET 25 MG, 100	
HUMIRA SUBCUTANEOUS* 40 MG/0.8ML		MG.....	744
.....	705	INTRON A.....	745
HYALGAN.....	711	<i>introvale</i> .....	746

INTUNIV .....	747	<i>junel fe 1/20</i> .....	781
INVEGA ORAL TABLET EXTENDED RELEASE 24 HR* 1.5 MG, 3 MG, 9 MG		JUXTAPID ORAL CAPSULE 10 MG, 5 MG	
.....	748	.....	783
INVEGA ORAL TABLET EXTENDED RELEASE 24 HR* 6 MG	749	JUXTAPID ORAL CAPSULE 60 MG, 40 MG, 30 MG .....	782
INVOKAMET .....	750	KADIAN .....	784
INVOKAMET XR .....	751	KALBITOR .....	785
INVOKANA .....	752	KALYDECO .....	786
<i>ipratropium bromide nasal</i> .....	753	KALYDECO .....	787
IPRIVASK .....	754	KANUMA .....	788
<i>irbesartan</i> .....	755	KAPVAY ORAL TABLET EXTENDED RELEASE 12 HR* .....	789
<i>irbesartan-hydrochlorothiazide</i> .....	756	<i>kariva</i> .....	790
IRENKA .....	757	KAZANO .....	791
IRESSA .....	758	<i>kelnor 1/35</i> .....	792
ISENTRESS ORAL TABLET .....	759	KEPPRA XR ORAL TABLET EXTENDED RELEASE 24 HR* 500 MG .....	793
ISENTRESS ORAL TABLET CHEWABLE .....	760	KEPPRA XR ORAL TABLET EXTENDED RELEASE 24 HR* 750 MG .....	794
<i>itraconazole oral</i> .....	761	KERYDIN .....	795
IXINITY INTRAVENOUS* SOLUTION RECONSTITUTED 1500 UNIT .....	762	<i>ketoconazole oral</i> .....	796
JADENU .....	763	<i>ketorolac tromethamine ophthalmic</i> .....	798
JAKAFI ORAL TABLET 10 MG .....	764	<i>ketorolac tromethamine oral</i> .....	797
JAKAFI ORAL TABLET 25 MG, 15 MG, 20 MG, 5 MG .....	765	KEVEYIS .....	799
JANUMET .....	766	KHEDEZLA .....	800
JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HR* 50-1000 MG .....	767	KINERET SUBCUTANEOUS* .....	801
JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HR* 50-500 MG, 100-1000 MG	768	KOATE-DVI .....	802
.....	768	KOGENATE FS .....	803
JANUVIA .....	769	KOGENATE FS BIO-SET .....	804
JARDIANCE .....	770	KOMBIGLYZE XR ORAL TABLET EXTENDED RELEASE 24 HR* 2.5-1000 MG .....	806
JENTADUETO .....	771	KOMBIGLYZE XR ORAL TABLET EXTENDED RELEASE 24 HR* 5-500 MG, 5-1000 MG .....	805
JENTADUETO XR ORAL TABLET EXTENDED RELEASE 24 HR* 2.5-1000 MG .....	773	KORLYM .....	807
JENTADUETO XR ORAL TABLET EXTENDED RELEASE 24 HR* 5-1000 MG	772	KOVALTRY .....	808
.....	772	KROGER BLOOD GLUCOSE KIT W/DEVICE .....	809
<i>jinteli</i> .....	774	<i>croger blood glucose test</i> .....	810
<i>jolessa</i> .....	775	KROGER PREMIUM BLOOD GLUCOSE .....	811
<i>jolivette</i> .....	776	<i>croger premium glucose test</i> .....	812
JUBLIA .....	777	<i>croger test</i> .....	813
<i>junel 1.5/30</i> .....	778	<i>kurvelo</i> .....	814
<i>junel 1/20</i> .....	779	KUVAN .....	815
<i>junel fe 1.5/30</i> .....	780	KYNAMRO SUBCUTANEOUS* .....	816

LAMICTAL ODT ORAL TABLET DISPERSIBLE 200 MG, 100 MG	818	LENVIMA 8 MG DAILY DOSE	848
LAMICTAL ODT ORAL TABLET DISPERSIBLE 25 MG	819	LESCOL XL	849
LAMICTAL ODT ORAL TABLET DISPERSIBLE 50 MG	817	<i>lessina</i>	850
LAMICTAL XR ORAL TABLET EXTENDED RELEASE 24 HR* 200 MG	822	<i>leuprolide acetate injection</i>	851
LAMICTAL XR ORAL TABLET EXTENDED RELEASE 24 HR* 300 MG, 250 MG	820	<i>levalbuterol tartrate hfa</i>	852
LAMICTAL XR ORAL TABLET EXTENDED RELEASE 24 HR* 50 MG, 25 MG, 100 MG	821	<i>levetiracetam er oral tablet extended release 24 hr* 500 mg</i>	853
LAMISIL ORAL PACKET 125 MG	823	<i>levetiracetam er oral tablet extended release 24 hr* 750 mg</i>	854
LAMISIL ORAL PACKET 187.5 MG	824	<i>levocetirizine dihydrochloride oral tablet</i>	855
<i>lamotrigine er oral tablet extended release 24 hr* 100 mg, 25 mg</i>	830	<i>levonest</i>	856
<i>lamotrigine er oral tablet extended release 24 hr* 200 mg</i>	829	<i>levonorgest-eth estrad 91-day oral tablet 0.1-0.02 &amp; 0.01 mg, 0.15-0.03 mg</i>	857
<i>lamotrigine er oral tablet extended release 24 hr* 300 mg, 250 mg</i>	828	<i>levonorgestrel-ethinyl estrad oral tablet 0.15-30 mg-mcg</i>	858
<i>lamotrigine er oral tablet extended release 24 hr* 50 mg</i>	831	<i>levora 0.15/30 (28)</i>	859
<i>lamotrigine oral tablet dispersible 100 mg, 200 mg</i>	825	LEXAPRO ORAL SOLUTION	860
<i>lamotrigine oral tablet dispersible 25 mg</i>	827	LEXAPRO ORAL TABLET 10 MG	862
<i>lamotrigine oral tablet dispersible 50 mg</i>	826	LEXAPRO ORAL TABLET 20 MG, 5 MG	861
<i>lansoprazole oral capsule delayed release</i>	832	LIALDA	863
LARIN FE 1.5/30	833	<i>liberty blood glucose meter</i>	864
LATUDA ORAL TABLET 20 MG, 120 MG, 40 MG	834	<i>liberty blood glucose monitor</i>	865
LATUDA ORAL TABLET 80 MG	835	LIBERTY NEXT GENERATION TEST	866
LAZANDA NASAL SOLUTION 300 MCG/ACT	836	LIBERTY NXT GENERATION MONITOR	867
LAZANDA NASAL SOLUTION 400 MCG/ACT, 100 MCG/ACT	838	<i>liberty test</i>	868
<i>leena</i>	840	<i>lidocaine external ointment</i>	869
<i>leflunomide oral</i>	841	<i>lidocaine-prilocaine external cream</i>	871
LEMTRADA	842	<i>lindane external lotion</i>	873
LENVIMA 10 MG DAILY DOSE	843	<i>linezolid oral suspension reconstituted</i>	874
LENVIMA 14 MG DAILY DOSE	844	<i>linezolid oral tablet</i>	875
LENVIMA 18 MG DAILY DOSE	845	LINZESS	876
LENVIMA 20 MG DAILY DOSE	846	LIPITOR	877
LENVIMA 24 MG DAILY DOSE	847	LIPOFEN	878
		LIPTRUZET	879
		LIVALO	880
		LO LOESTRIN FE	881
		LOESTRIN 1.5/30 (21)	882
		LOESTRIN 1/20 (21)	883
		LOESTRIN FE 1.5/30	884
		LOESTRIN FE 1/20	885
		LOFIBRA	886
		LOFIBRA	887
		<i>lomedica 24 fe</i>	888
		LONSURF ORAL TABLET 15-6.14 MG	889

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
Updated 12/2016



LONSURF ORAL TABLET 20-8.19 MG	890	METADATE CD ORAL CAPSULE	
<i>loryna</i>	891	EXTENDED RELEASE* 50 MG	926
<i>losartan potassium oral tablet 50 mg, 25 mg</i>	892	METADATE ER ORAL TABLET	
LOSEASONIQUE	893	EXTENDEDRELEASE* 20 MG	928
LOTRONEX	894	<i>methadone hcl oral solution 10 mg/5ml</i>	929
<i>lovastatin</i>	895	<i>methadone hcl oral solution 5 mg/5ml</i>	931
LOVAZA	896	<i>methadone hcl oral tablet</i>	930
LOVENOX	897	<i>methadone hcl oral tablet soluble</i>	930
<i>low-ogestrel</i>	898	<i>methadose oral tablet soluble</i>	932
LUMIGAN	899	<i>methamphetamine hcl</i>	933
LUMIZYME	900	METHYLIN ORAL SOLUTION 10 MG/5ML	
LUNESTA	901		934
<i>lutea</i>	902	METHYLIN ORAL SOLUTION 5 MG/5ML	
LYNPARZA	903		936
LYSTEDA	904	METHYLIN ORAL TABLET CHEWABLE	
LYZA	905	<i>methylphenidate hcl er (cd)</i>	935
MAKENA	906	<i>methylphenidate hcl er (la) oral capsule</i>	944
<i>maprotiline hcl</i>	907	<i>extended release 24 hour 30 mg</i>	945
MARINOL	908	<i>methylphenidate hcl er (la) oral capsule</i>	
<i>marlissa</i>	909	<i>extended release 24 hour 40 mg, 20 mg</i>	946
<i>matzim la oral tablet extended release 24 hr*</i>	910	<i>methylphenidate hcl er oral tablet extended</i>	
<i>180 mg, 360 mg, 300 mg</i>	911	<i>release 24 hr* 36 mg</i>	940
<i>matzim la oral tablet extended release 24 hr*</i>	912	<i>methylphenidate hcl er oral tablet</i>	
<i>240 mg</i>	913	<i>extendedrelease* 10 mg, 20 mg</i>	941
MAXALT	914	<i>methylphenidate hcl er oral tablet</i>	
MAXALT-MLT	915	<i>extendedrelease* 27 mg, 18 mg, 54 mg</i>	942
MAXIMA BLOOD GLUCOSE TEST	916	<i>methylphenidate hcl er oral tablet</i>	
<i>medroxyprogesterone acetate intramuscular*</i>	917	<i>extendedrelease* 36 mg</i>	943
<i>suspension</i>	918	<i>methylphenidate hcl oral solution 10 mg/5ml</i>	939
MEIJER BLOOD GLUCOSE	919	<i>methylphenidate hcl oral solution 5 mg/5ml</i>	
<i>meijer blood glucose test</i>	920		938
MEIJER PREMIUM BLOOD GLUCOSE	921	<i>methylphenidate hcl oral tablet</i>	937
	922	<i>metoprolol succinate er oral tablet extended</i>	
<i>meijer premium glucose test</i>	923	<i>release 24 hr* 100 mg, 50 mg</i>	947
<i>memantine hcl oral tablet 10 mg, 5 mg</i>	924	<i>metoprolol succinate er oral tablet extended</i>	
MENOPUR	925	<i>release 24 hr* 200 mg</i>	948
MENOSTAR	926	<i>metoprolol succinate er oral tablet extended</i>	
<i>mesalamine oral</i>	927	<i>release 24 hr* 25 mg</i>	949
METADATE CD ORAL CAPSULE		MEVACOR ORAL TABLET 40 MG	950
EXTENDED RELEASE* 10 MG, 60 MG, 40		MICARDIS	951
MG	924	MICARDIS HCT	952
METADATE CD ORAL CAPSULE		MICRODOT TEST	953
EXTENDED RELEASE* 20 MG	925	<i>microgestin 1.5/30</i>	954
METADATE CD ORAL CAPSULE		<i>microgestin 1/20</i>	955
EXTENDED RELEASE* 30 MG	927	<i>microgestin fe 1.5/30</i>	956

<i>microgestin fe 1/20</i> .....	957	NATPARA.....	998
<i>mimvey</i> .....	958	<i>necon 0.5/35 (28)</i> .....	999
MINIVELLE.....	959	<i>necon 1/35 (28)</i> .....	1000
MIRAPEX ER.....	960	<i>necon 1/50 (28)</i> .....	1001
MIRCERA INJECTION.....	961	<i>necon 10/11 (28)</i> .....	1002
MIRCETTE.....	962	NESINA.....	1003
MIRENA (52 MG).....	963	NEUPRO.....	1004
<i>mirtazapine oral</i> .....	964	NEURONTIN ORAL CAPSULE.....	1005
MITIGARE.....	965	NEURONTIN ORAL SOLUTION.....	1007
<i>modafinil oral tablet 100 mg</i> .....	968	NEURONTIN ORAL TABLET.....	1006
<i>modafinil oral tablet 200 mg</i> .....	966	NEUTEK 2TEK GLUCOSE/PRESSURE.....	1008
MODICON (28).....	970	NEUTEK 2TEK TEST.....	1009
MONOCLATE-P.....	971	<i>nevirapine er oral tablet extended release 24 hr* 100 mg</i> .....	1010
<i>mono-lynyah</i> .....	972	<i>nevirapine er oral tablet extended release 24 hr* 400 mg</i> .....	1011
<i>mononessa</i> .....	973	NEXAVAR.....	1012
MONONINE.....	974	NEXIUM 24HR ORAL TABLET DELAYED RELEASE.....	1015
MONOVISC.....	975	NEXIUM ORAL CAPSULE DELAYED RELEASE 40 MG.....	1013
<i>montelukast sodium oral</i> .....	976	NEXIUM ORAL PACKET.....	1014
<i>montelukast sodium oral</i> .....	977	NEXPLANON.....	1016
<i>morphine sulfate er beads</i> .....	980	<i>next choice one dose</i> .....	1017
<i>morphine sulfate er oral capsule extended release 24 hour</i> .....	979	NICODERM CQ.....	1018
<i>morphine sulfate er oral tablet extended release* 15 mg, 200 mg</i> .....	978	<i>nicorelief mouth/throat gum</i> .....	1019
<i>morphine sulfate er oral tablet extended release* 30 mg, 60 mg, 100 mg</i> .....	979	NICORETTE MOUTH/THROAT GUM.....	1020
MS CONTIN ORAL TABLET EXTENDEDRELEASE*.....	981	<i>nicotine step 1</i> .....	1022
MULTAQ.....	982	<i>nicotine step 2</i> .....	1023
MYALEPT.....	983	<i>nicotine step 3</i> .....	1024
MYGLUCOHEALTH TEST.....	984	<i>nicotine transdermal patch 24 hr</i> .....	1021
<i>myorisan oral capsule 10 mg, 40 mg, 20 mg</i> .....	985	NICOTROL.....	1025
.....	985	NICOTROL NS.....	1026
MYOZYME.....	986	<i>nifediac cc oral tablet extended release 24 hr* 30 mg</i> .....	1028
MYRBETRIQ.....	987	<i>nifediac cc oral tablet extended release 24 hr* 60 mg</i> .....	1027
MYTESI.....	988	<i>nifedical xl oral tablet extended release 24 hr* 30 mg</i> .....	1029
<i>myzilra</i> .....	989	<i>nifedical xl oral tablet extended release 24 hr* 60 mg</i> .....	1030
NAGLAZYME.....	990	<i>nifedipine er oral tablet extended release 24 hr* 30 mg, 90 mg</i> .....	1031
NAMENDA.....	991	<i>nifedipine er oral tablet extended release 24 hr* 60 mg</i> .....	1032
NAMENDA TITRATION PAK.....	992		
NAMENDA XR.....	993		
NAMZARIC ORAL CAPSULE EXTENDED RELEASE 24 HOUR 28-10 MG, 14-10 MG.....	994		
.....	994		
<i>naratriptan hcl</i> .....	995		
NATAZIA.....	996		
NATESTO.....	997		

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
Updated 12/2016

<i>nifedipine er osmotic release oral tablet extended release 24 hr* 60 mg</i> .....	1033	NUTROPIN AQ NUSPIN 20 .....	1068
<i>nifedipine er osmotic release oral tablet extended release 24 hr* 90 mg, 30 mg</i> .....	1034	NUTROPIN AQ NUSPIN 5 .....	1069
NIKKI .....	1035	NUVARING .....	1070
NINLARO .....	1036	NUVIGIL ORAL TABLET 200 MG, 150 MG, 250 MG .....	1071
<i>nisoldipine er oral tablet extended release 24 hr* 25.5 mg, 40 mg, 8.5 mg, 20 mg, 17 mg, 34 mg</i> .....	1037	NUVIGIL ORAL TABLET 50 MG .....	1073
<i>nisoldipine er oral tablet extended release 24 hr* 30 mg</i> .....	1038	NYMALIZE .....	1075
<i>nitroglycerin translingual solution</i> .....	1039	OALIVA ORAL TABLET 5 MG .....	1076
<i>nora-be</i> .....	1040	<i>ocella</i> .....	1077
NORDITROPIN FLEXPRO .....	1041	OCTAGAM .....	1078
<i>norethindrone oral</i> .....	1042	ODEFSEY .....	1079
<i>norgestimate-eth estradiol oral tablet 0.25-35 mg-mcg</i> .....	1043	ODOMZO .....	1080
<i>norgestim-eth estrad triphasic oral tablet 0.18/0.215/0.25 mg-35 mcg</i> .....	1044	OFEV .....	1081
NORINYL 1+35 (28) .....	1045	<i>ogestrel</i> .....	1082
NORINYL 1+50 (28) .....	1046	<i>olanzapine oral tablet 2.5 mg</i> .....	1084
NORLYROC .....	1047	<i>olanzapine oral tablet 20 mg, 5 mg, 7.5 mg, 10 mg, 15 mg</i> .....	1083
NOR-QD .....	1048	<i>olanzapine oral tablet dispersible</i> .....	1083
NORTHERA ORAL CAPSULE 100 MG .....	1050	<i>olanzapine-fluoxetine hcl</i> .....	1085
NORTHERA ORAL CAPSULE 300 MG, 200 MG .....	1049	OLEPTRO .....	1086
<i>nortrel 0.5/35 (28)</i> .....	1051	OLYSIO .....	1087
<i>nortrel 1/35 (21)</i> .....	1052	<i>omega-3-acid ethyl esters</i> .....	1088
<i>nortrel 1/35 (28)</i> .....	1053	ON CALL PLUS BLOOD GLUCOSE .....	1089
<i>nortrel 7/7/7</i> .....	1054	ON CALL VIVID BLOOD GLUCOSE .....	1090
NOVA MAX BLOOD GLUCOSE SYSTEM DEVICE .....	1055	<i>ondansetron</i> .....	1091
NOVA MAX GLUCOSE TEST .....	1056	<i>ondansetron hcl oral solution</i> .....	1092
<i>novarel</i> .....	1057	<i>ondansetron hcl oral tablet 4 mg, 24 mg</i> .....	1094
NOVOEIGHT .....	1058	<i>ondansetron hcl oral tablet 8 mg</i> .....	1093
NOVOLOG PENFILL SUBCUTANEOUS* .....	1059	ONETOUCH TEST .....	1095
NOVOSEVEN RT .....	1060	ONETOUCH ULTRA 2 .....	1096
NOXAFIL ORAL TABLET DELAYED RELEASE .....	1061	ONETOUCH ULTRA BLUE .....	1097
NUCALA .....	1062	ONETOUCH ULTRA MINI .....	1098
NUCYNTA .....	1063	ONETOUCH VERIO IN VITRO STRIP .....	1099
NUCYNTA ER .....	1064	ONETOUCH VERIO IQ SYSTEM .....	1100
NUEDEXTA .....	1065	ONFI ORAL TABLET 20 MG, 10 MG .....	1101
NUPLAZID .....	1066	ONGLYZA .....	1102
NUTROPIN AQ NUSPIN 10 .....	1067	ONSOLIS .....	1103
		ONZETRA XSAIL .....	1105
		OPANA ER ORAL .....	1107
		OPANA ER ORAL .....	1108
		OPANA ER ORAL TABLET EXTENDED RELEASE 12 HR* 20 MG, 5 MG, 10 MG, 40 MG, 30 MG .....	1106
		OPSUMIT .....	1109
		ORAMORPH SR ORAL TABLET EXTENDEDRELEASE* .....	1110

ORAVIG.....	1111	<i>paroxetine hcl oral tablet 30 mg, 40 mg</i> ....	1145
ORENCIA CLICKJECT.....	1114	PAXIL CR ORAL TABLET EXTENDED	
ORENCIA INTRAVENOUS*.....	1113	RELEASE 24 HR* 12.5 MG.....	1151
ORENCIA SUBCUTANEOUS*.....	1112	PAXIL CR ORAL TABLET EXTENDED	
ORENITRAM.....	1115	RELEASE 24 HR* 25 MG.....	1152
ORKAMBI.....	1116	PAXIL CR ORAL TABLET EXTENDED	
<i>orsythia</i> .....	1117	RELEASE 24 HR* 37.5 MG.....	1153
ORTHO DIAPHRAGM ALL-FLEX		PAXIL ORAL SUSPENSION.....	1148
VAGINAL DIAPHRAGM 70 MM.....	1118	PAXIL ORAL TABLET 10 MG, 20 MG	
ORTHO MICRONOR.....	1119	.....	1150
ORTHO TRI-CYCLEN (28).....	1120	PAXIL ORAL TABLET 40 MG, 30 MG	
ORTHO TRI-CYCLEN LO.....	1121	.....	1149
ORTHO-CEPT (28).....	1122	<i>peg 3350/electrolytes</i> .....	1154
ORTHO-CYCLEN (28).....	1123	<i>peg-3350/electrolytes</i> .....	1155
ORTHO-NOVUM 1/35 (28).....	1124	PEGASYS PROCLICK.....	1157
ORTHO-NOVUM 7/7/7 (28).....	1125	PEGASYS SUBCUTANEOUS* SOLUTION	
ORTHOVISC INTRA-ARTICULAR*.....	1126	.....	1156
OSENI.....	1127	PEGINTRON.....	1158
OTEZLA ORAL 10 & 20 & 30 MG.....	1128	PEG-INTRON.....	1159
OTEZLA ORAL TABLET.....	1129	PEG-INTRON REDIPEN PAK 4	
OVCON-35 (28).....	1130	SUBCUTANEOUS* KIT 120 MCG/0.5ML	
OVIDREL.....	1131	.....	1161
OXTELLAR XR ORAL TABLET		PEG-INTRON REDIPEN	
EXTENDED RELEASE 24 HR* 150 MG, 300		SUBCUTANEOUS* KIT 150 MCG/0.5ML,	
MG.....	1132	80 MCG/0.5ML, 50 MCG/0.5ML.....	1160
OXTELLAR XR ORAL TABLET		PENNSAID TRANSDERMAL SOLUTION 2	
EXTENDED RELEASE 24 HR* 600 MG		%.....	1162
.....	1133	PENTASA ORAL CAPSULE EXTENDED	
<i>oxybutynin chloride oral tablet</i> .....	1134	RELEASE* 250 MG.....	1163
<i>oxycodone hcl er oral 10 mg, 80 mg, 40 mg, 20</i>		PENTASA ORAL CAPSULE EXTENDED	
<i>mg</i> .....	1135	RELEASE* 500 MG.....	1164
<i>oxycodone-ibuprofen</i> .....	1136	PERFOROMIST.....	1165
OXYCONTIN ORAL.....	1137	PHARMACIST CHOICE AUTOCODE..	1166
<i>oxymorphone hcl er</i> .....	1138	<i>philith</i> .....	1167
<i>paliperidone er oral tablet extended release 24</i>		PICATO EXTERNAL GEL 0.015 %.....	1169
<i>hr* 3 mg, 1.5 mg, 6 mg</i> .....	1139	PICATO EXTERNAL GEL 0.05 %.....	1168
<i>paliperidone er oral tablet extended release 24</i>		<i>pioglitazone hcl</i> .....	1170
<i>hr* 9 mg</i> .....	1140	<i>pioglitazone hcl-glimepiride</i> .....	1171
<i>pamidronate disodium</i> .....	1141	<i>pioglitazone hcl-metformin hcl</i> .....	1172
PARAGARD INTRAUTERINE COPPER		PLAN B ONE-STEP.....	1173
.....	1142	PLAVIX ORAL TABLET 75 MG.....	1174
<i>paricalcitol oral</i> .....	1143	PLEGRIDY.....	1175
<i>paroxetine hcl er oral tablet extended release</i>		PLEGRIDY STARTER PACK.....	1176
<i>24 hr* 12.5 mg, 37.5 mg</i> .....	1146	POCKETCHEM EZ TEST.....	1177
<i>paroxetine hcl er oral tablet extended release</i>		POMALYST.....	1178
<i>24 hr* 25 mg</i> .....	1147	<i>portia-28</i> .....	1179
<i>paroxetine hcl oral tablet 10 mg, 20 mg</i> ....	1144		

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
Updated 12/2016

POTIGA ORAL TABLET 400 MG, 300 MG, 200 MG	1180	PRODIGY NO CODING BLOOD GLUC	1214
POTIGA ORAL TABLET 50 MG	1181	PROFILNINE INTRAVENOUS* SOLUTION	
PRALUENT	1182	RECONSTITUTED 1000 UNIT	1215
<i>pramipexole dihydrochloride er</i>	1183	PROFILNINE SD INTRAVENOUS*	
<i>pramipexole dihydrochloride er</i>	1184	SOLUTION RECONSTITUTED 500 UNIT,	
PRANDIMET	1185	1500 UNIT	1216
PRAVACHOL ORAL TABLET 20 MG, 80		<i>progesterone micronized oral</i>	1217
MG, 40 MG	1186	PROLIA	1218
<i>pravastatin sodium</i>	1187	PROMACTA	1219
PRECISION PCX	1188	PROMACTA	1220
PRECISION XTRA BLOOD GLUCOSE		PROMETRIUM	1221
	1190	<i>propafenone hcl er</i>	1222
PRECISION XTRA DEVICE	1189	PROTOPIC	1223
PRECISION XTRA MONITOR	1191	PROVIGIL	1225
PREFEST	1192	PROVIGIL	1227
<i>pregnyl</i>	1193	PROZAC ORAL CAPSULE 10 MG	1231
PREMARIN ORAL	1194	PROZAC ORAL CAPSULE 20 MG	1229
PREMPHASE	1195	PROZAC ORAL CAPSULE 40 MG	1230
PREMPRO	1196	PROZAC WEEKLY	1232
PREVACID 24HR	1198	PULMICORT	1233
PREVACID ORAL CAPSULE DELAYED		PULMICORT FLEXHALER	1234
RELEASE 30 MG	1197	PULMOZYME	1235
PREVACID SOLUTAB	1199	PURIXAN	1236
<i>previfem</i>	1200	QBRELIS	1237
PREZISTA ORAL SUSPENSION	1203	QUARTETTE	1238
PREZISTA ORAL TABLET 600 MG, 75 MG,		<i>quasense</i>	1239
150 MG	1201	QUDEXY XR ORAL 100 MG, 25 MG, 50	
PREZISTA ORAL TABLET 800 MG	1202	MG	1240
PRISTIQ	1204	QUDEXY XR ORAL 200 MG, 150 MG	
PRIVIGEN	1205		1241
PROCARDIA XL ORAL TABLET		<i>quetiapine fumarate oral tablet 100 mg, 50 mg</i>	
EXTENDED RELEASE 24 HR* 30 MG			1243
	1207	<i>quetiapine fumarate oral tablet 200 mg</i>	1244
PROCARDIA XL ORAL TABLET		<i>quetiapine fumarate oral tablet 25 mg</i>	1245
EXTENDED RELEASE 24 HR* 90 MG, 60		<i>quetiapine fumarate oral tablet 400 mg, 300</i>	
MG	1206	<i>mg</i>	1242
PROCENTRA	1208	QUILLICHEW ER ORAL 30 MG	1247
PROCRIT	1209	QUILLICHEW ER ORAL 40 MG, 20 MG	
PROCYSBI ORAL CAPSULE DELAYED			1246
RELEASE 25 MG	1211	QUILLIVANT XR	1248
PROCYSBI ORAL CAPSULE DELAYED		<i>quinine sulfate oral</i>	1249
RELEASE 75 MG	1210	<i>ra blood glucose monitor</i>	1250
PRODIGY AUTOCODE BLOOD GLUCOSE		<i>ra nicotine transdermal</i>	1251
DEVICE	1213	RA TRUETEST TEST	1252
PRODIGY AUTOCODE BLOOD GLUCOSE		<i>rabeprazole sodium</i>	1253
KIT	1212	RANEXA	1254



RAVICTI.....	1255	REVATIO ORAL TABLET.....	1291
RAZADYNE ORAL TABLET.....	1256	REVEAL BLOOD GLUCOSE TEST.....	1292
REBETOL ORAL SOLUTION.....	1257	REVLIMID.....	1293
REBIF REBIDOSE SUBCUTANEOUS*.....	1259	REXALL BLOOD GLUCOSE TEST.....	1294
REBIF REBIDOSE TITRATION PACK.....	1259	REXULTI.....	1295
SUBCUTANEOUS*.....	1260	REYATAZ ORAL CAPSULE 200 MG.....	1296
REBIF SUBCUTANEOUS*.....	1258	REYATAZ ORAL CAPSULE 300 MG, 150 MG.....	1297
REBIF TITRATION PACK.....	1261	RIASTAP.....	1298
SUBCUTANEOUS*.....	1261	RIGHTEST GS100 BLOOD GLUCOSE.....	1299
RECLAST.....	1262	RIGHTEST GS300 BLOOD GLUCOSE.....	1300
<i>reclipsen</i> .....	1263	RIGHTEST GS550 BLOOD GLUCOSE.....	1301
RECOMBINATE.....	1264	RILUTEK.....	1302
RECTIV.....	1265	<i>riluzole</i> .....	1303
REFUAH PLUS BLOOD GLUCOSE TEST.....	1266	<i>risedronate sodium oral tablet 150 mg</i> .....	1306
RELENZA DISKHALER.....	1267	<i>risedronate sodium oral tablet 35 mg</i> .....	1304
RELION PRIME MONITOR.....	1268	<i>risedronate sodium oral tablet 5 mg, 30 mg</i> .....	1305
RELISTOR ORAL.....	1269	<i>risedronate sodium oral tablet delayed release</i> .....	1304
RELISTOR SUBCUTANEOUS* KIT.....	1271	RISPERDAL M-TAB ORAL TABLET.....	1310
RELISTOR SUBCUTANEOUS* SOLUTION.....	1270	DISPERSIBLE 2 MG, 1 MG, 0.5 MG.....	1311
12 MG/0.6ML.....	1270	RISPERDAL M-TAB ORAL TABLET.....	1311
RELISTOR SUBCUTANEOUS* SOLUTION.....	1272	DISPERSIBLE 3 MG.....	1311
8 MG/0.4ML.....	1272	RISPERDAL M-TAB ORAL TABLET.....	1309
RELPAK.....	1273	DISPERSIBLE 4 MG.....	1309
REMERON.....	1274	RISPERDAL ORAL TABLET 3 MG, 1 MG, 2 MG, 0.5 MG, 0.25 MG.....	1307
REMERON SOLTAB.....	1275	RISPERDAL ORAL TABLET 4 MG.....	1308
REMICADE.....	1276	RISPERIDONE M-TAB ORAL TABLET.....	1315
REMODULIN.....	1277	DISPERSIBLE 2 MG, 0.5 MG, 1 MG.....	1316
<i>repaglinide-metformin hcl</i> .....	1278	RISPERIDONE M-TAB ORAL TABLET.....	1316
REPATHA.....	1279	DISPERSIBLE 3 MG.....	1316
REPATHA PUSHTRONEX SYSTEM.....	1280	RISPERIDONE M-TAB ORAL TABLET.....	1317
REPATHA SURECLICK.....	1281	DISPERSIBLE 4 MG.....	1317
REPRONEX.....	1282	<i>risperidone oral tablet 1 mg, 2 mg, 0.25 mg, 0.5 mg</i> .....	1312
REQUIP XL ORAL TABLET EXTENDED.....	1284	<i>risperidone oral tablet 3 mg</i> .....	1313
RELEASE 24 HR* 12 MG.....	1284	<i>risperidone oral tablet 4 mg</i> .....	1314
REQUIP XL ORAL TABLET EXTENDED.....	1283	<i>risperidone oral tablet dispersible 0.5 mg, 1 mg, 2 mg</i> .....	1312
RELEASE 24 HR* 4 MG, 6 MG, 8 MG.....	1283	<i>risperidone oral tablet dispersible 3 mg</i> .....	1313
RESCULA.....	1285	<i>risperidone oral tablet dispersible 4 mg</i> .....	1314
RESTORIL ORAL CAPSULE 22.5 MG, 7.5 MG.....	1286	RITALIN.....	1318
RETIN-A.....	1287		
RETIN-A MICRO.....	1288		
RETIN-A MICRO PUMP.....	1289		
REVATIO INTRAVENOUS*.....	1290		
REVATIO ORAL SUSPENSION.....	1290		
RECONSTITUTED.....	1290		

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
Updated 12/2016

RITALIN LA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 30 MG, 10 MG .....	1319	SEROSTIM SUBCUTANEOUS* SOLUTION RECONSTITUTED 4 MG, 6 MG, 5 MG .....	1353
RITALIN LA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 40 MG, 20 MG .....	1320	<i>sertraline hcl oral concentrate</i> .....	1354
RITALIN LA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 60 MG .....	1321	<i>sertraline hcl oral tablet 100 mg</i> .....	1356
<i>rivastigmine</i> .....	1322	<i>sertraline hcl oral tablet 25 mg</i> .....	1357
<i>rivastigmine tartrate</i> .....	1323	<i>sertraline hcl oral tablet 50 mg</i> .....	1355
RIXUBIS .....	1324	SHAROBEL .....	1358
<i>rizatriptan benzoate</i> .....	1325	SIGNIFOR .....	1359
<i>ropinirole hcl er oral tablet extended release 24 hr* 12 mg</i> .....	1327	SIGNIFOR LAR .....	1360
<i>ropinirole hcl er oral tablet extended release 24 hr* 6 mg, 8 mg, 4 mg, 2 mg</i> .....	1326	<i>sildenafil citrate oral</i> .....	1361
<i>rosuvastatin calcium</i> .....	1328	SIMCOR ORAL TABLET EXTENDED RELEASE 24 HR* 1000-40 MG, 500-40 MG .....	1362
ROZEREM .....	1329	SIMCOR ORAL TABLET EXTENDED RELEASE 24 HR* 500-20 MG, 750-20 MG, 1000-20 MG .....	1363
RUCONEST .....	1330	SIMPONI ARIA .....	1365
RYTHMOL SR .....	1331	SIMPONI SUBCUTANEOUS* .....	1364
SABRIL .....	1332	<i>simvastatin oral</i> .....	1366
SABRIL .....	1333	SINGULAIR ORAL PACKET .....	1367
SAFYRAL .....	1334	SIRTURO .....	1368
SAIZEN .....	1335	SKYLA .....	1369
SAMSCA ORAL TABLET 15 MG .....	1337	<i>sm nicotine transdermal</i> .....	1370
SAMSCA ORAL TABLET 30 MG .....	1336	SMARTEST BLOOD GLUCOSE TEST .....	1371
SANCUSO .....	1338	SMARTEST EJECT .....	1372
SAPHRIS .....	1339	SMARTEST PROTEGE .....	1373
SAVELLA .....	1340	<i>sodium phenylbutyrate oral powder 3 gm/tsp</i> .....	1374
SAVELLA TITRATION PACK .....	1341	<i>solia</i> .....	1375
SEASONIQUE .....	1342	SOLIRIS .....	1376
SEEBRI NEOHALER .....	1343	SOLUS V2 TEST .....	1377
SELZENTRY ORAL TABLET 150 MG .....	1344	SOMAVERT .....	1378
SENSIPAR .....	1345	SONATA ORAL CAPSULE 10 MG .....	1379
SEREVENT DISKUS .....	1346	SONATA ORAL CAPSULE 5 MG .....	1380
SEROQUEL ORAL TABLET 200 MG .....	1349	SORIATANE ORAL CAPSULE 10 MG, 17.5 MG, 25 MG .....	1381
SEROQUEL ORAL TABLET 25 MG .....	1347	SOVALDI .....	1382
SEROQUEL ORAL TABLET 300 MG, 400 MG .....	1348	SPIRIVA HANDIHALER .....	1383
SEROQUEL ORAL TABLET 50 MG, 100 MG .....	1350	SPIRIVA RESPIMAT .....	1384
SEROQUEL XR ORAL TABLET EXTENDED RELEASE 24 HR* 150 MG, 200 MG .....	1351	SPORANOX ORAL CAPSULE .....	1385
SEROQUEL XR ORAL TABLET EXTENDED RELEASE 24 HR* 300 MG, 400 MG, 50 MG .....	1352	SPORANOX PULSEPAK .....	1386
		<i>sprintec 28</i> .....	1387
		SPRITAM .....	1388
		SPRIX .....	1389

SPRYCEL ORAL TABLET 140 MG, 100 MG	1390	SYLATRON SUBCUTANEOUS* KIT 200	1427
SPRYCEL ORAL TABLET 20 MG, 80 MG, 50 MG, 70 MG	1391	MCG, 4 X 200 MCG, 300 MCG, 600 MCG, 4 X 300 MCG	1428
<i>sronyx</i>	1392	SYMBICORT	1429
STELARA INTRAVENOUS*	1393	SYMBYAX ORAL CAPSULE 12-25 MG, 6-25 MG, 6-50 MG, 12-50 MG	1430
STELARA SUBCUTANEOUS*	1394	SYMLIN	1431
STIOLTO RESPIMAT	1395	SYMLINPEN 120 SUBCUTANEOUS*	1432
STIVARGA	1396	SYMLINPEN 60 SUBCUTANEOUS*	1433
STRATTERA	1397	SYNAGIS	1434
STRIBILD	1398	SYNJARDY	1435
SUBOXONE SUBLINGUAL FILM 12-3 MG	1403	SYNRIBO	1436
SUBOXONE SUBLINGUAL FILM 8-2 MG, 4-1 MG, 2-0.5 MG	1399	SYNVISC INTRA-ARTICULAR*	1437
SUBOXONE SUBLINGUAL TABLET		SYNVISC ONE INTRA-ARTICULAR*	1438
SUBLINGUAL	1401	<i>tacrolimus external</i>	1440
SUBSYS	1405	TAFINLAR	1441
SUBSYS	1407	TAGRISO	1442
SULAR ORAL TABLET EXTENDED		<i>take action</i>	1443
RELEASE 24 HR* 17 MG, 8.5 MG, 34 MG	1409	TALTZ	1444
<i>sulfasalazine oral</i>	1410	TAMIFLU ORAL CAPSULE	1445
<i>sulfazine</i>	1411	TAMIFLU ORAL SUSPENSION	1446
SULFAZINE EC	1412	RECONSTITUTED 6 MG/ML	1447
<i>sumatriptan nasal</i>	1413	TANZEUM	1448
<i>sumatriptan succinate oral</i>	1414	TARCEVA	1449
<i>sumatriptan succinate refill subcutaneous*</i>	1417	TASIGNA	1450
<i>sumatriptan succinate subcutaneous* 6 mg/0.5ml, 4 mg/0.5ml</i>	1415	TAYTULLA	1451
<i>sumatriptan succinate subcutaneous* solution 4 mg/0.5ml</i>	1415	<i>taztia xt oral capsule extended release 24 hour 120 mg, 180 mg, 360 mg, 300 mg</i>	1452
<i>sumatriptan succinate subcutaneous* solution 6 mg/0.5ml</i>	1416	<i>taztia xt oral capsule extended release 24 hour 240 mg</i>	1453
SUPARTZ INTRA-ARTICULAR*	1418	TECFIDERA	1454
SURE EDGE GLUCOSE MONITOR	1419	TECFIDERA	1455
SURE EDGE TEST	1420	TECHNIVIE	1456
SURECHEK BLOOD GLUCOSE MONITOR		TEKAMLO	1457
DEVICE	1421	TEKTURNA	1458
SURECHEK BLOOD GLUCOSE TEST	1422	TEKTURNA HCT	1459
SURE-TEST EASYPLUS MINI METER	1423	TELCARE BLOOD GLUCOSE TEST	1460
SURE-TEST EASYPLUS MINI TEST	1424	<i>telmisartan</i>	1461
SUTENT	1425	<i>telmisartan-amlodipine</i>	1462
<i>syeda</i>	1426	<i>telmisartan-hctz</i>	1463
		<i>temazepam oral capsule 7.5 mg, 22.5 mg</i>	1464
		TESTIM	1465
		<i>testosterone cypionate intramuscular* solution 100 mg/ml</i>	1468

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
Updated 12/2016



<i>testosterone cypionate intramuscular* solution</i>	<i>tramadol hcl er oral tablet extended release 24 hr*</i>
200 mg/ml..... 1469	..... 1500
<i>testosterone cypionate intramuscular* solution</i>	<i>tramadol-acetaminophen</i>
250 mg/ml..... 1467	..... 1502
<i>testosterone transdermal gel 10 mg/act (2%),</i>	<i>tranexamic acid oral</i>
<i>50 mg/5gm (1%), 25 mg/2.5gm (1%), 12.5</i>	..... 1503
<i>mg/act (1%)</i> ..... 1465	<i>tretinoin external cream</i>
<i>tetrabenazine oral tablet 12.5 mg</i>	..... 1505
..... 1471	<i>tretinoin external gel 0.01 %</i>
<i>tetrabenazine oral tablet 25 mg</i>	..... 1504
..... 1470	<i>tretinoin external gel 0.025 %</i>
TEVETEN HCT ORAL TABLET 600-25 MG	..... 1505
..... 1472	<i>tretinoin external gel 0.05 %</i>
TEV-TROPIN	..... 1507
..... 1473	<i>tretinoin microsphere</i>
TGT BLOOD GLUCOSE MONITORING	..... 1508
..... 1474	<i>tretinoin microsphere pump</i>
<i>tgt nicotine step one</i>	..... 1509
..... 1475	TRETIN-X EXTERNAL CREAM
<i>tgt nicotine step three</i>	..... 1510
..... 1476	TRETTEN
<i>tgt nicotine step two</i>	..... 1511
..... 1477	TRIBENZOR
<i>thrive mouth/throat gum 2 mg</i>	..... 1512
..... 1478	TRICOR
<i>tiagabine hcl oral tablet 2 mg</i>	..... 1513
..... 1480	<i>tri-legest fe</i>
<i>tiagabine hcl oral tablet 4 mg</i>	..... 1514
..... 1479	<i>tri-linyah</i>
TIAZAC ORAL CAPSULE EXTENDED	..... 1515
RELEASE 24 HOUR 240 MG	..... 1516
..... 1481	TRILIPIX
TIAZAC ORAL CAPSULE EXTENDED	..... 1517
RELEASE 24 HOUR 360 MG, 180 MG, 420	<i>trinessa (28)</i>
MG, 120 MG, 300 MG	..... 1518
..... 1482	TRI-NORINYL (28)
<i>tilia fe</i>	..... 1519
..... 1483	TRINTELLIX
TIROSINT	..... 1520
..... 1484	<i>tri-previfem</i>
TIVICAY	..... 1521
..... 1485	<i>tri-sprintec</i>
TIVICAY	..... 1522
..... 1486	TRIUMEQ
TIVORBEX	..... 1523
..... 1487	<i>trivora (28)</i>
TOBI	..... 1524
..... 1488	TROKENDI XR
TOBI PODHALER	..... 1525
..... 1489	<i>tropium chloride</i>
<i>tobramycin inhalation</i>	..... 1526
..... 1490	TROSPIMUM CHLORIDE ER
<i>tolterodine tartrate er</i>	..... 1527
..... 1491	TRUE2GO BLOOD GLUCOSE MONITOR
TOPAMAX SPRINKLE	..... 1528
..... 1492	TRUERESULT BLOOD GLUCOSE
<i>topiramate oral capsule sprinkle</i>	..... 1529
..... 1493	TRUETEST TEST
TOPROL XL ORAL TABLET EXTENDED	..... 1530
RELEASE 24 HR* 100 MG, 50 MG	TRUETRACK BLOOD GLUCOSE KIT
..... 1496	..... 1531
TOPROL XL ORAL TABLET EXTENDED	TRUETRACK SMART SYSTEM
RELEASE 24 HR* 200 MG	..... 1532
..... 1494	TRUETRACK TEST
TOPROL XL ORAL TABLET EXTENDED	..... 1533
RELEASE 24 HR* 25 MG	TRULICITY
..... 1495	TUDORZA PRESSAIR INHALATION
TOUJEO SOLOSTAR	AEROSOL POWDER, BREATH
..... 1497	ACTIVATED 400 MCG/ACT
TOVIAZ	..... 1534
..... 1498	TUSSICAPS
TRADJENTA	..... 1535
..... 1499	TWYNSTA
<i>tramadol hcl er (biphasic)</i>	..... 1536
..... 1501	TYBOST
	..... 1537
	TYKERB
	..... 1538
	TYSABRI
	..... 1539
	TYVASO
	..... 1540
	TYVASO REFILL
	..... 1541
	TYVASO STARTER
	..... 1542

TYZEKA.....	1543	<i>venlafaxine hcl er oral tablet extended release</i>	
UCERIS.....	1544	<i>24 hr* 225 mg, 37.5 mg, 75 mg</i> .....	1581
UCERIS ORAL.....	1545	<i>venlafaxine hcl oral tablet 25 mg, 100 mg</i>	
ULESFIA.....	1546		1577
ULORIC.....	1547	<i>venlafaxine hcl oral tablet 37.5 mg</i> .....	1579
ULTIMA TEST.....	1548	<i>venlafaxine hcl oral tablet 50 mg</i> .....	1578
ULTRACET.....	1549	<i>venlafaxine hcl oral tablet 75 mg</i> .....	1580
ULTRAM ER ORAL TABLET EXTENDED RELEASE 24 HR* 200 MG.....	1551	VENTAVIS.....	1585
ULTRAM ER ORAL TABLET EXTENDED RELEASE 24 HR* 300 MG, 100 MG.....	1550	<i>verapamil hcl er oral capsule extended release</i> <i>24 hour 100 mg, 300 mg</i> .....	1587
ULTRATRAK ACTIVE.....	1552	<i>verapamil hcl er oral capsule extended release</i> <i>24 hour 200 mg</i> .....	1586
ULTRATRAK PRO.....	1553	VESICARE.....	1588
ULTRATRAK PRO TEST.....	1554	<i>vestura</i> .....	1589
ULTRATRAK ULTIMATE MONITOR .....	1555	VIBERZI.....	1590
ULTRATRAK ULTIMATE TEST.....	1556	VICTORY AGM-4000 TEST.....	1591
UPTRAVI ORAL.....	1558	VICTORY BLOOD GLUCOSE SYSTEM .....	1592
UPTRAVI ORAL TABLET 1200 MCG, 400 MCG, 600 MCG, 1600 MCG, 1000 MCG, 1400 MCG, 800 MCG.....	1557	VICTOZA SUBCUTANEOUS*.....	1593
UPTRAVI ORAL TABLET 200 MCG.....	1558	VICTRELIS.....	1594
UTIBRON NEOHALER.....	1559	VIEKIRA PAK.....	1595
VALCHLOR.....	1560	VIEKIRA XR.....	1596
VALCYTE ORAL TABLET.....	1561	VIIBRYD ORAL TABLET.....	1597
<i>valganciclovir hcl oral solution reconstituted</i> .....	1563	VIIBRYD ORAL TABLET.....	1598
<i>valganciclovir hcl oral tablet</i> .....	1562	VIMIZIM.....	1599
<i>valsartan</i> .....	1564	VIMPAT ORAL SOLUTION.....	1600
<i>valsartan-hydrochlorothiazide</i> .....	1565	VIMPAT ORAL TABLET.....	1601
VARUBI.....	1566	<i>viorele</i> .....	1602
VASCEPA ORAL CAPSULE 1 GM.....	1567	VIRAMUNE XR ORAL TABLET EXTENDED RELEASE 24 HR* 100 MG .....	1603
VECAMYL.....	1568	VIRAMUNE XR ORAL TABLET EXTENDED RELEASE 24 HR* 400 MG .....	1604
VELETRI.....	1570	VIREAD ORAL TABLET.....	1605
<i>velivet</i> .....	1571	VISTOGARD.....	1606
VELTASSA.....	1572	VIVELLE.....	1607
VENCLEXTA ORAL TABLET 10 MG... ..	1574	VIVELLE-DOT.....	1608
VENCLEXTA ORAL TABLET 100 MG .....	1573	VIVLODEX.....	1609
VENCLEXTA ORAL TABLET 50 MG... ..	1575	VOCAL POINT BLOOD GLUCOSE TEST .....	1610
VENCLEXTA STARTING PACK.....	1576	VOGELXO PUMP.....	1613
<i>venlafaxine hcl er oral capsule extended release 24 hour 150 mg</i> .....	1583	VOGELXO TRANSDERMAL GEL 50 MG/5GM (1%).....	1611
<i>venlafaxine hcl er oral capsule extended release 24 hour 37.5 mg, 75 mg</i> .....	1582	VOLTAREN TRANSDERMAL.....	1615
<i>venlafaxine hcl er oral tablet extended release 24 hr* 150 mg</i> .....	1584	VONVENDI.....	1616
		VOTRIENT.....	1617

2016 Aetna Pharmacy Drug Guide - New Jersey Individual  
Updated 12/2016

VPRIV	1618	XTANDI	1657
VRAYLAR ORAL CAPSULE 1.5 MG	1620	XULANE	1658
VRAYLAR ORAL CAPSULE 3 MG	1621	XURIDEN	1659
VRAYLAR ORAL CAPSULE 4.5 MG, 6 MG	1619	XYNTHA INTRAVENOUS* KIT 500 UNIT, 250 UNIT, 2000 UNIT, 1000 UNIT	1660
VYTORIN	1622	XYNTHA SOLOFUSE	1661
VYVANSE	1623	XYREM	1662
WAVESENSE KEYNOTE PRO METER	1624	XYZAL ORAL TABLET	1663
WAVESENSE PRESTO	1625	YASMIN 28	1664
WELLBUTRIN	1626	YAZ	1665
WELLBUTRIN SR	1627	YERVOY	1666
<i>wera</i>	1628	<i>zaleplon</i>	1667
WIDE-SEAL DIAPHRAGM 60	1629	<i>zarah</i>	1668
WIDE-SEAL DIAPHRAGM 65	1630	ZAVESCA	1669
WIDE-SEAL DIAPHRAGM 70	1631	ZECUITY	1670
WIDE-SEAL DIAPHRAGM 75	1632	ZEGERID OTC	1671
WIDE-SEAL DIAPHRAGM 80	1633	ZELAPAR	1672
WIDE-SEAL DIAPHRAGM 85	1634	ZELBORAF	1673
WIDE-SEAL DIAPHRAGM 90	1635	ZEMBRACE SYMTOUCH	1674
WIDE-SEAL DIAPHRAGM 95	1636	ZEMPLAR ORAL CAPSULE 2 MCG, 1 MCG	1675
WILATE INTRAVENOUS* KIT	1637	<i>zenatane oral capsule 20 mg, 10 mg, 40 mg</i>	1676
WILATE INTRAVENOUS* SOLUTION RECONSTITUTED 500-500 UNIT, 1000-1000 UNIT	1637	ZENATANE ORAL CAPSULE 30 MG	1677
<i>wymzya fe</i>	1638	<i>zenchent</i>	1678
XALATAN	1639	<i>zenchent fe</i>	1679
XALKORI	1640	ZEPATIER	1680
XANAX XR	1641	ZETIA	1681
XARTEMIS XR	1642	ZINBRYTA	1682
XELJANZ	1643	ZIOPTAN	1683
XELJANZ XR	1644	<i>ziprasidone hcl</i>	1684
XELODA	1645	ZOCOR	1685
XENAZINE ORAL TABLET 12.5 MG	1646	ZOHYDRO ER	1686
XENAZINE ORAL TABLET 25 MG	1647	<i>zoledronic acid</i>	1687
XEOMIN	1648	ZOLINZA	1688
XGEVA	1649	<i>zolmitriptan oral</i>	1689
XIFAXAN ORAL TABLET 200 MG	1650	ZOLOFT ORAL CONCENTRATE	1690
XIFAXAN ORAL TABLET 550 MG	1651	ZOLOFT ORAL TABLET 100 MG	1692
XIGDUO XR ORAL TABLET EXTENDED RELEASE 24 HR* 10-1000 MG, 10-500 MG, 5-500 MG	1652	ZOLOFT ORAL TABLET 25 MG	1693
XIGDUO XR ORAL TABLET EXTENDED RELEASE 24 HR* 5-1000 MG	1653	ZOLOFT ORAL TABLET 50 MG	1691
XOLAIR	1654	<i>zolpidem tartrate er</i>	1695
XOPENEX HFA	1655	<i>zolpidem tartrate oral</i>	1694
XTAMPZA ER	1656	ZOMETA	1696
		ZOMIG NASAL SOLUTION 5 MG	1697
		ZOMIG ORAL	1698
		ZOMIG ZMT	1699
		ZORBTIVE	1700

ZORVOLEX .....	1701
<i>zovia 1/35e (28)</i> .....	1702
<i>zovia 1/50e (28)</i> .....	1703
ZUBSOLV SUBLINGUAL TABLET SUBLINGUAL 1.4-0.36 MG, 5.7-1.4 MG .....	1704
ZUBSOLV SUBLINGUAL TABLET SUBLINGUAL 11.4-2.9 MG .....	1710
ZUBSOLV SUBLINGUAL TABLET SUBLINGUAL 2.9-0.71 MG .....	1706
ZUBSOLV SUBLINGUAL TABLET SUBLINGUAL 8.6-2.1 MG .....	1708
ZURAMPIC .....	1712
ZYBAN .....	1713
ZYDELIG .....	1714
ZYKADIA .....	1715
ZYPREXA ORAL TABLET 15 MG, 5 MG, 7.5 MG, 10 MG, 20 MG .....	1716
ZYPREXA ORAL TABLET 2.5 MG .....	1717
ZYPREXA ZYDIS .....	1718
ZYTIGA .....	1719
ZYVOX ORAL TABLET .....	1720